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ABSTRACT
DEVELOPING A BIOSENSOR FOR THE DETECTION OF BACTERIA:
A COMPARISON OF METHODS FOR ISOLATING
BACTERIA-SPECIFIC ANTIBODIES
by Scott Walper
May 2010
The antigen-antibody interaction is known to be a high affinity and highly specific
interaction that can readily be used for the detection and identification of biological and
chemical agents. These studies were conducted to develop an efficient and cost-effective
method of obtaining bacteria-specific antibody molecules for integration into a fielddeployable biosensor. Antigen-binding molecules were obtained both as full-length IgG
molecules from a hybridoma cell line and as recombinant single-chain Fv (scFv)
antibodies isolated from naïve and immunize libraries. Monoclonal and recombinant
antibody systems were compared on the effectiveness of producing new, target-specific
molecules; the efficiency of production and purification of these molecules; and the
success/failure of integrating the molecules into the QCM biosensor for bacterial
detection. Although selection of individual hybridoma cell lines was not conducted,
monoclonal antibodies (mAbs) were obtained from an established cell line maintained in
a hollow-fiber bioreactor. Recombinant antibodies, scFvs, capable of binding bacterial
targets were isolated from libraries using a high-throughput phage display method of
selection. Protocols were established for the purification of monoclonal antibodies from
the bioreactor serum and scFvs from bacterial cell cultures to assess the efficiency of
readily obtaining antibodies for integration into the biosensor. Finally, methods of
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immobilizing antibodies and scFvs to the gold electrode of a standard QCM crystal were
explored to determine suitable procedures for consistent detection of target bacteria in
aqueous samples to the lowest limit of detection.
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CHAPTER I
INTRODUCTION
The biotechnology industry has expanded from the production of therapeutic and
pharmacological agents to the development of devices that aid in the detection and
identification of countless small molecules originating from chemical or biological
sources. Although detection assays at one time focused on common tests for the medical
field, such as glucose strip tests, pregnancy tests, etc.; the current world climate has
created a new market for devices capable of detecting far more sinister elements, such as
food-borne pathogens and weapons of both biological and chemical origin. Since the
terrorist attacks on the United States in 2001, the federal government has significantly
increased funding for the development of devices, such as sensors and analytical devices,
that will provide a first line of defense against an attack from terrorist groups. Funds
allocated for defense based projects has increased from a mere 50 million dollars in 2001
to nearly 6 billion for the 2009-2010 fiscal year (1). Increased threats of terrorist violence
and growing concern over the safety of our food network have significantly increased the
demand for these instruments.
Rapid and definitive detection of bacterial and viral agents is of critical importance to
the agricultural industry (2, 3), medical field (4), and for the bio-defense of the nation (5).
Traditional methods, such as direct plating to assess microbial contamination of samples
(6)

, requires several days for bacterial growth before an accurate analysis is possible.

Other methods such as polymerase chain reaction (PCR) (7, 8) and Enzyme-Linked
Immunosorbent Assay (ELISA) (9-11) require transport to a laboratory facility before
analysis can begin. While these methods may be effective in a hospital setting, a field-
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deployable device would be better suited for agriculture and bio-defense. Samples tested
at the site of concern would prevent building closures such as those associated with the
2001 anthrax scare and allow field agents to analyze products stored in warehouses, thus
eliminating costly delays and needless waste observed with the Salmonellae outbreak of
2008.
The development of biosensors has seen a dramatic increase in the past several years
(12)

. A biosensor is defined as an analytical device that couples a biological material (i.e.

an enzyme, antibody, nucleic acid, microorganism, tissue, etc.) or biomimic (imprinted
polymer, synthetic catalyst, etc.) to a physiochemical transducer. Transducers can be
optical (fluorescence-based or surface plasmon resonance), piezoelectric (quartz crystal
microbalance), electrochemical (amperometric or potentiometric) or micromechanical
(microcantilever) showcasing the diversity of the emerging field (13). Although the
development of biosensors that incorporate nucleic acids and enzymes is increasing, the
vast majority of current approaches utilizes antibodies for detection of biological agents.
The high affinity and specificity of antibodies for their target antigens is routinely
exploited for numerous scientific applications. Produced as a component of the immune
response to a foreign substance, antibody molecules bind surface features of the target
antigen called epitopes and contribute to the removal of the intruding entity from the host
organism (14). Antibody preparations are classified according to the source from which
they are obtained. Polyclonal antibodies are extracted directly from the serum proteins
and recognize numerous epitopes of the antigen. Enrichment of antibodies capable of
antigen recognition is accomplished following a series of immunizations of a host
organism that stimulate maturation of the lymphocytes In contrast, monoclonal
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antibodies, which are typically produced by immortalized lymphocyte cell cultures called
hybridomas, bind a single defined epitope of the antigen (15). Binding characteristics of
specificity and affinity of monoclonal antibodies, because they are produced from a
single cell line, are typically well defined. As with polyclonal antibodies, generation of a
hybridoma cell line is preceded by a series of host immunizations. Full-length antibodies
require considerable investments of time and money to develop. Recombinant antibodies,
which are produced in bacteria, can be utilized to circumvent the time and cost
constraints associated with antibody production.
The antigen-recognition domain of an immunoglobulin is formed from the N-terminal
100 – 110 amino acids of the heavy and light chain (16). Using molecular techniques, the
DNA sequences encoding the variable regions can readily be isolated and combined into
a single fusion gene referred to as a single chain Fv antibody (scFv) (17). Recombinant
scFvs have been constructed from the genetic material of hybridoma cells (18), spleen cells
(19, 20)

, or from peripheral blood lymphocytes (21) to form highly diverse libraries.

Selection against a target antigen can be accomplished using a variety of high-throughput
techniques, however, phage display is the dominant methodology. The phage display
protocol utilizes scFvs fused to the pIII protein of the M13 filamentous phage capsid. A
pool of phage particles is subjected to selection to isolate those displaying an scFv with
affinity for a particular antigen. Since the scFv gene is encoded in a phagemid vector that
is encased within the capsid, amplification of the recombinant antibody gene and
enrichment of antigen-specific scFvs are readily accomplished following each round of
selection. The phage display system has been utilized for the isolation of scFvs specific
for a range of targets including metabolites (21), carbohydrates (22), bacterial toxins (23), and
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a variety of cellular proteins and receptors (24, 25). Using high-throughput selection and
bacterial production, target-specific, recombinant antibodies can readily be obtained for
integration into a biosensor.
The microgravimetric quartz crystal microbalance (QCM) sensor is a piezoelectric
device that measures minuscule changes in mass through small increases or decreases in
the oscillation frequency of an A-T cut quartz crystal that lies between two electrodes,
generally coated with gold or some other reactive metal (26). A gold surface is most
commonly used due to the numerous attachment chemistries to which it is amenable.
Proteins can readily be immobilized to the gold electrode through either direct adsorption
to the gold surface or through covalent bond formation with terminal functional groups of
a self-assembled monolayer (27). Antibodies have been successfully integrated into QCMbased sensors for the detection of food-borne pathogens such as Listeria monocytogenes
(28)

, Escherichia coli (29, 30), and Salmonella spp. (26, 31-33) and have shown to be capable of

detecting 103 – 108 colony forming units (cfu)/ml.
Although IgG molecules have been successfully integrated into biosensors, significant
research has not been conducted with scFvs. The scFv is appealing to biosensor
applications because they can be rapidly isolated from highly diverse libraries and
thereby ensure adaptability to emerging threats. Additionally, the limited complexity of
the scFv allows the molecule to be produced in bacterial cell cultures in contrast to the
costly mammalian cultures needed for monoclonal antibody production. For this study,
the manufacture and integration of scFvs into a QCM-based biosensor were examined to
compare the potential of this system to established detection methods that use polyclonal
or monoclonal IgG preparations.
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CHAPTER II
LITERATURE REVIEW
Antibodies
The immune system responds to the presence of a foreign antigen with a series of cellto-cell interactions and chemical signals that stimulate an array of host defenses. One
such defense mechanism is the production of target –specific antibodies. Antibody is a
broad term used to describe proteins that are produced by mature lymphocytes, plasma
cells, in response to a foreign antigen (14). The basic antibody structure is comprised of
two identical subunits, each of which is formed from a heavy and light chain that are
bound through disulfide bonds. The heavy chains, which are used to classify the
molecule, can further be sub-divided into five isotypes, ( - IgA; - IgG; - IgE;
IgM;

-

- IgD) based on conserved sequences in their so-called constant domains.

Although the primary structure of the constant domains does not affect antigen binding, it
does play a role in the functional properties of the molecules. Similarly, the light chain
subunits of antibodies are classified as either a kappa ( ) or lambda ( ) chains based on
conserved amino acid sequences. As with the heavy chain gene, the light chain is a
product of DNA recombination events that occur during B-cell maturation.
The antibody molecule can be divided into two distinct domains, termed Fab and Fc,
which are separable by digestion with the cysteine protease papain. The Fab domain
contains the antigen-binding site, which is formed from the N-terminal 100 – 110 amino
acids of both heavy and light chain subunits (Figure 1). Referred to as the variable
domain, this N-terminal portion is highly diverse in amino acid sequence and contributes
to the ability of the immune system to respond to countless foreign antigens. This is in
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contrast to the constant domains of the Fc fragment, which are relatively conserved in
amino acid sequence. Antibodies interact with other cells and components of the immune
system through interactions with amino acids and structural motifs of the Fc domain to
facilitate antigen clearance (14, 34).

Figure 1. Structure of the IgG Antibody
The basic antibody is a homodimer comprised of identical heavy and light chain
subunits. The molecule can be divided into two fragments through enzymatic
cleavage. The Fab portion contains the antigen-binding domain; the Fc portion
stimulates immune responses (complement, receptor binding).
Image constructed with Yasara (yasara.org) software and the anti-HIV IgG crystal
structure (PDB IGG1)
The heavy and light chain genes are composed of four clusters of gene segments (V –
D – J – C) that are rearranged at the gene level in countless combinations to generate the
incredible diversity of antibody molecules produced by the immune system. The constant
(C) gene clusters, which reside at the 3’ end of the gene, rearrange to define the antibody
isotype. The 5’ end of the gene encodes the antigen recognition portion of the antibody
and is formed from the variable (V), diversity (D), and joining (J) gene clusters. The
expansive heavy chain immunoglobulin gene of humans, approximately 1 million base
6

pairs in length, is comprised of 95 or more V-segments, over 20 D-segments, and 9 Jsegments. Both

and

light chains are similarly organized, although there is some

variation in the number of V, D, and J-gene segments. During antibody maturation, a
complex mechanism of gene recombination occurs between the V-D-J gene segments
until a functional rearrangement is achieved. This process occurs independently on each
of the chromosomes that carry genes for heavy and light chain subunits (34). The genetic
recombination events that occur within the V – D – J gene clusters result in the structural
diversity of antigen-binding domains of individual immunoglobulins and form the basis
for the ability of the immune system to respond to countless antigens.
In the primary immune response to an antigen, low-affinity IgM antibodies are
produced as a first line of defense. The pentameric structures are quite effective at
aggregating antigens and at stimulating the complement system, however, the rapidity
with which they are produced suggests that little maturation of the V-D-J segments has
occurred, resulting in low-affinity binding. It has been suggested by several research
groups that the IgM heavy chain gene is similar to the original germ-line gene (35, 36). In
contrast to IgM, IgG antibodies are produced in higher concentrations during the
secondary response to an antigen (37). Individual plasma cells producing IgG antibodies
have undergone substantial recombination of the V – D – J gene clusters. The resulting
IgG antibodies have a greater diversity of structure in the variable domain. IgG antibodies
produced in response to an antigen generally exhibit improved affinities and target
specificities compared to their IgM counterparts, a result of the clonal expansion process
(35)

.
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An antibody binds a specific feature on the surface of an antigen referred to as an
eptiope. Much like other protein – protein interactions, the antigen – antibody association
is the product of electrostatic and van der Waals forces between the epitope and the
amino acid side chains of the antigen-binding domain. Not all antibodies will bind the
same epitope, and different antibodies that target the same epitope will not necessarily
bind with equivalent affinity. The success of the immune system, therefore, lies in the
production of a barrage of antibodies, many of which will recognize different epitopes
present on the same antigen. Since a mature lymphocyte, or plasma cell, produces a
single antibody molecule of defined epitope specificity and affinity, countless
lymphocytes are employed by the immune system to generate the polyclonal antibody
repertoire required for elimination of the foreign antigen.
Polyclonal antibodies, which are usually extracted from the serum of immunized
animals, have been used for numerous applications in the scientific and medical field for
well over a century. While effective, the high diversity of antibodies within the
polyclonal pool can often lead to non-target interactions that complicate the interpretation
of results (38, 39). Additionally, because polyclonal antibodies are produced from
individual immunized animals, lot-to-lot variation frequently skews experimental
reproducibility (40). In 1975, however, Köhler and Milstein developed a method of
producing immortalized lymphocyte cell cultures capable of continuous production of an
antibody clone with singular specificity (15). These cells lines, termed hybridomas, were
generated through the fusion of a plasma cell and a myeloma cell. Hybridoma cultures
can be maintained indefinitely in tissue culture, overcoming the limitations imposed by
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the brief life span of the progenitor plasma cell and provide a continuous source of
monoclonal antibodies with defined binding characteristics.
Hybridoma cell lines are constructed through the fusion of plasma cells, generally
acquired from the spleen of mice or rabbits, with cancerous myeloma cells. Maturation of
lymphocytes is promoted through successive immunizations with a specific antigen to
enrich for plasma cells producing antibodies with improved binding characteristics. The
myeloma cells, prior to fusion, undergo selection to ensure that they are not producing
antibodies themselves and are deficient in the hypoxanthine-guanine
phosphoribosyltransferase gene (HGPRT) that is involved in the salvage pathway of
acquiring nucleotides. The HGPRT gene deletion allows for the selection of hybridomas
from the non-fused plasma and myeloma cells in HAT (hypoxanthine-aminopterinthymidine) medium. The aminopterin in this medium inhibits de novo nucleotide
synthesis forcing cells to utilize the salvage pathway for survival. The myeloma cells,
which are HGPRT - , can only survive following successful fusion with a plasma cell
which recovers the HGPRT gene. Hybridoma selection is usually followed by clonal
selection through limiting dilution of cells to ensure antibodies are produced from a
single cell clone (41). Once monoclonal cell lines are established, assays for antigen
affinity and specificity allow identification of those that produce antibodies with desired
binding characteristics. The development of a new hybridoma cell line can take several
months to a year for each antigen of interest.
Recombinant Antibodies
In 1972, Inbar et al. defined the antigen-binding domain of a full-length antibody by
cleaving the Fab fragment with pepsin and demonstrating that the N-terminal variable
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portions of the heavy and light chains, which associate through non-covalent interactions,
readily bound antigen equivalent to the full-length IgA antibody (16). This region, because
of the variability of amino acid sequence, was termed the variable fragment or Fv region.
The Fv region of the antibody molecule was further subdivided into four framework
regions, typically -sheet motifs, and three complementarity-determining regions (CDRs)
that form the actual antigen-binding domain. The framework regions, similar to the
constant domains of the whole antibody molecule, are generally, more conserved in
amino acid sequence and are thought to contribute primarily to the stability of the Fv
domain (42, 43). In contrast, the CDRs are of variable sequence, the product of the V-D-J
recombination events previously described. The diversity of the antibody repertoire is
credited to the sequences of the CDRs, allowing for the recognition and elimination of
countless antigens encountered by the host immune system (34).
The antigen-antibody interactions occur at the antigen-binding domain, a region
formed from the three CDRs of the heavy and light chain subunits. Preliminary efforts to
develop recombinant antibody technologies began with experiments that demonstrated
through genetic manipulation, that CDR sequences could be isolated and transferred from
one antibody to the next (44, 45). This discovery led to dramatic advances in therapeutic
antibody research that involved selection of antibodies with specific characteristics in
immunized animals and subsequent transfer of their CDRs to human antibodies for
medical applications (44, 46, 47).
Huston et al. utilized the techniques of CDR transfer to form a single fusion protein
comprised of the heavy and light chain variable domain sequences joined by a short
amino acid linker sequence. The recombinant protein was termed a single-chain Fv
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antibody or scFv (17) (Figure 2). Tethered by the linker sequence, the two variable
domains could be produced as a single protein that was capable of forming the antigenbinding domain independent of any stabilizing constant domains of the heavy and light
chains. Single chain Fv antibodies offered several advantages compared to monoclonal
antibodies produced in hybridoma cells. The scFvs provide an additional method of
immortalizing a particular antigen-specific antibody preventing loss through
contamination of the cell line (17, 48, 49). Additionally, once inserted into a bacterial
plasmid, the genetic sequences of the scFv can easily be manipulated to improve the
binding characteristics of the recombinant antibody (50, 51). Finally, recombinant
antibodies can readily be produced in bacterial or yeast cultures, which significantly
decreases the overall cost associated with antibody-based applications (52-54).
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Figure 2. A Single-chain Fv Antibody (scFv) and Gene
The scFvs are constructed using molecular techniques that isolate the gene
sequences of the antibody Fv domain and combine them into a single fusion gene. The
heavy and light chain variable sequences are separated by a short amino acid linker
sequence (12-15 amino acids) that allows non-covalent interactions between the two
sequences similar to those occurring in the full-length immunoglobulin. This allows
for the formation of the antigen-binding domain.

Recombinant antibodies manufactured from the genetic material of a hybridoma cell
line will theoretically exhibit the same binding characteristics of the parental antibody
molecule (18, 55). While this offers several advantages, the true power of recombinant
antibody technology lies not in the reproduction of a single antibody, but rather in the
ability to mimic the incredible diversity of the immune system. Just as a single scFv can
12

be constructed from one hybridoma cell line, an entire library of different scFvs can be
assembled from the numerous plasma cells that can be obtained from a primary lymph
node such as the spleen (18, 56). The untold number of genes for the heavy and light chain
variable domains can be extracted from lymph tissues and randomly combined to form
countless scFvs with varying specificities and affinities (57-60).
An scFv library can be constructed from the tissues of any number of host organisms
and only requires knowledge of conserved nucleotide sequences that flank the variable
domain region for PCR primer design. To date, recombinant antibody libraries have been
successfully constructed from human (61-63), rabbit (19, 56, 64, 65), chicken (66), mouse (18, 67),
shark (68, 69), and llama (60, 70) sources. Recombinant antibody libraries are typically
classified as one of two types, either naïve or immunized. As the name implies, an
immunized antibody library is constructed from a host that has been subjected to a series
of immunizations and is enriched for lymphocytes with immunoglobulins genes that
encode for antigen specific antibodies. In contrast, naïve libraries are assembled from
lymphocytes of a host that has not purposely been exposed to a particular antigen. The
naïve library, therefore, is expected to demonstrate a greater diversity of scFvs capable of
binding numerous target antigens (71, 72). Although antibody libraries are typically
constructed from tissues of high lymphocyte concentration such as the spleen and bone
marrow (61, 65, 73), scFv libraries have also been constructed from both peripheral blood
lymphocytes (64, 74) and pools of hybridoma cell cultures (18, 75).
The success isolating scFvs from libraries is dependent upon the incredibly high
diversity of antigen-binding domains present. Immunized libraries, which are enriched
for antigen-specific scFvs, typically possess a clonal diversity of 105 or greater (76, 77). The
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naïve library attempts to simulate the clonal diversity of the host immune system;
therefore clonal diversities of 109 or more are sought during library constructions (20, 62, 71,
78)

. To select for scFvs with the desired binding affinity and specificity, a high-throughput

method of selection must be employed. Although alternatives are available, the preferred
method of selection is phage display.
Phage Display
George Smith first utilized the filamentous bacteriophage to isolate genes that encode
the antigens for specific antibodies (79). In his research, Smith incorporated foreign coding
sequences in frame to the gene for the pIII protein of the virion capsid. The amino acids
encoded by these DNA sequences were expressed as fusions to the capsid protein. To
identify the target gene, antibodies known to bind an antigen of interest could be
immobilized to a solid support and used to retain phages displaying peptides similar to
the epitope of the target antigen. The gene encoding these peptide sequences, encoded in
the phage display vector, could then be sequenced and used to identify the full-length
gene that encoded the target antigen through a direct comparison of recombinant and host
gene sequences. This early research led to the rapid expansion of display technologies.
Smith’s research utilized filamentous bacteriophages, bacterial viruses that
encapsulate a ssDNA genome within an elongated protein capsid. Filamentous
bacteriophages infect a number of gram-negative bacteria and replicate within the
infected host without inducing cell lysis (57, 59). Although the f1, M13, and fd
bacteriophages are all highly similar in structure and life cycle, the M13 phage, is used
extensively in the phage display technique and will be the focus of this discussion.
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The M13 genome is a small circular ssDNA molecule that encodes ten proteins
essential to viral replication within the host bacterium (80, 81). Five of the genes encode
proteins that form the viral capsid. The most abundant capsid protein, pVIII, is present in
thousands of copies and forms the main body of the virion. The pVII and pIX proteins,
which interact with the membrane pore formed by pIV (82, 83), are located at one terminus
of the capsid. These are the first proteins to emerge from the bacterium. The pIII and pVI
proteins, located at the opposing tip of the capsid, are responsible for bacterial infection
and release of the virion from the bacterium. The remaining viral proteins (pII, PX, pI,
and pIV) are involved in replication and assembly of the phage particle.
Although success has been achieved with all five capsid proteins (84), display
technologies have primarily utilized the pIII protein, which is well characterized in
sequence and structure (85). The pIII protein is comprised of 406 amino acids and
organized into three domains. Each domain is separated by a glycine-rich linker region
that, in addition to the N-terminus, can be utilized for incorporation of a foreign gene.
The CT domain (residues 257 – 406) is buried within the phage particle and contributes
to the release of the intact phage from the bacterium. The two N-terminal domains N1
(residues 1 – 68) and N2 (residues 87 – 217) are involved in phage infection. Binding of
the N2 domain to the F pilus of E. coli cells induces a conformational change in the pIII
protein that enables its N1 domain to interact with the bacterial protein TolA, which is
located adjacent to the F-pilus, and facilitates docking of the viral particle. The actual
mechanism of phage DNA entry into the bacterium is not known (59).
Since, the pIII protein is the primary protein of infection, wild-type copies of the
protein are required to ensure phage propagation. Foreign genes can be cloned directly
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into the phage genome; however, precautions must be taken to ensure that the protein is
encoded in frame to maintain expression of downstream domains of the pIII protein.
When this method is employed, all five copies of the pIII protein should contain the
foreign protein. In actuality, however, proteolytic enzymes of the host bacterium will
excise some number of these proteins restoring the wild-type (wt) protein and permitting
bacterial infections (81). While the direct cloning method was demonstrated successful, an
alternative strategy was developed by Barbas III et al. that utilized a bacterial plasmid to
express of viral genes (58). These vectors contain a truncated portion of the pIII protein
(CT domain) with upstream restriction enzyme cleavage sites that facilitates the cloning
of the foreign gene in frame with this viral capsid protein (58). In the presence of M13
DNA, the recombinant protein is expressed as a pIII fusion protein and incorporated into
the phage capsid. Since the ssDNA phage genome contains wt pIII protein, which is also
expressed during phage replication, only one to three copies of the capsid protein will
contain the recombinant protein (57, 58). This system, which relies on the expression of
both recombinant fusion and wt pIII protein from two different DNA sources, is referred
to as a 3 + 3 vector system (81).
The laboratory of Dr. Barbas III has produced several phagemid vectors that are
applicable to phage display system. The four most commonly used vectors have been
adapted to facilitate the expression of both single-chain Fab and single chain Fv
antibodies with a variety of eptiope tags that facilitate detection and purification. The
basic phage vector from this laboratory relies on a lacZ promoter to control transcription
of the recombinant antibody gene, which is cloned into unique SfiI restriction enzyme
sites. In addition to an antibiotic resistance gene for selection, the plasmid also encodes
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an ompA leader sequence that ensures targeting of the translated protein to the periplasm,
where integration into the phage capsid occurs. The pComb3 XSS vector, one of the four
vectors from the Barbas labs, also includes two epitope tags, a hexa-histidine tag (6xHis)
and a hemaglutinin (HA) eptiope, that can be used for purification and detection of the
recombinant scFv (57). Display on the phage capsid is accomplished through a fusion to a
truncated pIII protein (aa 230 – 406). The pIII protein is preceded by an amber stop
codon that allows for expression of the scFv gene (without the pIII fusion) and epitope
tags in non-suppressor bacterial strains. A schematic of relevant domains of the pComb3
XSS vector can be seen in Figure 3.

Figure 3. Schematic of the pComb3 XSS Phagemid Vector
The lacZ promoter regulates the transcription of the scFv gene cloned into the phage
vector using the unique SfiI restriction sites. The scFv gene is cloned in frame with two
epitope tags (6xHis and HA) and the truncated portion of the pIII protein. In the
presence of a helper phage that encodes all of the wt proteins for phage replication, the
scFv gene is expressed and incorporated into the phage capsid.
VH/ VL – are the scFv genes separated by the linker (L). The Shine-Delgarno (SD) and
ompA are represented in the approximate location. The “*” represents the amber stop
codon.
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Selection of ScFvs through Biopanning
The method that leads to enrichment of target-specific recombinant antibodies from
the scFv library is referred to as biopanning. Through iterative rounds of selection against
the target antigen and subsequent amplification of scFv-expressing phage, the large,
diverse scFv repertoire is enriched to those scFvs that are able to bind the target antigen.
The traditional biopanning protocol involves an antigen or ligand that is immobilized to a
solid support such as a microtiter plate for selection (20, 22). The simplicity of the protocol,
however, has allowed researchers to adapt the method to satisfy experimental
requirements including centrifugation of whole cell antigens (86, 87), antigen coated
magnetic beads (21, 88, 89), flow cytometry with antigen coated microspheres (90, 91) and
numerous other methods. Regardless of the binding and selection protocol, bound phage
are eluted from the antigen and amplified in a bacterial culture. Generally, a defined
number of biopanning rounds are conducted prior to the analysis of individual selected
scFv clones. A diagram of a typical biopanning protocol utilizing antigen immobilized to
a solid support is shown in Figure 4.
The phage display system in combination with recombinant antibody technology is a
powerful tool that can readily be adapted to the isolation of scFvs with specificity for
nearly any antigen. Combined with high-throughput screening methods, recombinant
antibodies have been isolated against pathogenic bacteria (87) and their toxins (92), epitopes
of cancer cells (93), explosives (94), and countless other small molecules. The potential
applications of the recombinant antibodies and the phage display system are limited only
by the creativity of the researcher.
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Figure 4. Selection of Antigen–Specific scFvs through Biopanning
Phages displaying the scFv library are incubated with antigen immobilized
to a solid. Non-bound phages are removed through washes, leaving behind
those that display scFvs with affinity for the target antigen. These molecules
are eluted and amplified through infection of a bacterial culture.
Biopanning is conducted for several rounds to enrich for those scFvs that
have the highest affinity for the antigen.
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Biosensors and the Quartz Crystal Microbalance (QCM)
A biosensor is defined as an analytical device that integrates a biological material into
a physiochemical transducing device (95). The biological element can include any natural
biological material (tissues, organelles, cells, antibodies, enzymes, etc.), recombinantly
produced biological material (scFvs, aptamers, etc.) or biomimic (synthetic receptors or
ligands, combinatorial ligands, etc.). The transducer can be based on optical,
electrochemical, piezoelectric, micromechanical or a number of other suitable formats.
While the range of possible biosensor principles is expansive, a biosensor is simply a
device capable of detecting interactions between a target molecule and a biological
material that is then relayed to an external source for interpretation. Although biosensors
can utilize a diverse array of transducers, the piezoelectric quartz crystal microbalance
platform, which is the transducer of the biosensor used in this study, will be discussed
exclusively.
The first piezoelectric device, which converts mechanical signals such as sound
waves into electrical signals, was described by Raleigh (96) in regards to the
piezoelectricity of the quartz crystal. The quartz crystal, like all piezoelectric materials,
responds to an electrical potential with a proportional internal mechanical stress or
deformation (97). When an alternating electrical field is applied, acoustic waves are
generated as the crystal vibrates near its resonant frequency (98). The direction of the
acoustic wave, with respect to the crystal surface, can be controlled by the cut of the
quartz in relation to the crystal axes. The AT- cut quartz crystal, which is the most
conducive to QCM-based biosensors, produce an acoustic wave that travels perpendicular
to the crystal surface (99). The deposition or removal of mass and/or changes in viscosity
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or conductivity of the solution surrounding the crystal affect the oscillation frequency of
the crystal which is compared for sample analysis (100).
Sauerbrey first described QCM for in vacuo measurements of the rate of film
deposition to the crystal surface by (101). From his studies, the Sauerbrey equation that
correlates changes in frequency to the addition of mass was derived:

where f is the change in resonant frequency, fR is the resonant frequency,

Q

is the

density of the crystal, m in the change in mass, and d and A are the dimensions of the
crystal in regards to thickness and area, respectively. For defined crystals in which the
frequency constant of the quartz (N) is known the equation can be reduced further as seen
in the equation above. The Sauerbrey equation is limited to measurements of thin, rigid
films and is therefore not always appropriate for analysis of aqueous solutions (102).
Modifications to the Sauerbrey equation have been made by numerous researchers to
account for resistance that is attributed to the viscosity and density of the liquid
surrounding the crystal surface. These modifications to the Sauerbrey equation allow
QCM analysis of complex solutions (97, 103, 104).
The standard A-T cut QCM crystal is placed between two electrodes that are
comprised of any conductive metal. Electrodes coated with a thin layer of gold are most
often used because of the low reactivity of the element and its suitability for numerous
attachment chemistries. Biomaterials, or specifically proteins, can be immobilized to the
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gold electrode either through direct adsorption to the surface or through a modification of
the gold surface that provides terminal functional groups for covalent attachment.
Adsorption of the proteins to the surface can involve direct interaction between the
protein and the gold of the electrode (31, 32) or between the protein and a thin polymer
layer such as polystyrene that is applied through spin-coating (105, 106). Direct protein
adsorption to the gold surface occurs throuhg van der Waals interaction or binding
between sulfhydryl groups of amino acid side chains while binding with polystyrene is a
product of hydrophobic forces. Crystal surfaces prepared using the direct adsorption are
often regenerable and stable for extended periods (107).
Covalent attachment of the proteins to the surface can be accomplished following
functionalization of the gold surface with silanes, thiols, sulfides, or even thin reactive
films that will interact with the gold (27). Chemistries to functionalize gold surface using
this reagents are well described in the literature. In addition to these traditional chemical
methods, self-assembly of monomeric subunits on the gold surface has proven quite
successful. Self-assembled monolayers (SAM) consist of organized organic molecules
with various functional groups (silanes, carboxyls, amines) on the gold surface (108). In
this study, a SAM with a terminal carboxyl group was utilized for the attachment of
antibodies to the crystal surface. Following formation of the SAM layer, the target
protein is attached through the formation of an amide bond facilitated by the chemical
cross linker 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) (EDC). This chemical
reaction activates the terminal carboxyl group of the SAM layer and facilitates bond
formation with free amine groups of the target protein. As with non-covalent methods,
proteins can either be attached directly through any number of chemistries or indirectly
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through interaction with a second protein. The indirect method of attachment is
frequently utilized with antibody molecules since orientation of the molecule is critical
for their activity. For this method of attachment, the interaction between protein A and
the Fc domain of immunoglobulins is generally exploited to generate a functional QCM
surface (109-111). Although more complicated to produce, the surfaces formed through
covalent immobilization of proteins offer additional stability to the QCM surface,
particularly if solutions of high ionic strength are analyzed which would display proteins
directly absorbed to the gold surface (27).
The QCM microbalance platform has been utilized for the detection of bacteria (26, 28,
30, 112)

, viruses (113, 114), DNA (115, 116) and countless small –molecule chemical and

biological agents. The QCM-platform is a robust system that can easily be adapted to
different experimental conditions. Sample analysis is based on a simple change in
frequency that can easily be interpreted by end-users. Finally, the device is of limited
complexity, requiring only a crystal, oscillator, and frequency counter and is therefore
amenable to filed-deployment.
Objective of this Study
In recent years there has been a considerable increase in the demand for devices
capable of detecting a range of biological and chemical agents. Although a number of
methods have been developed that are used in a laboratory environment, there is a need
for a device that can easily be deployed and utilized by field agents and first responders.
To be suitable for use by such a diverse group of end-users, a biosensor will have to be of
limited complexity, produce results that are easily interpretable, and is adaptable to an
array of potential targets and applications.
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To satisfy these requirements, a prototype biosensor was constructed that is based on a
quartz crystal microbalance platform. The device was designed to provide an instrument
of limited complexity that can readily withstand the rigors of field conditions and provide
a simple yes/no decision following sample analysis. The detection portion of the
biosensor is based on antigen-antibody interaction to provide high specificity for the
target. Two systems, monoclonal antibody and recombinant antibody production were
examined to determine which method was most suitable to commercialization and able to
satisfy the adaptability requirement of the biosensor.
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CHAPTER III
EXPERIMENTAL PROCEDURES
Routine Apparatus
Solutions and media were prepared from chemicals obtained primarily from Thermo
Fisher Scientific, Sigma Aldrich, or VWR. Chemicals and reagents were weighed using
either a Mettler Toledo Model Ab54-S or PB303-S digital balance. An Orion 720A+
meter and Orion 8102BUWP electrode were used for pH measurements. The meter was
calibrated using a minimum of two control buffers (pH 4.0, pH 7.0, or pH 10.0).
Deionized water was obtained from a Barnstead NANOpure Diamond ultra-filtration
system at measured resistivity of 18.2 M /cm.
Sterilization of media and other solutions was performed using either a Steris Amsco
Lab 250 or a 3031-S autoclave. All bacterial cultures, unless otherwise specified, were
grown at 37 C in either a New Brunswick G24 environmental incubator shaker or a
Series 25 incubator shaker. Bacterial plates were incubated at 37 C in a Fisher Scientific
Isotherm incubator. Short-term storage of plates and cell lysates was accomplished using
a General Electric Hotpoint refrigerator. Precision Microprocessor controlled 280 Series
water bathes were maintained at 37 C and 42 C for restriction enzyme digests and
transformations. A VWR Digital Heatblock was used for higher temperature restriction
digests and protocols requiring elevated temperatures.
Centrifugation of small liquid samples was performed using an Eppendorf tabletop
centrifuge model 5417c. Centrifugation of larger culture volumes, phage preparations,
and other separations were accomplished using Beckman Avanti Model J-26 XP or J301centrifuges and either JA 25.50 or JLA 16.250 rotors. Separation of the Pseudomonas
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aeruginosa outer membrane proteins was accomplished using a Beckman L7-65
ultracentrifuge and JS 24.38 rotor. Low speed centrifugation of intermediate scale cell
cultures and solutions was executed using a Damon Sorvall IEC HN-SII clinical
centrifuge.

Buffers and Solutions
Antibiotics
Ampicillin
Prepared at stock concentrations of 100 mg/ml in sterile water.
Working concentration - 100 g/ml
Carbenicillin
Prepared at stock concentrations of 100 mg/ml in sterile water.
Working concentration – 100 g/ml
Kanamycin
Prepared at stock concentrations of 50 mg/ml in sterile water.
Working concentration – 50 g/ml
Tetracycline
Prepared at stock concentrations of 5 mg/ml in 70% ethanol.
Working concentration – 10 g/ml
Gentamicin
Obtained as a solution at a concentration of 50 mg/ml

Chromatography Buffers
DEAE Affi-gel blue
Buffer A
20 mM Tris-HCl (pH 7.2)
28 mM NaCl
Buffer B
20 mM Tris-HCl (pH 7.2)
0.6 M NaCl
Buffer C
20 mM Tris-HCl (pH 8.0)
1.4 M NaCl
Protein G
Column buffer
20 mM Na2HPO4 / NaH2PO4 (pH 7.0)
Elution buffer
0.2 M glycine-HCl (pH 2.5)
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Nickel – nitrilotriacetic acid (Ni2+-NTA)
Lysis buffer
50 mM Na2HPO4 / NaH2PO4 (pH 6.0)
100 mM NaCl
10% glycerol
1 mg/ml hen egg white lysozyme
1:20 dilution of B-PER II bacterial protein extraction reagent
Buffer A
50 mM Na2HPO4 / NaH2PO4 (pH 6.0)
300 mM NaCl
10% glycerol
25 mM imidazole
1 mM PMSF/PTSF
Buffer B
50 mM Na2HPO4 / NaH2PO4 (pH 4.0)
1.5 M NaCl
10% glycerol
25 mM imidazole
1 mM PMSF/PTSF
Elution buffer
50 mM Na2HPO4 / NaH2PO4 (pH 6.0)
300 mM NaCl
10% glycerol
250 mM imidazole
1 mM PMSF/PTSF
Denaturing Ni2+-NTA chromatography
Denaturing buffer
6 M guanidinium hydrochloride
20 mM sodium phosphate (pH 7.8)
500 mM NaCl
Buffer A
8 M urea
20 mM sodium phosphate (pH 7.8)
500 mM NaCl
Buffer B
8 M urea
20 mM sodium phosphate (pH 6.0)
500 mM NaCl
Buffer C
8 M urea
20 mM sodium phosphate (pH 4.0)
500 mM NaCl
250 mM imidazole
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Colony Lysis Buffer
0.2 % (v/v) Triton X-100
1 mg/ml RNAse A
Plasmid DNA Extraction (Alkaline Lysis)
Solution I
50 mM glucose
25 mM Tris-HCl (pH 8.0)
10 mM EDTA (pH 8.0)
Solution II
0.2 N NaOH
1 % w/v Sodium dodecyl sulfate
Always prepare fresh
Solution III
4 M sodium acetate
Add glacial acetic acid to a pH of 4.8
Resuspension solution
0.25 M sodium acetate pH 5.2
1 mM EDTA
RNA Extraction
DEPC water for RNA extraction
0.2 ml of diethyl pyrocarbonate
100 ml deionized water
Shake rigorously then autoclave
Mammalian cell lysis solution
50 mM Tris pH 8.0
100 mM NaCl
5 mM MgCl2
0.5% (v/v) Nonidet P40
Osmotic Shock Buffer
500 mM sucrose
100 mM Tris-HCl (pH 8.0)
1 mM EDTA
Phosphate Buffer Saline (PBS)
137 mM NaCl
2.7 mM KCl
4.3 mM Na2HPO4
1.4 mM KH2PO4
5X Phage Precipitation Solution
20% (w/v) PEG 8000
15% (w/v) NaCl
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SDS-PAGE Gel Preparation Solutions
1.5 M Tris-HCl (pH 8.8)
0.5 M Tris-HCl (pH 6.8)
10% (w/v) SDS
40% acrylamide: Bisacrylamide, 29:1
TEMED (N,N,N',N'-Tetramethylethylenediamine)
10% (w/v) ammonium persulfate
4X SDS-PAGE Loading Buffer
200 mM Tris-HCl (pH 6.8)
40% (v/v) glycerol
8% (w/v) SDS
10% (v/v) 2-mercaptoethanol
SDS-PAGE Running Buffer
25 mM Tris base
192 mM glycine
1% (w/v) SDS
Tris Borate EDTA Buffer (TBE)
89 mM Tris base
89 mM boric acid
2 mM EDTA (pH 8.0)
Tris EDTA Buffer (TE)
10 mM Tris-HCl (pH 8.0)
1 mM EDTA
autoclave prior to use
Transfer Buffer (Immunoblotting)
25 mM Tris base
192 mM glycine
20% (v/v) methanol

Media
Dulbecco’s Modified Eagle Medium Modified for Bioreactors (DMEM)
1x DMEM high glucose
4.00 mM L-glutamine
4500 mg/L glucose
without sodium pyruvate
10% low IgG Fetal bovine serum
Gentamicin diluted to a final concentration of 100 g/ml
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Luria-Bertani (LB)
10 g/L bacto tryptone
5 g/L yeast extract
10 g/L NaCl
for solid media 15 g/L of agar (1.5% w/v) is added prior to autoclaving
for top agar (phage titering) 7.5 g/L of agar (0.75% w/v) is added prior to autoclaving
Superbroth (SB)
30 g/L bacto tryptone
20 g/L yeast extract
10 g/L MOPS (pH 7.0)
Super Optimal Broth (SOB)
20 g/L bacto tryptone
5 g/L yeast extract
0.5 g/L NaCl
After autoclaving add:
10 ml of filter-sterilized 1M MgCl2
10 ml of filter-sterilized 1M MgSO4
Super Optimal Broth with Catabolite Repression (SOC)
20 g/L bacto tryptone
5 g/L yeast extract
0.5 g/L NaCl
After autoclaving add:
10 ml of filter-sterilized 1M MgCl2
10 ml of filter-sterilized 1M MgSO4
10 ml of filter-sterilized 40% glucose

Standard Protocols
Unless otherwise stated, the following methods were employed during standard
experiments. Deviations from these protocols will be described in the appropriate
sections.
Isolation of plasmid DNA
Plasmid DNA was isolated from Escherichia coli TOP10 cells (Invitrogen) or c2925
(dcm-/dam-) cells (NEB) primarily with the Zippy Plasmid Miniprep kit (Zymo
Research) according to the manufacturer’s protocol.
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Large-scale plasmid isolation for construction of the phage display libraries utilized
an alkaline lysis protocol (117). A 50 ml E. coli culture grown in Luria Bertani media (LB)
containing the appropriate antibiotics was transferred to a 250 ml polypropylene bottle
and centrifuged at 5,000 x g in a JLA16.25 rotor. The supernatant was decanted and the
pellet resuspended in 2 ml of alkaline lysis solution I. A 3 ml volume of solution II was
added to the resuspension to facilitate cell lysis. The bottle was gently rolled to mix the
contents and then incubated at room temperature for 5 min. Lysis was neutralized with
2.5 ml of solution III. The sample was incubated for 5 min on ice then centrifuged at
15,000 x g for 15 min at 12 – 13 C in the JLA16.25 rotor. The supernatant was then
transferred to a 30 ml polypropylene screw-top tube and placed on ice. The nucleic acids
were extracted from the supernatant with an equivalent volume of a phenol: chloroform
mixture (1:1). The solution was vortexed, then centrifuged at 7,700 x g in a JA25.50 rotor
for 10 min. The upper aqueous phase was transferred to a 15 ml conical tube. A half
volume of isopropanol (3.5 ml) was added to the solution, mixed gently by inversion, and
then incubated for a minimum of 10 min at room temperature. Precipitated nucleic acids
were pelleted by centrifugation at 7,700 x g for 10 min at 4 C in a JA 25.50 rotor. The
supernatant was discarded and the pellet air-dried. To remove RNA, the pellet was
dissolved in 1 ml of resuspension solution containing RNase A at a final concentration of
25 g/ml. The solution was incubated for 30 min at 37 C in a water bath. Remaining
protein contaminants were removed with a second phenol: chloroform extraction,
followed by centrifugation at 1,000 x g in a Damon-Sorvall IEC HN-SII clinical
centrifuge for 10 min. The aqueous phase was transferred to a 1.5 ml microcentrifuge
tube, 0.5 ml of isopropanol was added and the sample was incubated for 10 min at room
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temperature. Precipitated plasmid DNA was pelleted by centrifugation at 10,600 x g and
4 C in an Eppendorf centrifuge for 10 min. The supernatant was decanted, the pellet air
dried and then resuspended in 100 l of sterile water. Plasmid DNA was quantitated
using a Nanodrop ND-1000 spectrophotometer.
Resolution of DNA via Electrophoresis
For large DNA molecules, agarose gels (0.8 – 1.0% (w/v)) were prepared using
certified molecular biology grade agarose (Bio-Rad) dissolved in 1 x Tris Borate EDTA
(TBE) buffer using a Sharp Carousel microwave. An International Biotechnologies
Model MPH apparatus with a 120 cm3 gel slab or a Continental Lab Products, Inc. Model
75.710 apparatus with a 60 cm3 gel slab were routinely used for gel electrophoresis. A
Bethesda Research Laboratories Life Sciences, Inc. Model 250 power supply was used
for all experiments. Diagnostic gels were resolved at 150 V for 60 min unless otherwise
stated. A standard 10x endostop solution was diluted to a final 1x concentration for gel
loading. DNA standards were either Promega 1Kb DNA ladder (G5711), New England
Biolabs (NEB) 1 Kb ladder (N3232), NEB 100 bp ladder (N3231), or NEB PCR marker
(N3234). Gels were stained for 10 min in ethidium bromide (0.5 g/ml), washed briefly
in deionized water then visualized using either an Alpha Innotech alphaimager or a
Versadoc 4000 MP system (Bio-Rad).
Restriction Enzyme Digestion
DNA was digested with an assortment of restriction endonucleases for either cloning
or diagnostic purposes. Enzymes BamHI, EcoRI, KpnI, HindIII, SacI, SpeI, XbaI, and
XhoI were acquired from New England Biolabs. Digests were generally conducted in 0.5
ml tubes for volumes of 20 - 50 l. Reactions consisted of 500 ng of plasmid DNA, the
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appropriate buffer supplied by the manufacturer, BSA diluted to a final concentration of
0.1 mg/ml, and 10 U of enzyme. The aforementioned enzymes were incubated for 2 - 3 h
at 37 C in a water bath. For the restriction enzyme SfiI (Roche Diagnostic Laboratories),
the 50 C incubation was maintained for 3 - 5 h.
Isolation of DNA Fragments Using Agarose Gel Extraction
Restriction digest and PCR products were resolved by agarose gel electrophoresis.
The ethidium bromide stained gel was transferred to a Vilber Lourmat Model TFP-M/WL
transilluminator where the appropriate band was excised using a razor blade. The gel
slice was transferred to a 1.5 ml microfuge tube and weighed using a Mettler Toledo
digital balance. The Zymoclean Gel DNA Recovery Kit (Zymo Research) was used
according to the manufacturer’s protocol.
DNA Ligation and Transformation of Chemically Competent E. coli
DNA ligations were conducted in 0.5 ml tubes at room temperature for 3 h unless
otherwise stated. The 10 l reaction contained T4 DNA ligase buffer (50 mM Tris-HCl
(pH 7.5), 10 mM MgCl2, 1 mM ATP, and 10 mM dithioreitol), 100 ng of DNA, and 20 U
of T4 DNA ligase (NEB). The pCR Blunt II TOPO ligation reaction was assembled
according to the manufacturer’s protocol with 1 l of vector DNA, 4 l of PCR product,
and 1 l of the manufacturer supplied salt solution (1.2 M NaCl, 0.06 M MgCl2). The
reaction was incubated at room temperature for 20 min prior to transformation of
chemically competent E. coli cells.
A variety of chemically competent E. coli cells were used for transformation of
ligation products (see Appendix). Typically, 5 l of the T4 ligation reaction or 3 l of the
pCR Blunt II TOPO ligation reaction were combined with 12.5 - 25 l of chemically
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competent cells in a 3 ml polypropylene tube. The suspension was placed on ice for 30
min then subjected to a 30 - 45 s heat shock at 42 C. The tubes were immediately
returned to ice for 2 min. A 300 l aliquot of room temperature Super Optimal with
Catabolite-repressor (SOC) media was added to the cells, which were then transferred to
a 37 C shaker incubator for 1 h. Aliquots of this culture were then plated to selective
media to identify clones containing the ligation product.
Rapid Analysis of Transformants (Colony Lysis)
A small portion of an individual colony was transferred to a 0.5 ml microfuge tube
containing 3 l of sterile water and 8 l of colony lysis buffer using a sterile 20 - 200 l
pipette tip. The cells were suspended in the lysis solution by vigorous mixing with the
pipette tip. The microfuge tubes were then heated at 100 C for 30 – 60 s to lyse the cells.
The samples were cooled on ice for 2 min prior to the addition of 4 l of restriction
enzyme mix (1.4 l of appropriate NEB buffer, 0.14 l of 100X BSA, 10 U of enzyme
(0.5 l), 2 l of sterile water). The reactions were incubated at 37 C for 1 h prior to
separation of digestion products using agarose gel electrophoresis.
SDS-PAGE and Immunoblotting
Protein concentration was determined using a bicinchoninic acid (BCA) assay (118).
Absorbance measurements at 562 nm were made using a Beckman Coulter DU 800
spectrophotometer. Protein samples were separated electrophoretically by sodiumdodecyl sulfate polyacrylamide gels (SDS-PAGE) using a 12% acrylamide 1.0 mm gel
and a Mini-protean 3 system (Bio-Rad). Electrophoresis was conducted at 100 V for 90
min. For visualization of the protein bands, the gel was first washed for 1 h in distilled
water then stained for an additional 1 h using Gel Code Blue reagent (Thermo Fisher
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Scientific). The staining solution was removed and replaced with an excess of distilled
water to destain the gel overnight. The Versadoc 4000MP was used for image capture.
Immunoblot analysis of separated protein samples was accomplished following initial
transfer from the acrylamide gel to a 0.45 m nitrocellulose membrane using a Mini
Transfer-Blot cell (Bio-Rad). Transfer was conducted at 4 C and 100 V for 90 min in
transfer buffer. The nitrocellulose membrane was blocked with a PBS-0.1% triton x-100
(v/v) containing 5% low fat dried milk solution for a minimum of 1 h. The blocking
solution was decanted and replaced with a solution of the same composition that
contained the primary antibody of appropriate dilution. After an hour incubation with the
primary antibody, the membrane was subjected to wash steps consisting of an initial wash
with PBS containing 0.1% triton x-100, then with the blocking solution, and then
followed again with the PBS-triton solution. The secondary antibody was diluted in
blocking solution and incubated with the membrane for 1 h. The secondary antibody was
then decanted and the wash steps were repeated. Antibody binding was visualized either
with a Nitro-Blue Tetrazolium Chloride and 5-Bromo-4-Chloro-3'-Indolyphosphate pToluidine Salt (NBT/BCIP Pierce) substrate for alkaline phosphatase-conjugated
secondary antibodies, or a Supersignal WestPico chemiluminescent substrate (Thermo
Fisher Scientific) for secondary antibodies with a horseradish peroxidase (HRP)
conjugate.
Some immunoblots were visualized by exposing X-ray film to light emitted from
HRP-conjugated antibodies and chemiluminescent substrate. Following a standard
immunoblotting protocol, the nitrocellulose membrane was sealed in Saran wrap then
placed, protein side up, in a light-sealed exposure cassette. A piece of Kodak Scientific
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Imaging Film was placed on top of the nitrocellulose membrane and exposed for 30 s to
10 min. The film was removed and developed in Kodak developer and fixer reagents.
Images of the developed film were scanned using either the Alpha Innotech or Versadoc
instruments.
Live and heat-killed bacterial samples were immobilized to nitrocellulose
accomplished using a Minifold 96 well dot blot apparatus (Schleicher & Schuell, Inc.) or
a 48 well slot blot apparatus (Bio-Rad). This protocol was employed for assays that
examined monoclonal antibody or scFv activity against bacterial targets. Bacteria were
suspended in PBS and immobilized on the nitrocellulose membrane using a vacuum
aspiration connection to a laboratory sink. Following complete aspiration of liquids from
individual wells, the membrane was removed and allowed to air dry. The membrane was
then developed as described for the immunoblot protocol. Visualization of monoclonal
antibody or scFv binding was accomplished with alkaline phosphatase or HRPconjugated secondary antibodies as detailed above.
Isolation of Outer Membrane Proteins from Pseudomonas Species
The method for isolation of outer membrane proteins was modified from the work of
Hancock et al. (119-121) and Schnaitman et al (122). A 50 ml overnight culture of
Pseudomonas aeruginosa in LB media was transferred to a 250 ml polypropylene bottle
and centrifuged at 15,000 x g and 4 C for 15 min to pellet the cells. The cells were
washed three times in 30 mM Tris-HCl (pH 8.0) buffer to remove residual media. The
final cell pellet was resuspended in 20 ml of 30 mM Tris-HCl (pH 8.0) buffer, 20%
sucrose (w/v), 1 mg/ml DNase I and 1 mg/ml RNase A. The cells were broken by three
passes of the suspension through a French pressure cell at 16,000 psi. Additional lysis

36

was ensured with the addition of 2 mg of chicken egg white lysozyme and a 10 min
incubation on ice. The lysate was transferred to a 50 ml conical tube and the cell debris
pelleted at 1,000 x g for 20 min.
The supernatant was transferred to a new tube and diluted with a 14 ml volume of the
30 mM Tris-HCl (PH 8.0), 20%sucrose buffer. A step gradient was prepared with a 14 ml
layer of 70% (w/v) sucrose and 14 ml of 60% (w/v) sucrose in a Beckman 40 ml
polycarbonate ultracentrifuge tube. A 10 ml volume of the cell lysate was carefully
layered atop the sucrose gradient and fractionated by centrifugation using a Beckman L7
ultracentrifuge with a JS 24.38 rotor. Centrifugation was conducted for 5 h at 104,000 x g
and 4 C. Distinct regions of separated material were identified, based on color and
turbidity, and transferred and to new tubes.
Hybridoma Maintenance
Murine hybridoma cultures, Ma1-6 (ATCC CRL-1783) and Ma7-4 (Mansel Griffith,
the University of Toronto), were continuously maintained in Falcon tissue culture flasks
in a Sheldon Manufacturing Reach-In dry CO2 incubator at 37 C in an atmosphere
supplemented with 8% CO2. The cultures were grown in Dulbecco’s Modified Eagle
Medium (Hyclone) supplemented with 100 g / ml of gentamicin (Gibco), 2 mM Lglutamine (Gibco), and 5 - 20% low IgG fetal bovine serum (Hyclone) depending upon
the health of the culture. The culture was passaged into successively larger volumes
(12.5 cm3, 75 cm3, 150 cm3) until a maximum cell density and viability suitable for
inoculation of a bioreactor was reached.
Cell viability was determined by a direct count of viable cells using a Fisher Scientific
hemacytometer and a trypan blue stain (Gibco). Confluent cells were dislodged from the
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T-flask by forcibly striking the bottom of the T-flask several times with the palm of the
hand. A 20 l volume was then transferred aseptically to a 0.5 ml microcentrifuge tube
that contained 20 l of 0.4% trypan blue and 40 l of sterile PBS. A 10 l aliquot of this
solution was transferred to the hemacytometer for a direct count of viable hybridoma
cells. The ratio of live unstained to dead cells (blue) was calculated to determine the
viability of the culture. The approximate cell density could be derived from the number
of viable cells. Cultures were maintained at greater than 80% viability and a cell number
of approximately 1x105 cells/ml. Cultures that demonstrated lower than 80% viability
were supplemented with a higher percentage of FBS to invigorate the culture.
In addition to growth in T-Flasks, hybridoma cultures were also maintained in a
hollow-fiber bioreactor (Fibercell Systems). Hybridomas were grown in either a medium
polyurethane 20 kDa MWCO cartridge capable of supporting cell cultures of
approximately 109 cells/ml, or a large polyurethane 5 kDa MWCO cartridge capable of
supporting cultures of approximately 1011 cells/ml. The high cell densities of the
bioreactors were attained by a steady supply of nutrients provided by both a circulating
medium that passed through the intercapillary space (ICS) and serum rich medium that
filled the extra-capillary space (ECS) in which the cell culture was maintained.
Measurement of the glucose levels within the ICS medium guided the rate of ECS
harvest and ICS medium replacement. A glucose assay reagent kit (Sigma) containing
ATP, oxidized NAD, hexokinase and glucose-6-phosphate dehydrogenase was used to
calculate the approximate amount of glucose in the ICS media. The enzymatic reaction
produces reduced NADH, which could be quantitated by measuring the absorbance at
340 nm in a Beckman Coulter DU800 spectrophotometer. For determination of glucose
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concentration, a 1 ml aliquot was aseptically removed from the ICS medium and diluted
three-fold in sterile water. A 20 l aliquot of this dilution was added to 600 l of the
glucose assay reagent and incubated at room temperature for 15 min. The absorbance
value at 340 nm was determined for samples and controls consisting of the reagent only
and the unused DMEM medium. The concentration of glucose in the sample medium was
determined using the Beer-Lambert law. The ICS medium was exchanged when the
glucose concentration dropped below 2.25 mg/ml, which is half the initial concentration
in the DMEM. The antibody-containing ECS medium was exchanged every second day
during periods of optimal growth.
Monoclonal Antibody Purification
DEAE Affi-gel blue purification. DEAE Affi-gel blue purification of monoclonal
antibody required an initial ammonium sulfate precipitation step to remove a substantial
portion of the BSA and contaminating serum proteins. A saturated ammonium sulfate
solution, 5.8 M (NH4)2SO4 (pH 7.4), was added slowly to an equal volume of ECS
medium while stirring at 4 C to obtain a 50% saturated solution. After 30 - 60 min at
4 C the solution was transferred to 250 ml screw-top bottles (Nalgene) and centrifuged at
10,000 x g. The supernatant was decanted and the pellet washed 2 - 3 times with a 50%
saturated (NH4)2SO4 solution with centrifugation as above between each wash. The final
pellet was resuspended in 20 mM Tris-HCl (pH 7.2) and dialyzed in 12,000 - 14,000
MWCO dialysis tubing in 4 L of the same buffer for 3 – 4 h with a minimum of two
buffer exchanges. Following dialysis, the pH was adjusted to pH 7.2 using either 1 M
HCl or 1 M NaOH.
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The DEAE Affi-gel blue matrix was prepared following the manufacturer’s protocol
to remove unbound dye material. The resin was slowly transferred to a 2.5 x 10 cm
Econo glass column (Bio-Rad) until a bed volume of approximately 5 ml was established.
A 2.5 cm flow adapter was attached to the column and connected to a Biologics
Workstation (Bio-Rad). The column matrix was equilibrated with a minimum of ten bed
volumes of Buffer A prior to loading of the dialyzed sample at a constant flow rate of 1.0
ml/min. The column was washed with a minimum of ten bed volumes using Buffer A to
remove non-bound proteins. To elute the monoclonal antibody, a three stage salt gradient
was used. The optimized protocol is shown in Table 1.

Table 1 – DEAE Affi-Gel Blue Purification Protocol
Volume

Salt concentration

Fraction size

Elution

10 ml isocratic flow

0.03 M

1.25 ml

None

60 ml gradient

0.03 – 0.08 M

1.25 ml

Antibody

30 ml gradient

0.08 – 0.13 M

1.25 ml

BSA

30 ml gradient

0.13 – 0.60 M

1.25 ml

Transferrin

Protein G purification. Monoclonal antibody purification was conducted using a
pre-packed Hi-Trap Protein G affinity column and Bio-Rad Econo gradient system. The
Bio-Rad apparatus included a Model EP-1 Econo pump, a model EM-1 UV monitor, and
a model EG-1 gradient monitor. Protein concentrations were monitored as UV
absorbance that was recorded using a LKB Bromma 2210 2-channel recorder.
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The Hi-Trap column was first equilibrated with 10 bed volumes of column buffer at a
flow rate of 1.0 ml/min. The column was washed with a minimum of 10 bed volumes of
column buffer after sample loading, until a baseline absorbance value (280 nm) was
reached. The IgG antibody was eluted in the first several collected fractions with a 0.2 M
glycine-HCl (pH 2.5) solution at a flow rate of 3 ml/min. Elution fractions that contained
protein based on absorbance measurement were pooled together and dialyzed in 4 L of
PBS (pH 8.0).
Murine scFv Construction
A 10 ml volume of cell suspension was removed from a confluent Ma1-6 T-Flask and
transferred to a 15 ml Falcon screw-top tube. Cells were centrifuged at 300 x g in a
Damon IEC HN-SII clinical centrifuge for 5 min at room temperature. The supernatant
was decanted and the cell pellet washed three times with ice-cold PBS (pH 7.4).
Following the final wash, the cells were resuspended in 375 l of ice-cold lysis buffer
and incubated 5 min on ice to promote lysis. The lysate was transferred to 1.5 ml
microfuge tubes and centrifuged at 21,000 x g at 4 C for 2 min. The supernatant was
transferred to a new tube and 4 l of 20% SDS added (final concentration 0.2%). The
sample was vortexed for 30 seconds. Proteinase K was added to a final concentration of
125 g/ml and the tube was transferred to a 37 C water bath for 15 min. A phenol:
chloroform: isoamyl alcohol (25:24:1) extraction was performed, followed by a
chloroform: isoamyl alcohol (24:1) extraction . An ethanol precipitation using DEPCtreated 3M sodium acetate (pH 5.2) and two volumes of absolute ethanol was stored
overnight at -20 C. The sample was centrifuged at maximum speed (21,000 x g) for 15
min at 4 C. The supernatant was decanted and the pellet washed with 1 ml of 75%
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ethanol and 25% 0.1 M sodium acetate (pH 5.2). The sample was again centrifuged, the
pellet dried, and finally resuspended in 100 l of DEPC-treated water. The purified RNA
was converted to cDNA using the iScript cDNA synthesis kit (Bio-Rad) and the
manufacturer’s protocol.
Amplification of the heavy and light chain variable domain gene was accomplished
using a standard reaction mixture and combinations of forward and reverse primers
obtained from the literature (67). The PCR reaction consisted of 1x Pfu turbo buffer (20
mM Tris-HCl (pH 8.8), 2 mM MgSO4, 10 mM KCl, 10 mM (NH4)2SO4, 0.1% Triton X100, 0.1 mg/ml nuclease-free BSA), 0.5 M of both the forward and reverse primer, 125
M of each dNTP (dATP, dCTP, dTTP, and dGTP), 2 U of Pfu Turbo polymerase
(Stratagene), 50 ng of cDNA, and sterile water to a final volume of 20 l. Reactions were
performed in a 0.2 ml thin-walled PCR tube in a Bio-Rad MyCycler thermocycler with
gradient capabilities. Annealing temperatures varied greatly for the heavy chain reactions,
therefore the gradient function of the thermocycler was employed to ensure optimal
temperature for each primer combination. The standard reaction consisted of 30 cycles;
95 C for 30 s, 48-59 C for 30 s, and 72 C for 30 s. A final elongation cycle of 72 C for
10 min and a hold at 4 C was also included in each thermocycler program.
Heavy and light chain variable domain genes were combined into a single fusion gene
using an overlap extension PCR (oePCR) (Figure 5). The scFv template was generated in
the first five rounds of PCR in which no primers were present and the complementary
regions of the linker region served to initiate amplification. Exponential amplification
began in cycle six, after primers for the 5’ and 3’ ends were added. The reaction was
assembled as previously described with an equivalent quantity, 25 ng, of the heavy and
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light chain DNA included as template. An initial hot start cycle of 95 C for 3 min was
followed by 5 cycles of 95 C for 60 s, 70 C for 60 s, and 72 C for 90 s. The forward and
reverse primers heavy1-6F and kappa1-6R were added to a final concentration of 0.5
M each. An additional 25 cycles of 95 C for 60 s, 65 C for 60 s, and 72 C for 90 s
were conducted. The final elongation cycle and temperature hold were as previously
described.

Figure 5. Single Chain Fv Antibody Construction
Schematic representation of the PCR construction of an scFv molecule. The
initial heavy and light variable domain genes are isolated from a cDNA pool.
Primers are designed to generate complementary overhanging regions to
facilitate gene fusion and to create unique restriction enzyme cleavage sites for
subsequent cloning reactions.
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Preparation of B. thuringiensis Cells for Rabbit Immunization
A 3 ml culture of B. thuringiensis was grown in LB media at 30 C overnight and used
to inoculate a 500 ml culture. The optical density of the culture was assessed periodically
until the cells reached an OD600 = 0.1. The cells were pelleted via centrifugation and
resuspended in PBS (pH 7.4) three times to remove residual media. A Gram stain was
performed to ensure there was no contamination of the Bacillus culture. A malachite
green stain ensured that the cells were in a vegetative state and spore development had
not begun. The cell pellet was resuspended in a minimal volume of PBS. Formalin was
added to a final concentration of 1.0% and followed by an overnight incubation at 4 C.
The cells were again pelleted and washed repeatedly with PBS solution to remove
residual formaldehyde. Aliquots were plated onto LB media to ensure complete
bactericidal activity of the formalin. Formalin-killed B. thuringiensis were sent to
Cocalico Biologicals, Inc. (Reamstown, PA) for immunization of two rabbits.
Construction of a Rabbit scFv Library
A suitable separate work area was cleaned with RNase Zap (Ambion) to reduce RNA
degradation. Using sterile technique and instruments both autoclaved and treated with
RNase Zap, 200 mg of spleen material was cut and transferred to a 50 ml conical Falcon
tube containing 2 ml of Trizol reagent (Invitrogen). The tissue was homogenized with a
Powergene 700 homogenizer (Fisher Scientific) and the RNA purified with a subsequent
chloroform extraction and isopropanol precipitation. The final pelleted material,
comprised largely of RNA, was resuspended in DEPC-treated water.
Rabbit RNA was converted to cDNA using the SuperScript First Strand DNA
Synthesis Kit (Invitrogen) according to the manufacture’s protocol. Briefly, 2.5 g of
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RNA was combined with dNTP solution (1 mM each dNTP), and 50 ng of oligo-dT
primer in 10 l of DEPC-treated water. The reaction was heated at 65 C for 5 min then
transferred to ice for 1 min. A reaction mixture comprised of buffer (20 mM Tris-HCl
(pH 8.4), 50 mM KCl), 5 mM MgCl2, 10 mM DTT, and 40 U RNaseOUT (recombinant
ribonuclease inhibitor) was added. The reaction was incubated at 42 C for 2 min before
50 U SuperScript II Reverse Transcriptase was added to the reaction. The sample was
incubated first at 42 C for 50 min, then at 70 C for 15 min. The reaction was allowed to
cool on ice before 2 U RNase H were added and the sample incubated 20 min at 37 C to
remove residual RNA.
The heavy and light chain variable domain gene sequences were amplified using all
possible primer combinations obtained from the literature (57) and cross referenced with
the known sequences within the Kabat publications (123). PCR was conducted in 0.2 l
thin-walled PCR tubes using a the MyCycler thermocycler and the Expand High Fidelity
PCR system (Roche). The PCR reaction consisted of 300 – 500 ng of cDNA, Expand
High Fidelity Buffer 2 (proprietary), 0.2 M of each dNTP, 0.1 M each primer, and 3.5
U of Roche High Fidelity Enzyme Mix (Taq and Tgo DNA polymerases). Reactions were
subjected to an in initial hot start cycle of 95 C for 5 min followed by amplification for
25 cycles with parameters of 95 C for 30 s, 50 C for 30 s, and 72 C for 60 s. A 10 min
elongation cycle at 72 C and a 4 C cycle concluded amplification.
Gel purified heavy and light chain genes were combined using an oePCR reaction as
previously described. The thermocycler parameters for gene fusion included an initial hot
start cycle at 95 C for 4 min, followed by 5 cycles of 95 C for 45 s, 45 C for 30 s, and
72 C for 2 min to form the scFv template. Exponential amplification was conducted for
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30 cycles with parameters of 95 C for 45 s, 55 C for 30 s, and 72 C for 2 min. The
reaction was concluded with the standard elongation cycle and temperature hold.
Library Transformation (Electroporation)
Electroporation of electrocompetent E. coli XL1-Blue (Stratagene) was used for
transformation of the scFv library prior to phage display. A Bio-Rad Gene Pulser, 0.2
mm electroporation cuvettes and parameters of 25 F, 2.5 Kv, and 200

were used for

electroporation. A 100 l aliquot of electrocompetent cells was used for each individual
transformation reaction. Immediately following electroporation, 1 ml of super optimal
broth with catabolite repressor (SOC) was added to the cuvette and the cells transferred to
a 50 ml conical tube. The cuvette was washed two additional times with 2 ml of SOC to
complete transfer of the cells. The cells were allowed to recover for 1 h at 37 C before 10
ml of SB medium containing 20 g/ml carbenicillin and 10 g/ml tetracycline were
added. A 2 l aliquot was removed, diluted 1:100, and plated onto selective medium to
determine the ligation and transformation efficiency. The liquid culture was grown an
additional h at 37 C before being transferred to a 500 ml baffled flask containing 183 ml
super broth (SB) medium with the selection antibiotics. A 2 ml volume of VCSM13
helper phage was added to the culture to induce phage production, which proceeded
overnight at 30 C.
Transformation of the naïve rabbit library was accomplished using the highlyelectrocompetent E. coli strain SS320 prepared through bacterial mating of E. coli strains
MC1061 and XL1- Blue according to the methods of Sidhu et al. (124). Electroporation
was conducted using the same parameters in a BTX Electro Cell Manipulator Model
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ECM630 apparatus. Electrocompetent cells XL1-Blue and SS320 cells were prepared
according to Barbas III et al. (57).
Production of Helper Phage
The VCSM13 helper phage (Stratagene) was used to induce production of the scFvphage fusion during the biopanning process and for phage ELISA. Phages were prepared
according to Barbas III et al (57) and stored as 50 ml aliquots in SB medium at 4 C. Direct
counts of plaque forming units and spectrophotometric absorbance measurements at 270
nm were conducted for quantitation (125).
Library Amplification
Prolonged storage at 4 C can lead to loss of scFv activity through denaturation or
cleavage of the scFv from the pIII phage protein. The scFv library was, therefore,
reamplified prior to any biopanning experiment to ensure that phage displayed active
scFvs. The following protocol is only slightly modified from the methods of Barbas III et
al. (57).
An aliquot of SB medium (3 ml) containing tetracycline was inoculated with 100 l of
XL-1 Blue from glycerol stocks. The culture was grown for 3 – 5 h at 37 C until an
OD600 = 1.0 was reached. A 2 ml volume of this culture was removed and transferred to a
50 ml conical screw-top tube and then inoculated with a 50 l aliquot of a biopanning or
library phage preparation followed by a 15 min incubation at room temperature. A total
of 6 ml of SB medium containing 25 g/ml carbenicillin and 10 g/ml tetracycline was
added to the culture. A 2 l aliquot was removed and added to 198 l of SB medium; of
this dilution, 100 l, 10 l, and 1 l volumes were plated onto selective medium to
determine efficiency of infection. The remaining 8 ml culture was incubated for 1 h at
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37 C at which point additional carbenicillin was added to adjust the final concentration to
100 g/ml. The culture was incubated another hour at 37 C. To induce phage production,
the 8 ml culture was transferred to 91 ml of SB medium containing antibiotics and 1 ml
of 1013 cfu/ml VCSM13 bacteriophage in a 500 ml baffled flask. The culture was grown
overnight at 30 C to allow phage propagation.
The overnight culture was transferred to a 250 ml polypropylene bottle and
centrifuged at 4000 x g for 15 min at 4 C. The supernatant was transferred to a new 250
ml bottle to which 25 ml of a 5X Polyethylene glycol 8000/NaCl was added. The solution
was mixed for several minutes then incubated on ice for a minimum of 30 min. The
precipitated phages were pelleted at 15,000 x g for 30 min at 4 C. The supernatant was
decanted and the bottle inverted on paper towels for 10 min to allow excess media to
drain. The sides of the bottle were gently washed with 2 ml of PBS containing 1% BSA
to recover the phage. This solution was transferred to a 1.5 ml microfuge tube and
centrifuged at 21,000 x g and 4 C for 5 min to pellet debris. The supernatant was
transferred to a new 2 ml tube for biopanning.
Selection of Target-Specific scFv (Phage Display)
Target bacteria were pelleted from an overnight culture at 6,000 x g in an Eppendorf
benchtop microcentrifuge. The cell pellet was resuspended in 1 ml of PBS (pH 7.4) then
washed and centrifuged three times to remove residual media. Following the final wash
step, the optical density (OD600) was measured as previously described.
Bacteria were diluted from the washed overnight cells to an OD600 = 1.0 in PBS
buffer. A 100 l aliquot was transferred to a 96 well Costar high binding polystyrene
microtiter plate, sealed with a mylar sheet, then incubated at 37 C for 1 h . The plate was
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washed two times with water to remove non-bound bacteria, sample wells were filled
with PBS containing 3% BSA for 1 h at 37 C to block any remaining binding sites of the
microtiter plate and limit non-specific phage recovery. The initial round of biopanning
required four such wells of target bacteria, while all subsequent rounds required only two
wells.
The standard phage display protocol followed the methods of Barbas III et al. (57).
Briefly, 50 l of a newly prepared phage preparation were added to each of the wells
containing the immobilized bacterial target. The plate was again sealed and incubated at
37 C for 1 h. The non-bound phages were then discarded and 150 l of PBS containing
0.5% Tween 20 were added to each of the wells. The solution was mixed using an
Ovation multi-channel pipette programmed to mix 100 l volumes five times. The plate
was left at room temperature for 5 min before the wash solution was discarded. The
washes were repeated five times in the first two rounds then ten times in the last two
rounds of biopanning. Following the last set of washes 50 l of 0.2 M glycine-HCl (pH
2.5) was added to each well to elute bound scFv-phage from the immobilized bacteria.
The solution was mixed ten times then transferred to 2 l of 1.5 M Tris-HCl (pH 8.8) to
neutralize the solution. A 2 ml aliquot of XL1-Blue culture (OD600 = 1.0) was inoculated
with the phage elution and incubated at room temperature for 15 min to allow phage
infection. The scFv pool was then amplified overnight as described above (library
amplification).
Specificity of scFvs for target bacteria was improved using a negative selection
protocol during biopanning. These experiments were conducted as described above with
a slight modification to remove those scFv that recognized conserved epitopes of non49

target bacteria. In rounds three and four of biopanning, the phage preparation was
incubated first with immobilized non-target bacteria for 1 h using the aforementioned
microtiter plate method. The sample was then mixed five times using a micropipetter to
dislodge loosely bound phage particles. The non-bound phages were then transferred to a
second well of the microtiter plate that contained the target bacteria and incubated for 1 h
at 37 C. The standard protocol for plate washes and amplification of target-specific scFvphage was applied as described. The negative selection protocol was performed a
minimum of two times before examination of individual clones.
The efficiency of scFv binding during the biopanning was examined at each round of
selection. Following the addition of 6 ml SB medium containing antibiotics, a 2 l
aliquot of the phage amplification culture was removed and transferred to 198 l of SB
(1:200 dilution). Aliquots of 1 l, 10 l, and 100 l respectively, were plated onto
selective medium to determine the phage output in terms of cfu/ml. Additionally, the
approximate number of phages initially used for biopanning was determined by plating
dilutions of the phage preparation. Aliquots (2 l) of the phage preparation used for
biopanning were diluted in SB medium by factors of 107, 108, and 109, respectively, and
then used to infect a 100 l of XL1-Blue culture (OD600 = 1.0). A 51 l aliquot of each
culture was plated immediately onto selective medium. The percentage of bound phage
was determined from a direct count of cfu on both the biopanning output and phage input
(107 -109 dilutions) plates.
Assessing Biopanning Efficiency (Phage ELISA)
The phage enzyme-linked immunosorbent assay (ELISA) protocol was used to
monitor the enrichment of target-specific scFvs through successive rounds of selection.
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Target bacteria were prepared from overnight cultures and immobilized on a microtiter
plate as previously described. The sample wells were blocked with PBS containing 3%
BSA for a minimum of 1 h at 37 C prior to the addition of scFv-phage preparations.
Phage concentrations were determined for each preparation by measuring OD270, then
diluted to OD270 = 0.5 in PBS (pH 7.4) containing 1% BSA. A 100 l aliquot of the
diluted phage was added to the immobilized bacteria, the microtiter plate was then sealed
and incubated at 37 C for 1 h. The plate was rigorously washed ten times with water to
displace weak and non-specific binders. An anti-M13 HRP-conjugated (Stratagene)
secondary antibody was diluted 1:1000 in PBS containing 1 % BSA then incubated for an
additional h at 37 C. The plate was again washed ten times with water to remove excess
secondary antibody. To visualize phage binding, 100 l of 3,3’,5,5’tetreamethylbenzidine (TMB) substrate was added to each well. The reaction was
terminated with the addition of 100 l of 1 M HCl, which produced a yellow color.
Absorbance at 450 nm was measured using a Model 680 microplate reader (Bio-Rad).
The Microplate Manager software was used for data acquisition and Microsoft Excel was
used for graphical representation.
Colony Screening to Identify scFv
Direct method. Individual colonies from biopanning output plates were examined
for the presence of the scFv gene using a colony lysis protocol and SfiI restriction enzyme
digest. Colonies that contained the phagemid vector and scFv gene insert were used to
inoculate 3 ml LB medium containing 100 g/ml carbenicillin. Plasmid DNA was
isolated and transformed into chemically competent Escherichia coli DH5 using a heat

51

shock protocol. Small-scale expression trials were conducted to further characterize the
scFv.
Plate lift assay. A plate lift assay was performed either directly from phage output
plates or from overnight patch plates using the protocol of Radosevic et al. (126). A
Whatman Protran BA 85 membrane was placed directly on either the output or patch
plate and incubated at 37 C for 1 h to facilitate transfer of bacteria to the membrane.
Concurrently, a second membrane was submerged in a Petri dish containing 10 ml of
5x106 cells/ml target bacteria in PBS solution. The antigen-coated membrane was
incubated for 1 h at room temperature, then allowed to air-dry. Both the antigen-coated
membrane and the colony replica membrane were layered onto an LB plates containing
antibiotics and 1 mM IPTG plate as demonstrated in Figure 6. The plate was incubated
overnight at 37 C to allow expression of the scFv and diffusion to the antigen-containing
membrane.
The replica membrane was removed and transferred to a new, antibiotic-containing
LB plate to maintain individual colonies. The antigen-coated membrane was dried for 1
h, then transferred to a Petri dish containing a blocking solution of PBS plus 4% dried
milk. Blocking was conducted at room temperature for 1 h. The blocking solution was
discarded and replaced with the primary antibody solution of a 1:1000 dilution of a
mouse anti-HA antibody (Abcam) in PBS containing 0.05% Tween-20. The membrane
was incubated as above for 2 h. The primary antibody was followed by a standard set of
three washes as described in the immunoblot protocol. A goat anti-mouse IgG alkaline
phosphatase conjugate (Sigma) diluted 1:2000 served as the secondary antibody, which
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was allowed to remain on the membrane for 1 h then followed by a repeat of the washes
as described. Target bound scFvs were visualized with an NBT/BCIP substrate.

Figure 6. The Plate Lift Assay
Schematic of the plate lift assay for high throughput analysis of biopanning output
plate. The protocol was utilized for the high-throughput identification of scFv specific
for target bacteria.
Target bacteria were immobilized to a nitrocellulose membrane which was
transferred onto an LB plate containing IPTG. A second nitrocellulose membrane was
used to replicate the colonies from biopanning output plates. The replica membrane
was layered atop the antigen containing membrane and all were incubated at 37 C.
ScFv expressed from individual colonies diffused to the antigen-coated membrane.
The antigen-coated membrane was developed using an immunoblot protocol to
identify individual clones that produced scFv with affinity for the target bacteria.
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Microtiter plate assay. Microtiter plate screening of phage output plates was
adapted from the protocols of Bradbury et al. (127) to identify colonies expressing
functional scFvs. Briefly, colonies from biopanning output plates were patched onto
individual wells of a 96-well polystyrene microtiter plate containing 100 l of SB
medium with 100 g/ml carbenicillin and 2% glucose (w/v). The plates were incubated at
30 C overnight in a New Brunswich Series 25 incubator shaker at 250 rpm. The
following morning, a 50 l volume of SB medium containing 2% glucose (w/v) and 30%
glycerol (v/v) was added to each well to generate a master plate that could readily be
stored at -80 C. A second, expression microtiter plate containing 100 l of SB medium
plus antibiotics and 0.1% (w/v) glucose was inoculated with 2 l of culture from the
corresponding well of the master plate. The plate was covered with a mylar sheet and
incubated at 37 C for 2 – 3 h. A 50 l aliquot of SB medium with antibiotics and 3 mM
isopropyl ß-D-1thiogalactopyranoside (IPTG, final concentration of 1 mM) was added to
each of the wells of the microtiter plate. The plate was sealed and incubated at 30 C
overnight to allow for expression of the scFvs. A third antigen microtiter plate was
prepared with target bacteria immobilized using the method described in the biopanning
section. The expression plate was centrifuged at 3000 rpm in a Hettich Zentrigun Rotanta
460 microtiter plate centrifuge for 15 min to pellet the bacteria. Prior to addition of the
soluble scFv, the bacteria-coated microtiter plate was blocked with a solution of PBS (pH
7.4) and 4% dried milk for 1h at 37 C. A 100 l volume of the expression plate
supernatant was added to each corresponding well of the antigen plate. The microtiter
plate was sealed and incubated for 2 h at 37 C. Non-binding scFvs were removed by
washing each well of the plate five times with a steady stream of water. A volume of 100
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l of a rat anti-HA HRP (Roche) secondary antibody diluted 1:1000 in PBS/milk
blocking solution was added to each well followed by an additional 1 h incubation at
37 C. A TMB substrate and 1 M HCl stop solution were used as previously described to
identify clones expressing functional, target-recognizing scFvs.
Examination of scFv Activity and Specificity (Osmotic Shock & ELISA)
Individual positive clones identified using one of the three methods described (direct,
plate lift, microtiter) were used to inoculate 3 ml of SB medium containing 100 g/ml
carbenicillin. A 30 ml SB with antibiotics culture was inoculated with 100 l of the
overnight culture and grown for 3 h at 37 C. The scFv expression was induced with 0.5
mM IPTG and allowed to proceed overnight (12 – 16 h) at 37 C. Following induction,
the culture was pelleted at 3000 rpm in a clinical centrifuge at 4 C. The supernatant was
discarded and the pellet resuspended in 1 ml of osmotic shock buffer as described by
Kipriyanov (128). The cell suspension was incubated on ice for 30 min and the
centrifugation repeated. The supernatant was transferred to a 1.5 ml microfuge tube.
The cells from overnight cultures of a panel of test bacteria (Bacillus subtilis, Bacillus
thuringiensis, Escherichia coli strain DH5 , Citrobacter freundii, Enterococcus faecium,
Listeria monocytogenes, Pseudomonas fluorescens, Pseudomonas putida, Proteus
vulgaris, Serratia marcescens, Salmonella enterica, and Salmonella enterica serovar
Typhimurium) were pelleted, washed three times in PBS, and quantitated via OD600 as
previously described. Bacterial suspensions were diluted to a value of OD600 = 1.0 in
PBS (pH 7.4) solution. Aliquots (100 l) of the bacterial dilutions were added to
individual wells of a 96-well microtiter plate. Immobilization of the bacteria was
accomplished either through incubation at 37 C for 1 h or overnight incubation at 4 C.
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Non-bound bacteria were removed from the microtiter plate by gentle washing with
distilled water. The antigen plate was blocked with PBS with3% BSA for 1 h at 37 C
prior to the addition of the soluble protein fraction which was isolated via osmotic shock
and diluted 1:1 in PBS containing 1% BSA. The plate was sealed and incubated at 37 C
for 2 h. Non-bound proteins were removed with five washes of each well with water. The
rat anti-HA HRP secondary antibody was diluted 1:3000 in PBS with1% BSA. The plate
incubated as previously described and then washed ten times with water to remove nonbound secondary antibody. Binding of the scFv was detected with the colorimetric TMB
substrate and 1 M HCl stop solution. Absorbance at 495 nm was measured with a BioRad Model 680 microplate reader, graphical analysis of data was accomplished using
Microsoft Excel to assess scFv specificity.
Expression and Purification of scFv
Overnight cultures of E. coli strains containing the scFv gene within the phagemid
vector or an alternate expression vector were grown at 37 C in the presence of the
appropriate antibiotics and used to inoculate at a ratio of 1:100 50 – 500 ml of SB
medium The cultures were grown for 2 – 3 h at 37 C until they reached an OD600 = 0.4 –
0.6 (mid-log phase of growth). Expression of scFv was induced with 0.5 – 1 mM IPTG
(final concentration) and the culture maintained for 5 – 16 h at either 25 C or 37 C.
The cell culture was transferred to 250 ml polypropylene bottles and centrifuged at
4,000 x g for 15 min and 4 C. The supernatant was discarded and the pellet either stored
at -80 C or directly lysed for purification. The cell pellet was resuspended in 1/20th
volume of lysis solution containing 1 mg/ml chicken egg white lysozyme (Sigma
Aldrich) and a 1:20 dilution of B-PER II bacterial protein extraction reagent (Pierce). The
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suspension was agitated on a rocker plate at room temperature for 30 min to facilitate cell
lysis and sonicated on ice six times for 30 seconds each with a Branson sonifer 450
sonicator at a 100% duty cycle and an output control of 7. Separation of soluble and
insoluble material was accomplished via centrifugation at 48,000 x g for 30 min at 4 C.
The supernatant was transferred to a new tube and the pellet resuspended in an equivalent
volume of PBS buffer.
The purification of scFvs was accomplished using the terminal 6xHis tag of the scFv
and a Ni2+ - nitrilotriacetic acid (Ni-NTA)-conjugated agarose resin (Invitrogen). A 1 – 5
ml volume of the Ni-NTA resin was transferred to 2 ml microfuge tubes and pelleted via
centrifugation. The supernatant was discarded and the resin resuspended in 500 l of
column Buffer A. Five to six washes were sufficient to remove all residual ethanol of the
matrix storage buffer. The supernatant fraction of the cell lysate was combined with the
equilibrated resin overnight at 4 C in a 50 ml conical tube using a New Brunswick Model
TC-7 roller drum. To limit binding of non-scFv proteins to the Ni-NTA resin, imidazole
was added to the batch slurry to a final concentration of 20 mM. The slurry was slowly
added to a 1.5 x 10 cm glass Econo column. Flow rate was controlled manually with a
stop cock to an approximate rate of 1 ml/min. The column was washed with a minimum
of ten bed volumes Buffer A. A second wash of ten bed volumes was performed with a
high-salt, low pH Buffer B to displace loosely bound bacterial proteins. An additional ten
bed volumes of Buffer A was used to reduce the salt concentration. The scFv was
collected using Buffer A with 250 mM imidazole (Sigma Aldrich) in three elution
fractions. Fractions 1 and 2 were equal in volume to the column bed volume while
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fraction 3 was twice the bed volume. Each elution was collected following a 30 min
incubation of the column matrix in the presence of the imidazole solution.
For denaturing Ni2+-NTA purification, the insoluble pellet material was first
resuspended in 5 ml Denaturing Buffer per 1 g of cell pellet. The solution was stirred at
room temperature for 1 h then centrifuged at 10,000 x g for 15 min at 4 C. The
supernatant was transferred to a 50 ml conical tube containing 2 - 5 ml of Ni-NTA resin
that had previously been equilibrated in Denaturing Buffer. The slurry was incubated at
4 C in a rotator wheel overnight. Chromatography was conducted at room temperature
using a Econo glass column as previously described. Following sample loading, the
column was washed with a minimum of ten bed volumes of the denaturing buffer. A
second series of washes was conducted with five bed volumes of denaturing Buffer A.
Washing of the column with denaturing Buffer B continued until an absorbance less than
0.01 at 280 nm was attained as measured with the Nanodrop spectrophotometer. The
scFv were eluted from the column with denaturing Buffer C as described above.
Renaturation of the scFvs was accomplished by a step-wise removal of the urea from
the elution fractions either through dialysis or an on-column method (129). In the dialysis
method, the elutions were transferred to 12,000-14,000 MWCO dialysis tubing and
placed in 1 - 2 L of Buffer A solution. Following a 2 h incubation a 4 C, enough 0.01 M
Tris (pH 8.0), 0.1 M Na2HPO4 buffer was added to dilute the concentration of urea to 6
M. The addition of buffer lacking urea was repeated a minimum of five more times, with
2 h between each dilution, until the urea concentration was negligible. For on-column
renaturation the same stepwise decrease in urea concentration was performed. Prior to
elution, the column matrix was washed with 5 bed volumes of Buffer A with the urea
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concentration gradually reduced (6 M, 4 M, 2 M, 1 M, 0.5 M, 0.25 M, 0 urea) as above
until no urea remained. The renatured scFvs were eluted with a denaturing buffer C that
contained no urea.
For some experiments, scFv recovered from the Ni2+-NTA column were subjected to
a second affinity purification column that targeted the HA epitope tag. The column
matrix was formed from the EZview Red Anti-HA affinity gel (Sigma) agarose resin to a
bed volume of 0.3 – 0.5 ml. The column was washed with PBS (pH 7.4) / 0.1 mM
PMSF/PTSF prior to sample loading. Eluates from Ni2+-NTA purification were pooled
and dialyzed in PBS to remove the excess salt and imidazole prior to column loading.
The dialyzed sample was passed over the column matrix a minimum of three times to
allow for scFv immobilization to the column matrix. The column was washed with ten
bed volumes of PBS (pH 7.4) to remove contaminating proteins. The scFvs were eluted
with a 0.2 M glycine-HCl (pH 2.3 - 2.5) solution. Fractions containing scFvs were
dialyzed in PBS (pH 7.4).
Immobilization of scFvs to a Gold Electrode
Standard 1 cm 5 MHz quartz crystal microbalance slides with gold electrodes were
obtained from Stanford Research Systems, Inc. (Sunnyvale, CA). Prior to use, the gold
electrode was cleaned with 500 l of a Piranha solution (3:1 H2SO4 : 30% H2O2) for 3
min. The crystal was then rigorously washed with water then ethanol and allowed to dry.
A solution of 0.1 M 3-mercaptopropionic acid (Sigma) and 0.1 M 11-mercaptoundecanoic acid (Sigma) was prepared in ethanol and applied directly to the gold
electrode. Formation of the self-assembled monolayer (SAM) was conducted for a
minimum of 3 h at room temperature. Non-bound SAM material was removed by
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submerging the crystal in ethanol prior to use. Individual crystals were removed from the
ethanol and rigorously washed with water then inserted into the crystal oscillator arm.
The surface was washed an additional three times with 500 l of degassed PBS (pH 7.4)
before the baseline measurement of frequency and resistance was established.
Immobilization of antibody molecules (IgG or scFv) required the activation of the
carboxyl groups of the SAM using a 0.2 M 1-ethyl-3-(3dimethylaminopropyl)carbodiimide (EDC), 0.1 M N-hydroxysuccinimide (NHS)
solution. A 500 l aliquot of the EDC/NHS solution was reacted with the SAM for 15
min then removed and the surface washed with a single volume (500 l) of PBS.
Monoclonal IgG and scFv were attached directly to the surface through a random, free
amine group of the molecule. Monoclonal antibodies were added at a saturating
concentration of 3 g of total protein based on the research of Prusak-Sochazewski et al.
(33)

. For the scFvs, 3 – 7 g of total protein from elutions of Ni2+-NTA purification were

directly added to the surface. The antibody solutions reacted with the surface for 30 – 60
min to facilitate the formation of the amide bond. Alternatively, an indirect method of
scFv attachment utilized the rat anti-HA HRP antibody that was bound to the SAM. The
anti-HA antibody was diluted to 25 U in 500 l of PBS (pH 7.4) then added to the crystal
surface for 30 - 60 min. For both methods, direct and indirect, unreacted acid groups of
the SAM were inactivated with a 50 mM Tris (pH 7.4) solution. ScFv immobilization
was completed for the indirect method with the addition of 5 g of total protein obtained
from Ni2+-NTA elutions in 500 l of PBS (pH 7.4). The scFv solution remained on the
surface for 30 – 60 min and was then discarded. The surface washed three times with
PBS (pH 7.4) and a new baseline of frequency and resistance established.
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QCM Detection of Target Bacteria
Baseline frequency and resistance were determined with 500 l of degassed PBS on
the crystal surface. Target and non-target bacteria were prepared from overnight cultures
after washing three times in PBS (pH 7.4) buffer as previously described. The bacteria
were diluted to the desired optical density, which could be correlated with an
approximate cell number per ml of solution. A 10 l aliquot of the bacterial suspension
was added directly to the 500 l volume of PBS on the crystal surface. Frequency and
resistance measurements were monitored for 15 min at which point the surface was
washed three times with PBS buffer to displace non-specifically bound bacteria. The final
frequency and resistance measurements were determined with 500 l of PBS on the slide
surface.
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CHAPTER IV
RESULTS
Experiments described herein were conducted to develop methods of rapidly obtaining
target (bacterial, viral, etc.)-specific antibodies that could readily be incorporated into a
field-deployable biosensor. The study examined a system of monoclonal antibody (mAb)
production and several methods of producing recombinant scFvs to determine which
approach would be most amenable to commercialization and also demonstrate the
versatility needed to be readily adaptable to emerging threats. Both monoclonal
antibodies and recombinant scFvs were integrated into a QCM-based biosensor to
facilitate the detection of bacterial targets in aqueous solutions.
Monoclonal Antibodies from Hybridoma Cell Lines
Initial studies of antibody production focused on the acquisition and use of mAbs from
hybridoma cell lines. Target-specific mAbs are readily isolated from hybridoma cells,
immortalized lymphatic cells that can be maintained indefinitely as a cell culture. The
murine hybridoma cell line Ma1-6 (ATCC CRL-1783) produces isotype IgG1 antibodies
specific for an outer membrane protein H2 of Pseudomonas aeruginosa PAO1 strain
H103 (ATCC 47085). Specificity of Ma1-6 antibody for Pseudomonas spp. was
demonstrated by Hancock et al. (130).
Bioreactors, such as the Fibercell system used in these studies (Figure 7), allow
hybridoma cell cultures to grow to significantly higher cell density compared to static
flask or shaker cultures, improving productivity (131, 132). The Fibercell system allows the
hybridoma cells to form confluent layers on hollow polymer fibers that supply a steady
source of nutrients from a circulating medium. The fibers have a low molecular weight
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cut-off, ensuring that the excreted antibodies are retained within the growth chamber
while small waste products are released into the circulating medium. Cell densities of 109
– 1011 cells/ml viable cells have been reported, a density three to five orders of magnitude
greater than that attainable in tissue culture flasks (133).

Figure 7. The Fibercell Hollow-Fiber Bioreactor
Schematic of the bioreactor hollow fiber chamber. Hybridoma cells adhere to low
molecular weight cut-off polymer fibers that remove waste products and deliver
nutrients via circulating ICS medium. The bioreactor chamber, in which the culture is
maintained, is filled with the antibody-containing ECS medium.
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Efficient monoclonal antibody production required optimization of the Fibercell
system. To monitor overall health of the culture, the concentration of the primary carbon
source, glucose, was measured every one to two days, which determined when both the
antibody-containing extra-capillary space (ECS) medium was collected and the
circulating medium replaced. As glucose levels decreased, the lactic acid concentration
increased, resulting in a lower pH. As these events occurred, the overall culture viability
began to wane. To ensure optimum culture vitality and mAb production, the ECS and
circulating media were replaced when glucose levels decreased below 50%. Additional
control of culture vitality could be exerted by adjusting the percentage of fetal bovine
serum (FBS) in the ECS medium. Bioreactors were inoculated with a 10% FBS
supplement of the ECS. This concentration could be gradually decreased to a final
concentration of 2% FBS if the culture was expanding too rapidly, as judged by the
results from the glucose assays.
Media collected from the extra-capillary space contained not only the desired
monoclonal antibody, but also numerous other serum proteins including a low
concentration of contaminating antibodies from the FBS and a high concentration of
BSA. Initially, a purification strategy was developed that utilized a bifunctional affinity /
ion exchange resin. DEAE Affi-gel Blue, an agarose resin modified with
diethylaminoethyl (DEAE) functional groups and conjugated to a Cibacron Blue F3GA
dye, is designed to bind the antibody through the anionic exchange capabilities of the
DEAE functional groups. Serum BSA, which is retained by the Cibacron dye, requires
higher stringency than the mAb to be eluted from the column.
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Initial trials with the DEAE Affi-gel Blue column proved unsuccessful in removing all
contaminating proteins and purifying mAbs from of the ECS medium. The high
concentration of BSA saturated the Cibacron dye and was found in all fractions eluted
from the column. To compensate, an ammonium sulfate precipitation was performed
prior to column chromatography to remove the majority of the BSA from the serum. The
precipitated proteins were dialyzed to remove excess salts then passed over the DEAE
Affi-gel Blue column. This modification to the protocol improved the purity of the
monoclonal antibody fractions. As shown in Figure 8, mAbs were eluted from the
column with a low salt gradient (30 – 80 mM NaCl) over 30 fractions that were
subsequently concentrated with PEG-8000 and dialyzed. The mAb eluates were free of
BSA, which remained bound to the column until the salt concentration was greater than
100 mM.
The DEAE Affi-gel Blue protocol proved suitable for obtaining monoclonal IgG free
of contaminating serum proteins. The initial ammonium sulfate precipitation step and the
subsequent steps necessary to concentrate the antibody, however, made this method
impractical for large-scale purifications. Alternative methods of concentrating the
protein, such as Amicon centifugal concentrators, were not investigated but may have
improved the results of this purification method.
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Figure 8. DEAE Affi-Gel Blue Purification of Ma1-6 Monoclonal Antibody
Antibody –containing ECS from the bioreactor was ammonium sulfate precipitated to
remove excess BSA then loaded onto a 5 ml DEAE Affi-gel Blue matrix. Monoclonal
antibody was separated from contaminating serum proteins using a three step NaCl
gradient. Fractions from each of the gradient steps were examined using a 12%
acrylamide SDS-PAGE gel. Retention of BSA (fractions 68, 74, 88) and other serum
contaminants (fractions 95 and 100) is evident in the Coomassie stained gel (upper
image). An immunoblot was performed to confirm the presence of mAb in the elution
fractions (lower image). The heavy (H) and light (L) chains are indicated with arrows.
M – Broad range molecular weight marker (Bio-Rad); L – column load; W- washes
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An improved protocol that utilized a protein G–conjugated sepharose column was
employed for the purification of the mAb. The Fc portion of IgG antibody molecules
readily binds protein G, which is immobilized to a sepharose. This purification strategy
required no initial precipitation steps to reduce the concentration of BSA; rather, the
serum was diluted 1:1 with the column buffer to raise the pH of the column load. The
antibody was eluted from the column with a 0.2 M glycine –HCl (pH 2.5) solution, and
then dialyzed against PBS (pH 8.0) to raise the pH. The immediate neutralization of
eluted fractions with 1M Tris-HCl (pH 9.0), recommended by the manufacturer, caused a
significant amount of the antibody to precipitate from solution. Attempts to recover mAb
from the precipitated material did not yield functional antibody. To circumvent this
complication, a gradual adjustment of the pH through dialysis prevented aggregation
from occurring ensuring the activity of the mAb.
Purification of the Ma1-6 antibody using the protein G column required significantly
less time in sample preparation than chromatography using DEAE Affi-gel blue resin.
The mAb was eluted from the Protein G column as a single fraction, therefore there was
no need for concentration of the sample. As shown in the Coomassie stained gel (Figure
9), antibody could readily be obtained in a single fraction in which few contaminating
proteins were apparent. Given the simplicity of this method, protein G chromatography
was amenable to large-scale purification and used to obtain monoclonal antibodies for the
majority of experiments.
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Figure 9. Protein G Purification of Ma1-6 Antibody
A 20 l volume of the column load (L), flow-through (FT), column wash (W), and
eluted fractions (E) from the Protein G column were resolved by SDS-PAGE. BSA and
other serum contaminants are clearly absent in the eluted fraction as seen with Coomassie
stained gel (left image). Immunoblotting using an anti-IgG antibody (right image)
confirms the presence of mAb heavy (H) and light (L) chains.
Some mAb is found in the flow through and wash fractions suggesting the column was
overloaded.

While maintained within the Fibercell bioreactor, the Ma1-6 hybridoma culture
routinely yielded 100 mg of purified antibody per 1 L of ECS medium. A single reactor
produced an average of 600 ml of ECS harvest within a one-month period. The compact
size of the Duet pump and attached hollow-fiber reactors would allow several of these
systems to be maintained simultaneously in a standard microbiological incubator. Cell
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lines producing antibodies with varying specificities could be maintained concurrently
generating sufficient quantities of mAb for integration into a biosensor.
The binding activity of the Ma1-6 antibody was examined using an immunoblot
protocol in which bacteria were directly immobilized on a nitrocellulose membrane via a
dot blot apparatus. Equal cell numbers of two Pseudomonas spp. and E. coli cells, as
determined by optical density, were immobilized on the membrane as either live cells or
after being boiled for 15 min. Defined concentrations (0.250 – 1.0 g) of antibody
purified with both chromatographic methods were evaluated for binding activity toward
the Pseudomonas targets. Considerable affinity for both Pseudomonas species and
limited interaction with E. coli was observed for antibody from both purification methods
(Figure 10). The Ma1-6 antibody showed a greater affinity for heat-killed P. aeruginosa
samples than to the live bacteria. This was attributed to the glycocalyx that surrounds P.
aeruginosa which was likely destroyed by the heat treatment improving access to the H2
membrane protein target resulting in improved antibody binding. Antibody binding to P.
fluorescens, which only produces a capsule during log-phase growth (134), is nearly
equivalent for live and heat-killed samples, further evidence of interference by the
capsule of P. aeruginosa. The interaction of Ma1-6 with live and heat-killed E. coli
samples (Figure 10) is the product of secondary antibody interaction, which was shown in
controls for other experiments. Although it allowed for the confirmation of antibody
activity, the dot blot protocol could not be used for quantitation of antibody affinity via
densitometric analysis of the immunoblot since excess bacteria were frequently displaced
from the nitrocellulose membrane during wash steps. This phenomenon is clearly seen in
the E. coli samples.
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Figure 10. Dot Blot Assay to Assess Affinity of DEAE Affi-Gel Blue and Protein G
Purified Ma1-6
Approximately 106 live or heat-killed (HK) bacteria were immobilized in triplicate to
a nitrocellulose membrane using a slot blot apparatus and vacuum aspirator to assess
Ma1-6 antibody affinity for bacterial targets.
Antibodies purified using both chromatography methods exhibited the expected
affinity toward the Pseudomonas species. Quantitation of antibody binding was
impossible due to the loss of immobilized antigen as evidenced by the E. coli controls
and the variation in signal strength between replicate samples.

The Ma1-6 antibody was easily purified from the culture medium (ECS) and showed
reproducible interaction with the target and non-target bacteria. Although mAb could
readily be manufactured using hybridomas and Fibercell bioreactors, alternative systems
of antibody production were explored for several reasons. The biosensor model proposes
a device that can detect multiple bacterial targets, can readily be adapted to emerging
threats, and maintains an overall low cost of production that would make the system
suitable for commercialization. Generation and selection of hybridoma cell lines, even if
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not performed in-house, can take from several months to a year. Since each cell line
produces only one, monospecific antibody, the process would need to be repeated for
each bacterial target. Additionally, once a suitable cell line has been established, the cost
of maintaining mammalian cell cultures is prohibitively expensive. To circumvent these
problems a system of producing recombinant proteins in bacterial cultures was
investigated.
Construction of a Murine Single-Chain Fv Antibody (scFv)
The antigen-binding domain of an antibody is formed from only 100 – 110 amino
acids of the N-terminal portion of the heavy and light chain genes, a region defined as the
variable or Fv domain (16). These amino acid sequences can be isolated and combined into
a single fusion gene which when expressed will form a molecule capable of antigen
binding (17). The truncated molecule, referred to as an scFv, lacks the complexity of a fulllength antibody and can readily be produced in bacteria (52, 54, 135).
Initial experiments to construct an scFv gene were designed to reproduce the antigenrecognizing Fv portion of the monoclonal antibody Ma1-6 and generate a recombinant
antibody with similar or improved affinity for Pseudomonas species. Total RNA was
extracted from the hybridoma cell culture using and amplified by reverse transcription to
generate a cDNA pool. A pool of primers, based on conserved sequences flanking the
variable domains of both the heavy and light chain genes, was designed based on
information available in the literature (67). Primer pairs were used in all possible
combinations to amplify the variable domains of the target heavy and light chain genes
from the cDNA pool. PCR reactions were examined by gel electrophoresis to identify
those primer combinations that produced a product of approximately 300 bp (Figure 11).
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Most of the light chain primer pairs yielded an amplification product of the expected size
(lanes 2-7, 9, and 10), while few of the heavy chain primer pairs produced a DNA
fragment of the expected size (lanes 7, 9, and 12).

Figure 11. PCR Amplification of Murine Heavy and Light Variable Domain Genes
The heavy and light variable domain genes were isolated from the cDNA pool
using numerous combinations of forward and reverse primers that were specific for
the conserved regions flanking the variable domains.
PCR reactions were examined by electrophoresis on a 1% agarose TBE gel. DNA
was visualized with ethidium bromide and compared to DNA standards for amplicon
size estimated. Positive reactions were those that produced a product of 300 to 400 bp,
the anticipated size of the variable domain sequence.
The 300 bp bands were purified from the agarose gel and cloned into the pCR Blunt
II TOPO vector. Plasmid DNA containing putative gene inserts was identified using a
restriction enzyme digest with EcoRI, which only cleaves the vector on either side of the
inserted gene. The variable domain genes could not be identified strictly on size analysis
of PCR products and gel electrophoresis, therefore, plasmid DNA from twelve clones
was sent for sequence analysis to the University of Maine DNA Sequence Facility. Four
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of the twelve heavy chain clones and all of the light chain clones except two, contained
an identical gene sequence that produced an open reading frame when translated using
the Transeq software (www.ebi.ac.uk/Tools/emboss/transeq/index.html). A BlastN
(www.blast.ncbi.nlm.nih.gov) search of the mouse genome database was performed with
the nucleotide sequences that produced an ORF to identify highly similar genes within
the mouse genome. The top five genes returned by the BlastN search for both the heavy
and light chain gene sequences were reported IgG variable domain genes. The DNA
sequences were aligned using ClustalW (www.ebi.ac.uk/Tools/clustalw2/index.html) to
determine the percent similarity between the hybridoma-derived genes and those
identified by the BlastN search. ClustalX (136) was used for graphical representation of the
alignments. The heavy chain gene sequence (clone 13) demonstrated 79 - 89% identity
(Figure 12) with other known murine heavy chain variable domain sequences and the
light chain (clones 4 and 7) showed 78 - 98% identity (Figure 13). The strong homology
with known IgG sequences suggested that the isolated gene fragments were the variable
domains of the Ma1-6 heavy and light chain antibody. In addition to in silico analysis, the
deduced amino acid sequences of the amplified genes were further compared to murine
antibody sequences of the Kabat database (123), confirming that highly conserved
sequences of the framework regions were encoded by the isolated genes.
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Figure 12. Alignment of Amplified Heavy Chain Variable Domain Gene Sequences
Gene sequences exhibiting high identity to the putative heavy chain variable domain
sequence were identified using a BlastN search of the mouse genome. Each of the
identified genes was identified as variable domain of the mouse IgG heavy chain. Multiple
sequence alignments were performed using ClustalW and ClustalX programs. The
amplified heavy chain gene sequence was 79 to 89% identical to other variable domain
sequences.
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Figure 13. Alignment of Amplified Light Chain Variable Domain Gene Sequences
Gene sequences exhibiting high identity to the putative light chain variable
domain sequence were identified using a BlastN search of the mouse genome. Each
of the identified genes was identified as the variable domain of the mouse IgG light
chain. Multiple sequence alignments were performed using ClustalW and ClustalX
programs. The amplified light chain gene sequence was 78 to 98% identical to other
variable domain sequences.
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The scFv fusion gene was generated through overlap extension PCR (oePCR) of the
single heavy chain gene and both light chain genes. Primers were designed to add a DNA
sequence encoding a twelve amino acid glycine-serine repeat to the 3’ end of the heavy
chain coding sequence and a complementary sequence to the 5’ end of the light chain
coding sequence. This linker sequence served to combine the two genes through the
oePCR process (Figure 5). The heavy and light chain genes were amplified from the
respective plasmid DNAs and the products of these reactions purified using gel
electrophoresis to ensure there were no contaminating primers that may interfere with the
generation of the fusion gene template in the second round of PCR. Following the initial
five rounds of amplification, which elongated the two halves of the scFv template (Figure
1), forward and reverse primers were added and the reaction continued for another 25 30 cycles. The heavy-light chain fusion gene (scFv) was amplified exponentially
following primer addition, whereas heavy and light chain templates that did not fuse
during the initial five cycles were amplified linearly with a single primer. The scFv gene
of approximately 800 bp was the most prominent DNA band visible on the ethidium
bromide-stained agarose gel (Figure 14, lanes 4 - 6).
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Figure 14. Generation of the scFv Gene by Overlap Extension PCR (oePCR)
The heavy and light chain variable domain genes were combined into a single
fusion product using an oePCR protocol. Lanes 2 (no polymerase) and 3 (no
primers) are negative control. Lanes 4 - 6 clearly depict a product of
approximately 800 bp corresponding to the 767 bp, calculated size of the scFv
gene (arrow).

The amplified fragment was excised from the gel, cloned into the pCR Blunt II TOPO
vector, and the plasmid transformed in E. coli strain DH5 . Plasmid DNA from six
clones was sequenced to confirm the presence of the each of the genes in the translational
fusion. The terminal restrictions sites, BamHI and KpnI, and the C-terminal c-myc
eptiope tag (EQKLISEEDL) that was added to aid in detection and purification were also
confirmed. The clone scFv 4-2 was used for all future experiments.
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The scFv 4-2 gene was excised from the TOPO vector by BamHI / KpnI restriction
enzyme digestion and ligated into a similarly cut pProEx HTb vector. The pProEx vector
system allows for inducible, cytoplasmic expression of recombinant proteins under the
control of the lac promoter. Additionally, the pProEx vector encodes a C-terminal hexahistidine (6xHis) sequence that can be utilized for downstream applications including
immunoblot detection and purification using an immobilized metal affinity
chromatography (IMAC) protocol.
Small-scale expression trials were conducted with scFv 4-2 to assess the solubility of
the recombinant protein. While detectable by immunoblotting, scFv 4-2 was not visible
on Coomassie stained gels, suggesting that only small quantities were produced in E. coli.
Additionally, the vast majority of expressed scFvs was isolated as insoluble aggregates in
the lysed bacterial cell pellet (Figure 15, lanes labeled P). Several different expression
conditions, which included lower induction temperatures and IPTG concentrations, were
attempted to improve solubility and scFv expression. These conditions, however, were
not successful in improving the quantity of proteins expressed or their solubility.
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Figure 15. Small-Scale Expression of Murine scFv 4-2
Small-scale expression trials were conducted overnight at 37 C following
induction with 0.5 mM IPTG. The cell pellet was disrupted via sonication and the
soluble proteins separated from the insoluble material by centrifugation. SDSPAGE gels were loaded with equivalent quantities (30 g) of the pellet (P) and
soluble (S) fractions.
The Coomassie-stained gel on the left does not show over-expression of the
scFv protein at the expected MW of 35 kDa. ScFvs (arrow) are only detectable
through immunoblotting (right image). Furthermore, the recombinant scFv was
localized exclusively in the insoluble pellet in both of the clones examined.

To ascertain whether the mammalian scFv gene contained amino acid codons not
compatible with expression in E. coli, its sequence was compared to the codon usage
table for E. coli using the web-based Graphical Codon Usage Analyzer software
(www.gcua.schoedl.de). In silico analysis discerned that the scFv 4-2 gene contained
seven rare arginine (AGG or AGA) and two leucine codons (CTA) for which
complementary tRNAs were not readily available in E. coli. Since the codon bias may
have limited the expression level of scFv 4-2 in the E. coli strains used (DH5 and BL21)
79

the construct was transformed to the BL21–codon plus (RIL) strain, which expresses
plasmid-encoded tRNAs specific for rare codons of arginine and leucine. A small-scale
expression trial was conducted to assess whether the correction of codon bias improved
solubility of the scFvs. Despite several attempts at optimization, expression of scFvs was
neither improved in quantity nor in solubility in this bacterial strain.
Since the murine scFv could not be expressed as a soluble protein, it was necessary to
isolate the recombinant protein from the insoluble pellet material following denaturation
of the proteins with guanidinium hydrochloride. The solubilized, denatured scFvs were
separated from other cellular proteins using a modified IMAC protocol that included urea
in all buffers to maintain solubility. Eluates contained few contaminating proteins,
however, the scFvs appeared to have been degraded significantly during the purification
process evidenced by the presence of a second polypeptide of approximately 20 kDa,
which was confirmed by immunoblotting to possess the 6xHis epitope tag. The 20 kDa
protein was present in the elution fractions but not in the initial soluble or insoluble
fractions of the bacterial cells, suggesting the potential introduction of a protease during
dialysis (Figure 16).
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Figure 16. Purification of scFv 4-2 from the Insoluble Fraction
ScFv 4-2 was isolated from the pellet of lysed E. coli BL21-codon plus (RIL)
using a denaturation IMAC protocol.
The eluates contained few contaminating proteins, however, some degradation of
the scFv protein was observed in all of the elution fractions and may have been the
result of a protease introduced during dialysis.
The initial soluble fraction (S) obtained from cell lysis and the solubilized pellet
material (P) were included as positive controls. The monoclonal antibody Ma1-6
(mAb) was included as MW reference and purified recombinant His tagged Eut
protein was included as positive control (+) for the anti-6xHis antibody.
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The scFv 4-2 purified under denaturing conditions was allowed to refold by removing
urea from the scFv-containing fractions through a step-wise dialysis with a 2 – 3 hour
incubation in each buffer of decreasing urea concentration (129, 137).
Attempts to demonstrate binding activity of purified scFv 4-2 towards Pseudomonas
species proved difficult. Initially, the activity of the scFvs was examined using a dot blot
protocol identical to the one developed for the monoclonal antibodies (Figure 10).
Detection of scFv 4-2 binding was accomplished using antibodies that targeted either the
6xHis or the c-myc epitope tag. Unfortunately, both of the secondary antibodies showed
substantial non-specific interaction with the target and non-target bacteria by themselves
(Figure 17, lane labeled (-) ). Densitometric analysis of the signals suggested little
binding of scFv 4-2 to the target bacteria, with virtually no interaction seen with live
Pseudomonas samples. The highest signal intensities were only 20 to 25% above those
obtained for the negative control samples (secondary, HRP-conjugated antibody only).
Due to non-specific interaction of the secondary antibody, the dot blot assay was deemed
unsuitable for the assessment of the binding affinity of scFv 4-2.
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Figure 17. Target Affinity of Purified scFv 4-2 Following Renaturation
Equal numbers of live and heat-killed bacteria were immobilized in decreasing
numbers (1:1 dilution) to nitrocellulose by vacuum aspiration. The scFv 4-2 purified by
denaturating IMAC was examined for activity toward Pseudomonas species using an
immunoblot protocol. The secondary antibody used for detection was a goat anti-6xHis
HRP-conjugate at 1:1,000 dilution. The negative control (secondary antibody only) is
aligned with the scFv-developed blot on the left side (-).
The anti-6xHis HRP-conjugated antibody bound heat-killed samples of all three
Pseudomonas species. Densitometric analysis of the signal obtained for individual wells
minus background suggested that the signal was primarily the product of secondary
antibody interaction with bacteria.

To circumvent the non-specific interactions experienced with the dot blot, the outer
membrane proteins of P. aeruginosa were isolated from lysed bacterial cells that were
separated using a sucrose gradient and ultra-centrifugation according to protocols
reported in the literature (119-122, 138). Previous dot blot assays visualized antibody binding
to the bacterial surface, which was often complicated by non-specific interactions
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(Figures 10 and 17). Separation of outer membrane proteins via SDS-PAGE and
subsequent immunoblotting would allow for identification of scFv binding to the Ma1-6
target, outer membrane protein H2.
The cell lysate fractionated into three distinct regions (based on turbidity and color)
within the gradient that were isolated and resolved by SDS-PAGE. Immunoblots were
developed with either the Ma1-6 mAb or with scFv 4-2 in combination with either the
anti-6xHis or anti- c-myc secondary antibody. The membrane developed with Ma1-6
clearly identified the 20 kDa outer membrane protein H2 in all sucrose gradient samples,
however, there was no corresponding signal on either of the membranes developed with
scFv 4-2 (Figure 18). Based on these results and those obtained with the dot blot assay, it
was concluded that scFv 4-2 did not renature to yield a functional recombinant antibody.
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Figure 18. Analysis of ScFv 4-2 Binding Affinity Towards Outer Membrane Proteins
of P. aeruginosa
Membrane proteins of P. aeruginosa were fractionated using a sucrose gradient.
The cell lysate (L) and fractions (F1 – F3) containing the membrane protein H2 were
separated on a 12% denaturing, polyacrylamide gel.
A Coomassie stain of the membrane fractions is displayed on the left.
Immunoblots were developed with either Ma1-6 or scFv 4-2 as the primary
antibody. Secondary antibodies used for visualization are listed on each of the blots
above.

The murine scFv 4-2 was generated from a single hybridoma cell line, which did not
produce a soluble scFv in bacterial expression trials. The scFv could be recovered from
the insoluble material of expression cultures, however, the scFv was unable to bind the
target bacteria following renaturation. Construction of the scFv from a hybridoma cell
line was a low-throughput method that required a significant investment of time and
resources. To expedite obtaining scFvs with the desired characteristics of target
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specificity and solubility, a larger diverse antibody repertoire, or library, was constructed.
In conjunction with a high-throughput method of selection, the scFv library will provide
for a method of isolating scFvs with the desired target-specificity and affinity from a
highly diverse pool. This method would eliminate the time delays associated with
hybridoma development and selection, circumvent the potential complications
encountered with scFv 4-2, and improve the adaptability of the biosensor model by
allowing for the selection of scFvs against different bacterial targets.
Construction of an Immunized scFv Library
To facilitate the construction of the scFv library, the spleen, a primary lymph node,
from a rabbit immunized with formalin-killed Bacillus thuringiensis was obtained. Two
rabbits, demonstrating no significant serum antibodies toward the bacterial target, were
chosen for the immunization process. Following four rounds of inoculations with
formalin-killed bacteria, a final bleed was examined using the dot blot protocol. The
antibodies of these final bleeds demonstrated significant antigen recognition capabilities
as evidenced in Figure 19. The rabbits were exsanguinated and a spleenectomy was
performed.
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Figure 19. Enrichment of Target-Specific Antibodies through the Immunization of
Rabbits with Formalin-Killed B. thuringiensis
The serum of non-immunized rabbits was tested to ensure the absence of preexisting antibodies reactive toward B. thuringiensis. Two rabbits were subjected o four
rounds of inoculation with formalin-killed B. thuringiensis to generate a significant
immune response. Final bleeds were compared to the initial pre-bleed samples using a
dot blot protocol to demonstrate the increase in antibody recognition of the bacterial
target.

Total RNA was extracted from the rabbit spleen and converted to cDNA using the
iScript First Strand DNA Synthesis Kit. The product of the cDNA reaction served as
template for the subsequent amplification of the variable domain gene sequences. Primer
combinations and PCR reaction conditions for amplification of the heavy and light chain
genes were obtained from Barbas III et al. (57). Despite attempts to optimize reaction
condition, not all of the primer combinations produced a PCR product of the expected
size as seen in Figure 20. Similar to the construction of the murine scFv, the majority of
the light chain primer combinations were successful (lanes 1-8, 10) while many of the
heavy chain reactions failed (positives 2-5, 8-11, 15-16). This observation was deemed
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inconsequential since rabbits predominantly rearrange a single heavy chain gene,
therefore not all primers would be expected to succeed (64).

Figure 20. Amplification of Rabbit Heavy and Light Chain Variable Domain Genes
The heavy and light chain variable domain sequences were isolated from a cDNA pool
constructed from RNA isolated from a rabbit spleen. PCR products were examined by
electrophoresis on a 1% agarose gel. Ethidium bromide staining was used to identify
successful reactions, those with a product of approximately 400 bp.
Each lane of the gel represents a different combination of primer sequences. The
majority of the light chain reactions were successful (lanes 1-8, 10) while no amplification
occurred with several of the heavy chain primer combinations (positives 2-5, 8-11, 15-16).
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Although there is no way to accurately calculate the complexity of an scFv library, it
can be hypothesized that the diversity cannot exceed the number of transformants
obtained following a ligation transformation reaction (57). Since the diversity of the library
directly contributes to the potential of isolating scFvs with the desired target-specificities
and affinities, immunized libraries with calculated diversities of 105 – 107 are generally
sought. Constructing highly diverse libraries often requires numerous ligation
transformation reactions, therefore, small-scale (20 l) control ligation-transformation
experiments were conducted to determine the number of large-scale (100 l) reactions
that would be required to obtain a library with sufficient diversity. Based on the number
of colonies of the transformation output plates, six large-scale ligation reactions were
assembled. Transformation was accomplished through electroporation of XL1-Blue
electrocompetent cells. Direct counts of the output plates suggested an estimated diversity
of 7x106 clones, however, restriction digest analysis of individual clones determined that
only 70% of the clones of the library contained the scFv gene insert for a library size of
4.9x106. Although the diversity of the initial library was smaller than expected,
biopanning was conducted against B. thuringiensis to isolate a target-specific scFvs and
to establish protocols for phage display and the process of scFv selection.
The phage display system was utilized to isolate scFvs specific for target bacteria from
both the immunized and naïve scFv libraries. To isolate target-specific scFvs from these
libraries, biopanning was conducted against live bacteria immobilized to a 96-well
microtiter plate. This method of immobilization ensured that surface epitopes of the
bacteria would be in their native conformation within the bacterial cell outer membrane
or peptidoglycan layer. Additionally, preliminary antigen purification steps would not be
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required since the bacterial surface offered a large number of potential epitopes compared
to a single purified antigen. This would expedite the isolation of target-specific scFv for
new target bacteria. Unless otherwise stated, four rounds of selection were conducted
with increasing stringency of washes against the bacterial antigen.
Individual clones were isolated from biopanning output plates and screened using
several different methods throughout the project (Figure 21). In most instances, plasmid
DNA was extracted using a colony lysis protocol and digested with SfiI restriction
enzyme to identify clones containing the scFv gene. As will be demonstrated, nonspecific interactions between the M13 filamentous phage and the bacterial antigens
required a large number of individual colonies to be examined to identify those
containing the scFv gene. High-throughput methods such as the plate lift assay and the
microtiter plate assay were utilized in some trials to expedite the identification of clones
producing a functional scFv. Once a clone was identified, preliminary trials to assess
solubility and specificity of the scFv were conducted. In the initial biopanning trials,
solubility was examined first for clones containing the scFv gene using SDS-PAGE and
immunoblotting. Soluble scFvs were then purified using affinity chromatography and
examined for specificity via ELISA. In later experiments, specificity was considered a
priority and examined using scFvs that could rapidly be isolated from the periplasmic
space. Although acquired in limited quantities, the scFvs obtained using osmotic shock
could directly be tested for specificity and affinity for target bacteria via ELISA. The
osmotic shock protocol prevented time delays associated with purifying scFvs that failed
to demonstrate desired binding characteristics.
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Several different ELISA-based protocols are utilized throughout the biopanning
process. In general, phage ELISA protocols utilized equivalent concentrations of phage
from each round of biopanning that were diluted to equal OD270 measurements in a 1%
BSA solution. Specificity ELISAs for individual scFvs were conducted using either
affinity purified scFvs or scFvs isolated from the periplasmic space. For both of these
preparations, the precise quantity of scFv could not be determined. For affinity purified
scFv preparations, elution fractions were diluted to 3 g/ml in PBS/ 1% BSA for
analysis. The osmotic shock solutions were also diluted in PBS/ 1% BSA at a ratio of 1:1
prior to analysis. These dilutions were used in all experiments to maintain some level of
consistency. However, as was seen in later trials, there was significant variation in the
maximum absorbance values between individual clones. These observations may be
indicative of the affinity of the scFv, the product of poor expression or solubility, or some
other condition. However, since experimental conditions of expression and purification
are identical for each clone, comparison of scFvs between experiments could be made.
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Figure 21. Flow Chart of the Colony Screening Methods
Individual clones from biopanning rounds were screened using one of three
methods; colony digest, plate lift, or a microtiter assay. Soluble proteins
extracted from the periplasmic space were tested for target specificity prior to
more extensive characterizations that required affinity purification of scFvs.
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Bacillus thuringiensis Biopanning
A total of 72 clones were screened from the last round of biopanning. A significant
number of clones, approximately 90%, contained either no gene insert or a digest product
smaller than anticipated (~ 300 bp). Only 10% of the clones examined contained a digest
product of 800 bp, the correct size for a complete scFv gene (Figure 22, lane 13).

Figure 22. Restriction Analysis of Clones from B. thuringiensis Biopanning Round
Four
Plasmid DNA from individual colonies of biopanning round 4 output plates were
obtained using a direct colony lysis protocol. DNA was digested with the restriction
enzyme SfiI which cleaves at the 5’ and 3’ ends of the scFv gene. Digest products
were separated on a 1% agarose gel and visualized using ethidium bromide staining.
A minimal number of colonies (lane 13) exhibited a digest product of 800 bp, the
anticipated size of an scFv gene (arrow).

Plasmid DNA from clones containing the potential scFv gene was transformed into
the suppressor strain DH5 in which the scFv is expressed but translation of the pIII
protein is inhibited. Targeting of scFvs to the periplasm was maintained by the ompA
leader sequence encoded by the phagemid vector. Expression was conducted overnight at
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37 C, followed by sonication to lyse cells and centrifugation to separate soluble and
insoluble fractions. Solubility of the scFv was assessed via SDS-PAGE and
immunoblotting. Poor solubility was observed for the majority of the clones. Of the five
clones examined from round four of biopanning, a single clone, k18, exhibited soluble
scFvs (Figure 23). The scFvs were isolated from the soluble fraction using nickel affinity
chromatography (Ni2+-NTA).

Figure 23. Bacterial Expression of scFv k18
ScFv k18 was expressed in E. coli strain DH5 overnight at 37 C following
induction with 1 mM IPTG. The cell culture was pelleted, lysed via sonication, and
centrifuged to separate soluble and insoluble material. Protein concentration was
determined via BCA for the lysate (L), supernatant (S), and pellet (P) to ensure
equivalent loads (25 g) for SDS-PAGE. Non-induced (N) and induced (L) cells were
included as negative and positive controls, respectively.
No over-expression of scFv k18 is apparent in any fraction of the expression culture
as seen on the Coomassie stained gel (left). Expression of scFv k18 was confirmed
through immunoblotting (right with arrow)
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Elution fractions from the Ni2+-NTA column contained a considerable number of
contaminating proteins (Figure 24). Accurate quantitation of the scFvs was impossible
due to contaminating proteins present in higher concentrations of the elution fractions as
seen in the Coomassie stained gel. Regardless, sufficient quantities of scFvs were
obtained to allow for ELISAs to determine bacterial specificity.

Figure 24. Purification of scFv k18 via Affinity Chromatography
The soluble proteins isolated from an overnight expression culture were subjected
to Ni2+-NTAaffinity chromatography to isolate scFv k18. The flow-through (FT),
washes, and elutions were resolved on a 12% acrylamide well by SDS-PAGE.
ScFvs were not visible in the elution fractions, which did contain numerous other
contaminating proteins (Coomassie stained gel on left). The scFv k18 was visualized
in all elution fractions by immunoblotting (right image)

The specificity of scFv k18 was assessed using a panel of bacteria that included the
target bacterium B. thuringiensis and several non-target bacteria. The scFv k18 exhibited
varying affinities for several bacteria of the panel (Figure 25). Although the greatest non95

target interaction occurred with L. monocytogenes, a Gram positive bacteria of the panel,
substantial affinity was also shown for Gram negative bacterium. The scFv did not
consistently recognize a particular bacterial category (enteric, soil, marine, etc.),
therefore, affinity for the other non-target bacteria could not readily be explained.

Figure 25. Analysis of the Bacterial Specificity of scFv k18 via ELISA
ScFv k18 was purified from the soluble fraction an overnight expression culture
using Ni2+-NTA chromatography. The scFv k18 readily bound the target bacterium B.
thuringiensis and several other non-target bacteria of the panel.

A multi-specific scFv would result in numerous false positives when incorporated into
the biosensor. To improve the specificity of isolated scFvs a negative selection protocol
was employed during biopanning. E. coli was chosen as the non-target bacterium for
several reasons. The scFv k18 demonstrated significant affinity toward E. coli in ELISA,
which suggested a potentially abundant epitope present on both B. thuringiensis and E.
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coli. Secondly, E. coli is a gram-negative bacterium in contrast to the gram-positive
classification of B. thuringiensis. An initial selection against a gram-negative bacterium
may eliminate those scFvs specific for carbohydrate and other epitopes of the
lipopolysaccharide layer (LPS) of gram-negatives. Third, E. coli is an enteric bacterium
while B. thuringiensis is found within the soil. The surface structures of the two bacteria
would be adapted to survival in their particular habitat; the negative selection would
potentially eliminate scFvs targeting conserved epitopes of enteric bacteria.
The initial library was subjected to four rounds of standard biopanning and two
rounds of negative selection with E. coli as the non-target antigen. To circumvent delays
associated with the low-throughput direct method of colony analysis, a plate lift assay
was utilized. Phages were amplified from the last round of negative selection and serial
dilutions of the culture were plated onto selective media to produce output plates with 20
– 50 cfu. Colonies were replicate plated to nitrocellulose membrane and the activity of
their scFvs examined against live B. thuringiensis using the protocol of Radosevic et al.
(126)

. Seven of the twenty clones present on the output plate produced scFvs that bound

the bacterial target. These clones were subjected to small-scale protein expression trials.
ScFv isolated from the periplasmic space were tested using a whole-cell ELISA protocol
against a limited number of bacteria (B. thuringiensis, P. putida, S. enterica, and E. coli)
to assess specificity (Figure 26). Of the seven examined, four (b1, b3, r1 and r2)
demonstrated no activity toward any of the bacterial targets. The scFvs from clone b2
lacked specificity, binding all four bacterial targets with varying affinity similar to scFv
K18. Two clones, s24 and s25, expressed scFvs that recognized only B. thuringiensis.
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Figure 26. Bacterial Specificity of Clones Isolated through Negative Selection
Soluble scFvs were isolated from the periplasmic space of individual clones
identified following negative selection biopanning. The soluble scFv were assayed for
affinity toward the target bacterium (B. thuringiensis) and several non-target bacteria.
The scFv s24 and scFv s25 demonstrated high specificity for the target bacterium.

The scFv s24 proved to be insoluble during small-scale expression trials. Although the
scFvs isolated from the periplasmic space of this clone generated a positive signal in the
ELISA assay (Figure 26), the quantity of soluble scFvs was insufficient to proceed with
purification via affinity chromatography. The scFv s25 was also mostly insoluble,
however, there was a sufficient quantity of soluble scFvs to allow for subsequent
purification. As was observed with scFv k18, the recovered scFvs were only a minor
component in the column elutions and were visible only through immunoblotting.
Affinity purified scFv s25 was tested against the complete panel of bacteria via ELISA
(Figure 27). The scFv s25 exhibited little to no binding with the negative selection
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antigen, E. coli or any other bacteria of the panel. An absence of B. subtilis and L.
monocytogenes binding suggests that scFv s25 recognizes an epitope that is not
conserved among gram-positive bacteria.
The negative selection technique proved an effective method of enriching for scFvs
with high target specificity. Further analysis of specificity against a larger panel of
bacteria would be required to confirm monospecificity for B. thuringiensis, however,
since scFv s25 did not bind all of the other non-target, the scFv was considered an ideal
candidate for preliminary trials of the biosensor. In addition to B. thuringiensis detection,
the biosensor could be tested with the non-target bacterium to establish false positive and
false negative statistics for the prototype device.

Figure 27. Analysis of the Bacterial Specificity of scFv s25 via ELISA
The scFv s25, isolated via affinity chromatography exhibited significant
specificity to the B. thuringiensis target. Absorbance measurements for B.
thuringiensis were ten-fold higher than those contributed by the secondary antibody
alone. No significant interaction with non-target bacteria of the panel was detected.
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Bacillus anthracis Biopanning
Immunization of the rabbit with B. thuringiensis ensured the construction of an scFv
library enriched for those capable of binding conserved epitopes of Bacillus species. It
was postulated that from this library it would be possible to isolate scFvs capable of
recognizing other Bacillus targets of interest, particularly, Bacillus anthracis.
Irradiated vegetative B. anthracis cells were obtained from the Biodefense and
Emerging Infections Research Resource Repository – Critical Reagents Program, a
division of the American Type Culture Collection. Distribution of B. anthracis, due to its
potential as a bioweapon, is highly controlled. Since only a minimum quantity of the
bacteria was received from ATCC (1 ml solution at a concentration of 7.2 x 108 cfu/m),
105 bacteria, were immobilized for biopanning compared to the standard 107 cells for
other experiments. Kristina Clarke conducted five rounds of biopanning against B.
anthracis following the standard protocol.
Prior to analysis of individual clones, a phage ELISA protocol was employed to assess
enrichment of scFvs in each round of biopanning. The results of this assay would
determine which biopanning round would be most suitable for screening of individual
colonies. Although theoretically target-specific scFvs should be enriched with each
successive round, scFv-producing cells grow and divide more slowly than those clones
lacking an scFv gene (18). Given the poor growth, individual clones could potentially be
lost through excessive rounds of selection. The phage ELISA evidenced enrichment of
phage up to the third round of biopanning (Figure 28). The subsequent round showed a
marked decrease in absorbance potentially indicating a loss of target-specific molecules.
The scFvs capable of target recognition were not significantly enriched in the fifth round
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either, indicated by the absorbance value which was still well below the peak seen in
round three.

Figure 28. Enrichment of scFvs During Successive Rounds of B. anthracis Biopanning
Phage preparations from individual rounds of biopanning were examined via ELISA
to visualize enrichment of target-specific scFvs. Biopanning round three demonstrated a
greater than three-fold increase in the absorbance value compared to the initial library,
suggesting the greatest abundance of scFv capable of binding the target antigen.

Approximately 200 individual clones from the third biopanning round were examined
for the presence of the scFv gene. Although the phage ELISA suggested an enrichment of
target-specific scFvs in this round, only five clones contained a DNA fragment that could
be excised with SfiI. Of these, only two clones contained a full-length scFv gene (800
bp).
Small-scale expression studies for the two clones expressing scFv k4 and scFv k5
were conducted in E. coli strain BL21. A moderate level of protein expression; i.e. scFv
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bands visible on Coomassie stained gels (Figure 29), was seen for both clones. The
quantity of scFv present in the soluble fraction was sufficient for subsequent affinity
purification. In addition to the scFvs within the soluble fraction, as shown on the
immunoblot in Figure 29, both clones exported scFv protein to the culture medium. The
culture medium, although not previously examined, was shown by other researchers to
contain scFvs released into the medium when expression is conducted at temperatures
above 25 C (139-141). Although scFvs were not purified from the culture medium for these
clones, later experiments did examine the potential of obtaining soluble recombinant
proteins from this source.

102

Figure 29. Small-Scale Expression of scFv k4 and scFv k5
Equivalent protein concentrations (25 g) of the soluble (S) and insoluble (P)
fractions of the lysate were resolved using SDS-PAGE. A 20 l aliquot of the
culture medium (CM) was included to determine the extent to which scFvs were
secreted from the cells.
Moderate over-expression of the scFv is evident in clone k5 as evidenced by a
large protein band at approximately 35 kDa that is well defined on the Coomassie
stained image (left image with the arrow). A less visible, though still present, band
of the same MW can be observed in the supernatant fraction of scFv k5 as well as
the pellet material of scFv k4
A considerable proportion of protein was insoluble for both clones as evidenced
by immunoblot analysis (right image). However, both clones produced a sufficient
quantity of soluble protein to allow for subsequent IMAC purification and ELISAs.
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The scFv k4 and scFv k5 were purified from the soluble fraction of the culture lysate
using Ni2+-NTA affinity chromatography. Column elutions were examined with ELISA
to determine scFv specificity (Figure 30). Absorbance measurements for scFv k4 were
consistently three fold lower than those of scFv k5 for all bacteria of the panel. The scFv
k4 did exhibit reduced expression compared to scFv k5 (Figure 29), therefore, it is
unlikely that the elutions tested for scFv 4 and scFv k5 contained equivalent
concentrations of scFvs. This may have contributed to the lower absorbances for scFv k4.
Additionally, amino acid sequence analysis indicated only 76% similarity between the
two scFvs. Variations in the amino acid sequences of the CDRs may have contributed to
the differences in affinity for the panel bacteria.
Interaction with B. anthracis was minimal for both scFvs. Interestingly, the
absorbance values for the other gram-positive bacteria (B. subtilis, B. thuringiensis, and
L. monocytogenes) of the panel were three to four times greater than those measured for
gram-negative bacteria. Although contradicted by the B. anthracis sample, this
observation suggested that both scFvs potentially bound an epitope conserved among
gram-positive bacteria. To resolve this inconsistency, the B. anthracis sample was further
examined using microbial techniques to ensure there was no contamination that may
explain the results of the specificity ELISA. A Gram stain and light microscopy
confirmed that the sample was free of other bacteria or artifacts that may have
contributed to the optical density value that was measured. A malachite green stain, a
technique to stain bacterial spores, was also performed to further examine the sample. A
significant number of spores were present in the sample. A direct count of the cells within
the field of view revealed that approximately 60% of the bacteria contained a bacterial
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spore and that numerous free spores were present in the sample. The free spores would
contribute to the optical density of the sample, therefore cell densities calculated for both
biopanning and ELISAs would be overestimates. The high affinity for the other grampositive bacteria suggested that scFvs k4 and k5 were binding a surface epitope. The
lower percentage of intact bacteria in the B. anthracis sample combined with the
inaccurate calculations of cell density would explain the low absorbance values for both
scFv and the B. anthracis antigen. A vegetative bacterial sample, that could accurately be
quantitated, would be required to assess scFv affinity for the B. anthracis target.

Figure 30. Specificity of scFv k4 and scFv k5 Purified via Affinity Chromatography
Live bacteria were bound in triplicate to a microtiter plate at equivalent cell densities
based on optical density. ScFvs k4 and k5 were eluted from a Ni2+-NTA affinity column
as a heterogeneous solution
Both scFv k4 and scFv k5 bound primarily gram-positive bacteria of the panel (Abs >
0.1) although scFv k4 exhibited lower affinities compared to scFv k5. ScFv k5 did bind
some gram-negative bacteria, however, absorbance values were to 2 to 3 times less than
those for the gram-positive bacteria of the panel.
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The scFvs highly specific for B. anthracis were not readily isolated from the
immunized library. While two scFvs that did recognize epitopes of gram-positive bacteria
were isolated, no scFv was obtained that possessed the desired monospecificity that
would have made them suitable for use in the biosensor. Although the high spore
concentration in the B. anthracis sample obtained from ATCC provided some insight into
the ELISA results for scFv k4 and scFv k5, an scFv should have been isolated that bound
the spores themselves. Additionally, since there were still intact cells within the ATCC
sample, greater success should have been achieved in isolating scFvs specific for B.
anthracis surface epitopes.
Since the phage library was constructed from a rabbit immunized with B.
thuringiensis, a lack of scFv diversity may have contributed to the inability to isolate
scFvs to other target antigens. The scFv library was therefore examined against other
bacterial targets to assess diversity.
Pseudomonas species Biopanning
The specificity ELISAs of previous biopanning rounds identified scFvs with affinity
for Pseudomonas species (Figure 25, Figure 26). Biopanning against these targets was
conducted to ascertain if Pseudomonas-specific scFvs could be isolated from the
immunized library. Obtaining scFvs specific for a bacterial target other than the B.
thuringiensis immunogen would establish the diversity of the library.
Four rounds of biopanning were conducted using the standard biopanning protocol.
Analysis of phage preparations from each round of biopanning implied that enrichment of
target-recognizing scFvs had not occurred (Figure 31). For both Pseudomonas targets,
absorbance values measured after biopanning round five were only marginally above
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those for the initial library. In contrast, direct counting of colonies on phage input and
output plates, performed after each round of selection, continued to produce phagebinding efficiencies (10-3 to 10-5 % phage bound per round of biopanning) within
parameters established by Barbas III et al. (57) that are indicative of successful selection.
Since phages were recovered from each round of selection it was suspected that scFvs
were present, although likely of low affinity since they were not detected in the phage
ELISA.

Figure 31. Enrichment of scFvs During Pseudomonas Biopanning
Phage preparations from each round of biopanning were examined using ELISA
to visualize enrichment of target-specific scFvs. Absorbance values for each round
of biopanning did not increase significantly above those for the initial library
suggesting that enrichment of scFv capable of binding either Pseudomonas species
had not been achieved.

Forty clones from the fourth round of biopanning against P. aeruginosa were
examined to identify those with an scFv gene. None of the clones contained an insert.
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Screening of additional colonies from the third and fourth rounds of biopanning rounds
also failed to identify clones with an scFv gene insert.
The inability to isolate clones containing an scFv gene and the apparent lack of phage
enrichment suggested that the phages recovered during biopanning were the result of
non-specific interaction between the phages and the bacterial target. Such interactions
have been shown for M13 filamentous phages by other researchers (142). This non-specific
binding could occur with an undefined surface structure or perhaps with the capsule of P.
aeruginosa. Difficulties with P. aeruginosa as the target antigen had also occurred in
previous experiments. Although it was not determined whether it was the capsule or some
other characteristic of the bacterium, inhibition of antibody interaction with target
epitopes (Figure 10) and non-specific interactions with secondary antibodies (Figure 17)
was previously observed. Continued biopanning and colony screening was therefore not
pursued for this bacterium.
In contrast to the results obtained with screens for P. aeruginosa scFvs, DNA inserts
of either the expected 800 bp or the 300 - 400 bp truncated molecule were identified in
sixteen of the forty clones tested from P. putida output plates. Small-scale expression in
E. coli strain DH5 was conducted for the five clones that contained the full-length scFv
gene. Two of the clones, p6 and p12, expressed scFvs with sufficient solubility to allow
for subsequent affinity purifications and specificity ELISAs (Figure 32). Neither scFv
bound the P. putida target with high affinity. As with scFv k18 (Figure 25), both scFvs
bound a number of unrelated bacteria of the panel.
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Figure 32. Specificity ELISA of scFv p6 and scFv p12
Bacteria were immobilized in triplicate for specificity assays of scFv p6 and scFv
p12 isolated from the soluble fraction of overnight expression cultures using Ni2+NTA chromatography.
Neither scFv p6 nor scFv p12 exhibited substantial affinity for the P. putida
target. Both scFvs bound gram-positive and gram-negative bacterial targets with
varying affinities.

Two unique clones isolated from the last round of P. putida biopanning expressed
scFvs that exhibited minimal affinity for the bacterial antigen. While the results of the P.
aeruginosa biopanning (Figure 31) were likely the product of non-specific interaction
from the M13 phage, the lack of scFv enrichment observed for P. putida biopanning
could be attributed to a low scFv affinity for the target bacterium. Forty percent of the
clones examined contained a gene insert that could be excised by SfiI digest. Therefore,
unlike P. aeruginosa biopanning, the percentage of phages bound determined by direct
counts of input and output plates was likely the result of phage enrichment and not nonspecific interaction with M13. The washes performed during biopanning are not as
rigorous as those conducted during standard ELISA and may not have been sufficiently
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stringent to dislodge low-affinity scFvs from the immobilized bacteria. In contrast, during
the phage and specificity ELISAs, low-affinity scFvs would be removed in the washes
leaving no binders to detect. This would explain what appeared to be a lack of enrichment
in the phage ELISA as well as the low affinity for the P. putida target exhibited in the
specificity ELISA (Figure 32). Although additional clones could have been identified,
based on the results of the phage ELISA, it is unlikely that any would have shown the
desired target specificity or affinity for utilization in the biosensor.
Isolation of scFvs from the immunized library that exhibited high specificity and
affinity for B. thuringiensis was accomplished through a combination of standard and
negative selection biopanning. The immunized library, however, could not be
successfully employed to isolate scFvs with similar binding characteristics for other
bacterial targets. DNA sequence alignments (ClustalW) of all scFvs of interest (scFvs
k18, s24, s25, k4, k5, p6, and p12) did not suggest a lack of diversity of the scFv library.
ScFvs were only 80 – 85% similar, with sequence similarity existing primarily within the
framework regions of the heavy and light chain genes.
The host rabbit was immunized to enrich for lymphocytes producing antibodies
specific for surface epitopes of Bacillus species. In such excess, the heavy and light chain
genes from these cells may have masked the presence of other non-Bacillus antibody
genes. To increase diversity, with respect to both library size and antigen-recognition, an
scFv library from a non-immunized rabbit was constructed.
Construction of a Naïve scFv Library
Immunized animals are utilized as a source of highly specific antibodies that
demonstrate excellent affinities for their target antigens (21). Naïve antibody libraries
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circumvent the immunization process by relying on an scFv repertoire that exceeds that
of the immunized library and more closely mimics the clonal diversity of the host
immune system. Because the diversity is increased, the likelihood of isolating scFvs
capable of binding a target antigen should be increased. Naïve libraries have been used
with great success by several research groups to obtain scFvs specific for an array of
antigens (62, 72, 78). The naïve library used in this study was constructed to fulfill the
adaptability requirements of the biosensor and overcome the limited successes of the
immunized library in obtaining scFvs specific for non-Bacillus targets.
A naïve library was assembled from the spleen of a non-immunized, 4 - 6 week old
rabbit harvested by the Antibody Research Corporation (St. Charles, MO). Primers for
the IgG constant domains were used as before, however, since the initial immune
response is comprised primarily of IgM molecules, primers specific for the first constant
domain of the IgM heavy chain were also designed according to the literature (143-145). The
heavy and light variable domain genes were amplified via PCR from a cDNA pool, gel
purified, and combined into a fusion gene using an overlap extension PCR by Kristina
Clarke.
To improve the efficiency of transformation, a highly electrocompetent E. coli strain,
SS320, was generated from MC1061 and XL1-Blue following the protocols of Sidhu et
al. (124, 146). Bacterial mating was performed to transfer the F+ genotype of XL1 Blue to
the MC1061 strain. This generated E. coli strain SS320 that was conducive to phage
display and had the added benefit of high transformation efficiency by electroporation.
Following bacterial mating, cells were made electrocompetent utilizing the protocol of
Barbas III et al. (57).
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Small-scale ligation–transformation trials were performed as described for the
construction of the immunized library to assess both transformation efficiency of the
SS320 competent cells and to determine the number of ligations needed to achieve a
clonal diversity of 109. Based on the results of the initial trials, forty 100 l ligation
reactions were assembled. The library diversity, calculated as described in the
construction of the immunized library from the number of transformants following
electroporation of SS320 cells, was approximated to 8 x 108.
Salmonella typhimurium Biopanning
The naïve library was subjected to four rounds of standard biopanning against
Salmonella enterica serovar Typhimurium (referred to as S. typhimurium). As with
previous experiments, phage preparations from each round of biopanning were examined
by ELISA to determine if an enrichment of target-specific scFvs had occurred (Figure
33). The fourth round of biopanning showed a two-fold increase in the absorbance value
compared to the initial library. Although the results suggested only a modest increase in
the population of scFvs specific for the target antigen, individual colonies were isolated
and examined for the presence of the scFv gene.
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Figure 33. Enrichment of ScFvs During S. typhimurium Biopanning
Phage preparations from each round of biopanning were examined for binding affinity
toward S. typhimurium.
The fourth round of biopanning exhibited a two-fold increase in absorbance compared
to the initial library indicative of an enrichment of scFvs recognizing the target bacterium.

More than 200 individual clones were examined from the last round of biopanning
(some performed by Kristina Clarke). Unlike previous trials with P. aeruginosa and B.
anthracis, a significant number of the colonies examined (30%) contained an scFv gene.
Small-scale expression was conducted in E. coli strain BL21 to assess scFv solubility and
specificity for bacterial targets. Many of the clones expressed insoluble scFvs that
precipitated in the pellet fraction following cell lysis. Nine clones (scFv k20 – k26, scFv
s26, scFv s27) expressed recombinant antibodies with sufficient solubility to allow for
subsequent purification and specificity ELISAs. Although there was some variation in the
affinity for target and non-target bacteria, none of the scFvs demonstrated a substantial
specificity for S. typhimurium. The specificity ELISA for scFvs from two clones, s26 and
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s27, is shown in Figure 34. It was concluded, therefore, that the standard biopanning
protocol was not sufficiently stringent to isolate scFvs with improved target specificity.

Figure 34. Specificity of scFv s26 and scFv s27 Assessed via ELISA.
The scFv s26 and scFv s27 were purified using a Ni2+-NTA column and analyzed
via ELISA to assess target specificity. Values are corrected for background
absorbance from the secondary antibody.
Both scFvs lacked specificity for the S. typhimurium target and demonstrated affinity
for several bacteria of the panel.

To repeat the successes achieved with the immunized library and the isolation of the
highly specific scFv s25, a negative selection strategy was employed to enrich for scFvs
specific for S. typhimurium. L. monocytogenes, a Gram positive bacterium, was chosen as
the negative selection antigen because, like S. typhimurium these bacteria are flagellated
and capable of colonizing the gut of the same host organisms. Removing scFvs that bind
highly similar epitopes through negative selection may enrich for those that are specific
for unique epitopes of S. typhimurium.
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Figure 35. Enrichment of scFvs for S. enterica During Negative Selection
Phage preparations from each round of negative selection biopanning were
examined via ELISA to assess enrichment of scFvs capable of binding the S.
typhimurium target.
Affinity for the non-target bacterium was maintained despite the negative
selection protocol. An eight fold increase in absorbance was measured for S.
typhimurium and a thirteen fold for L. monocytogenes.

Analysis of the phage preparations by ELISA was performed after two rounds of
negative selection. The initial phage ELISA, however, indicated no significant decrease
in the interaction of the scFv pool with L. monocytogenes. An additional two rounds of
negative selection were performed. While the phage preparation of the final round was
enriched for scFvs capable of binding the target bacterium, there was also an unexpected
increase in binding for the non-target bacterium (Figure 35). The absorbance values for
the scFv targeting S. typhimurium following four rounds of negative selection increased
by nearly a factor of eight compared to the last round of standard biopanning (labeled
initial sample - Figure 35). Unfortunately, however, an approximately thirteen-fold
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increase in absorbance for L. monocytogenes was observed. Analysis of the phage ELISA
suggested an enrichment of scFvs capable of binding both S. typhimurium and L.
monocytogenes.
The phage pool from round four of negative selection was amplified and plated on
selective medium to isolate individual colonies. A high-throughput microtiter plate
method of screening colonies was implemented for analysis of these clones (59). This
method permitted several hundred colonies to be examined simultaneously for both scFv
expression and affinity for the bacterial target. Two hundred colonies obtained from the
output plates were screened in the first application of this method. Of these, 70 colonies
(35%) had an absorbance two-fold greater than background (absorbance ≥ 0.1). Positive
clones were patched onto solid medium for subsequent plasmid isolation and digestion
with SfiI. All of the clones examined except one contained an scFv gene smaller than that
of a full-length scFv (Figure 36). The microtiter plate assay was repeated using L.
monocytogenes as the immobilized antigen. A single clone of the 200 examined was
identified as a positive. Digest analysis of this clone also produced a smaller than
expected scFv gene. The small size of the scFv gene suggests that expressed recombinant
antibody is comprised of a single variable domain.

116

Figure 36. Restriction Digest Analysis Clones Isolated Following Negative
Selection Biopanning
Individual colonies identified with the microtiter method of screening were
grown on selection medium. Plasmid DNA, obtained through direct colony lysis,
was digested with SfiI to confirm the presence of the scFv gene.
Clones that will be further examined are identified at the top. The vector
backbone and scFv gene are indicated with arrows. All clones isolated from the
last round of negative selection contained a truncated scFv gene of 500 bp or
less.

The truncated scFv genes were amplified from individual clones via PCR and sent to
Northwoods DNA, Inc. for DNA sequencing. Analysis of the nucleotide sequence would
identify which of the variable domain genes was persisting through numerous rounds of
selection by forming a molecule capable of antigen binding. Sequence analysis showed
that the majority of the sequenced genes lacked a full-length light chain variable domain
gene (Figure 37). The linker sequence that facilitated heavy and light chain gene fusion
through oePCR, although not complete in all of the clones examined, could readily be
identified. Protein BLAST analysis was performed with the putative heavy chain gene,
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the amino acid sequences downstream of the linker. For all six scFv genes sequenced the
heavy chain variable domain gene of Oryctolagus cuniculus (rabbit) exhibited the
greatest similarity with an E value ≤ e-47.

Figure 37. Sequence Analysis of Truncated scFv Genes
Sequence analysis of individual clones isolated from negative selection
biopanning of the naïve library. The conserved amino acid sequence contributed
by the forward primer used in library construction is highlighted in purple and the
scFv linker sequence is highlighted in green. The scFv k18 gene is included to
illustrate the characteristic portions of the typical full-length scFv. With the
exception of scFv s38, all the scFvs isolated from the last round of biopanning lack
a complete light chain gene.

The negative selection process apparently eliminated the full-length scFvs that were
present during the initial biopanning rounds and enriched for truncated molecules that
were only a minor product initially. Other researchers have utilized recombinant
antibodies comprised of only the heavy chain variable domain of unusual
immunoglobulins of sharks and camels for the detection of a number of antigens (68, 69, 147,
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148)

. In light of these successes, the single domain, truncated scFv clones isolated from

the negative selection were further examined for protein expression and specificity
against the bacterial panel. The cell pellets that remained in the microtiter expression
plates were lysed and the soluble proteins resolved via SDS-PAGE. The molecular
weight of the recombinant proteins, visualized with an immunoblot (Figure 38), varied
from 15 kDa (scFv s28) to 29 kDa (scFv s36).
The low molecular weight of the scFvs visualized on the immunoblot was expected
for all of the molecules except scFv s38. The scFv s38 gene was a full-length gene
(Figure 37) that, based on in silico translation analysis using the Transeq program,
contained an open reading frame. The gene sequence was further examined using the
Graphical Codon Usage Analyzer software, which identified a sequence of seven
consecutive codons whose tRNA complements are in very low abundance (<10%) in E.
coli. This nucleotide sequence may have prematurely terminated translation of the scFv
by causing the ribosome to stall. A second potential translation start site was identified
within the light chain using GeneHacker software. In combination, these discoveries
explain the low molecular weight (20 kDa) scFv (Figure 38) produced by the full-length
scFv gene.
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Figure 38. SDS-PAGE Analysis of Truncated scFv Expressions
Bacterial pellets were recovered from microtiter plates and lysed at 100 C in
loading buffer. Proteins were resolved on a 12% acrylamide gel and transferred to
nitrocellulose for immunoblotting.
The scFvs varied significantly in molecular weight. Given the small size of the cell
pellet, equal cell densities may not have been examined. Expression of individual
scFvs could not be accurately compared between clones.

Proteins were isolated from the periplasm of small-scale expression cultures to assess
specificity of the truncated scFv molecules (Figure 39a). Unexpectedly, none of the scFvs
showed affinity for either of the Salmonella species examined. Additionally, the majority
of scFvs tested continued to bind L. monocytogenes despite multiple rounds of negative
selection biopanning. Based on the results obtained with the ELISA, the single domain
scFvs appear to form functional antigen-binding domains capable of binding bacterial
epitopes, although as with the full-length scFvs isolated prior to negative selection
(Figure 34), there was not significant specificity for S. typhimurium. In contrast, the scFv
120

s32, bound all bacteria of the panel with high affinity, displaying absorbance values ten to
twenty- fold higher than those of the other scFvs tested (Figure 39b). While other scFvs
such as scFv k18 (Figure 25) have been identified that bind several bacteria of the panel,
scFv s32 interacts strongly with all bacteria currently used. Further testing of this scFv
would be required to determine if the results of the specificity ELISA were the product of

A

B

Figure 39. Specificity of Truncated scFvs from Unique Clones Identified Following
Negative Selection Biopanning
Soluble scFvs s28, s32, s34, s36, s38 isolated via osmotic shock were tested for
bacterial specificity with ELISA.
The scFvs s28, s34, s36, and s38 bound only P. fluorescens and the negative selection
antigen L. monocytogenes with significant affinity (Abs > 0.1). Interestingly, none of
these scFvs had affinity for the S. typhimurium target. In contrast, scFv s32 bound all
bacteria (panel B) with high affinity, similar to the full-length scFv k18.
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true antigen-antibody interactions.
With the exception of scFv s25, all of the scFvs obtained through biopanning lacked
substantial specificity for target bacteria. While initially deemed advantageous, the
complexity of the bacterial cell surface and the numerous potential epitopes may have
been inhibitory to the isolation of scFvs specific for unique epitopes of target bacteria. To
examine this possibility, biopanning was conducted by Kristina Clarke against purified
O-antigen isolated from Salmonella typhimurium. The O-antigen is a complex of
oligosaccharides attached to proteins of the outer cell surface. These complexes, which
are often associated with virulence, can be used to identify particular strains of S. enterica
(149, 150)

. Utilization of the O-antigen during biopanning would enrich for scFvs with

improved specificity toward S. typhimurium by limiting the number of epitopes available
during selection.
The naïve library was subjected to five rounds of biopanning against the O-antigen, at
which point a phage ELISA was performed to assess enrichment of antigen-specific
scFvs (Figure 40). The microtiter plate assay was used initially to screen 60 individual
colonies from the last round of biopanning. Eighteen of clones examined (30%) bound
the immobilized O-antigen (Abs > 0.1). Positive clones were transferred to antibiotic
containing solid and liquid medium to facilitate further analysis via SfiI restriction
enzyme digestion. A single clone, k2, contained a full-length scFv gene insert. Plasmid
DNA from three of the other clones contained a gene product of approximately 200 bp all
others were empty vectors.

122

Figure 40. Enrichment of scFvs Specific for S. typhimurium O-antigen
Phage preparations from each round of biopanning were assessed using ELISA to
ascertain if enrichment of scFvs with affinity for the O-antigen of S. typhimurium
had occurred. A dramatic increase in scFvs binding the target antigen was evident in
the fourth and fifth rounds of selection. A fifteen-fold increase in the absorbance
measurement between the initial and last round of biopanning was observed.

Small-scale expression and specificity studies of scFv k2 were conducted as
previously described. Clone k2, as with other clones, did not produce an over-abundance
of recombinant protein during expression trials, scFv k2 could only be identified through
immunoblotting. Although the majority of the protein was insoluble (Figure 41),
sufficient quantities of soluble scFvs were isolated via Ni2+ -NTA affinity
chromatography to allow specificity to be examined via ELISA. The scFv k2 did
demonstrate affinity for the O-antigen itself and both bacteria of the Salmonella species.
However, as with other scFvs (scFv k18 – Figure 25 and scFv b2 – Figure 26), scFv k2
readily bound several bacteria of the panel (Figure 42).
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Figure 41. Small-Scale Expression of scFv k2
The soluble and insoluble fractions obtained following cell lysis were separated
via SDS-PAGE.
The scFv was not evident on the Coomassie stained gel (left image) but was
identified using a standard immunoblotting protocol (right image).
The majority of the scFvs are found in the insoluble pellet fraction.
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Figure 42. Analysis of Bacterial Specificity of scFv k2
The scFv k2 was purified using IMAC from the soluble fraction of an overnight
expression culture.
ScFv k2 readily bound the O-antigen and both Salmonella species in addition to
all of the non-target bacteria of the panel. Greater affinity for non-target grampositive bacteria compared to the O-antigen used in biopanning was observed.

Additional colonies were screened from the fourth and fifth rounds of biopanning,
however, no other full-length scFv genes were identified. Although single domain
antibodies isolated in previous biopanning attempts displayed binding capabilities (Figure
36), clones with a truncated scFv gene from these experiments were not examined. The
scFv gene was less than 200 bp in these clones, smaller than a typical variable domain
(300-330 bp).
Although antibodies specific for carbohydrates of the LPS have been reported in the
literature (151, 152), attempts to isolate O-antigen specific scFvs from the naïve library were
unsuccessful. It could not be determined based on these rounds of selection whether the
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inability to isolate a highly specific scFv was the product of the poor choice of antigen or
the diversity of the naïve library.
The naïve library was also selected for scFvs against L. monocytogenes by Kristina
Clarke. Phage preparations from each round of biopanning were assessed via ELISA,
however, no significant enrichment of scFvs was observed similar to the results of the
Pseudomonas biopanning (Figure 31). Several hundred colonies were screened using the
direct colony lysis protocol, however, a clone containing the scFv was not identified.
Biopanning of the initial library was repeated for the L. monocytogenes antigen to ensure
failures were not the product of unrecognized experimental complications. After four
rounds of selection using the standard protocol, two hundred additional colonies were
screened using the microtiter plate assay. None of the clones exhibited an absorbance
measurement above the background (Abs > 0.1). The failures of the biopanning against L.
monocytogenes were not anticipated due to the high affinity shown by other scFvs for this
antigen (Figures 25, 30, and 32). Additional biopanning was not conducted since at the
conclusion of this project a suitable explanation for the observed complications had not
been established.
Although several bacteria and a purified surface antigen were employed as targets, no
scFvs with improved target specificity were isolated from the naïve library. Library
construction, through the random combination of heavy and light chain genes, is thought
to produce a highly diverse scFv repertoire. While the true diversity of the scFv pool
cannot easily be determined, the DNA sequences of scFvs isolated during biopanning
were compared to assess variability within the CDR sequences. The heavy chain gene
sequences of all clones of interest were aligned using ClustalW. Nucleotide similarity

126

varied from 65 – 83 % identity for the heavy chain variable domain gene. ScFv genes
isolated from the naïve library displayed greater sequence variability compared to those
of the immunized library (80 – 85%), however, since the library did not yield scFvs with
the desired binding characteristics, the overall library diversity may still be inadequate.
Expression and Purification of scFv
Expression of scFv
ScFvs were initially expressed in either E. coli strain DH5 or BL21, suppressor
strains that inhibit the translation of the pIII phage capsid protein, to assess solubility and
provide sufficient quantities of scFvs to allow for subsequent specificity assays. For these
trials, the scFv gene was maintained in the phage display vector pComb3 XSS, which
provided for periplasmic localization of scFvs. Expression was generally conducted at
37 C with 1 mM IPTG added to induce expression. Cultures were maintained for 12 - 16
h prior to periplasmic extraction of soluble proteins via osmotic shock or lysis of the cell
pellet and Ni-NTA purification of scFvs from the soluble fraction. Under these
conditions, all of the scFvs demonstrated low expression and poor solubility (Figures 23,
29, and 41). Several different induction conditions (temperature, IPTG concentrations,
duration of expression), expression vectors, and bacterial strains were examined in an
attempt to improve both expression and solubility of scFvs. The scFv k18 was used for
these studies since it exhibited slightly improved expression levels compared to other
scFvs. A summary of plasmid expression vectors and the E. coli strains examined can be
seen in Table 2.
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Table 2. Plasmid Vectors Examined to Optimize scFv k18 Expression

Vector

Bacterial Strain

Expression

Solubility

pComb3 XSS

DH5 / BL21 / BL21 Codon Plus

+

++

pProEx Htc

BL21 Codon Plus

+

+

pET21 c

BL21 Codon Plus

+

+

pET41 c

BL21 Codon Plus

++++

+

Note.
Expression of scFv k18 was conducted in a number of bacterial strains and plasmid
vectors in an attempt to optimize expression. The pComb3 XSS vector targeted scFvs
to the periplasm which improved solubility. The pProEX and pET vectors utilized
cytoplasmic expression which decrease solubility slightly. Expression of scFv k18 as a
GST-fusion (pET41 c) dramatically improved the expression.
Solubility and expression are rated on a scale of one (lowest) to four (highest)
indicated by the “+” sign.

Expression conditions such as temperature, IPTG concentration, and duration of
induction were examined for scFv k18 in the pComb3 XSS vector. None of the examined
conditions succeeded in increasing expression of the recombinant proteins. As in the
preliminary trials, scFvs were detectable only via immunoblotting. A slight improvement
in solubility was observed for lower temperature induction (20 - 25 C) trials.
Adjustments to the IPTG concentration and the duration of induction had little affect.
Codon bias analysis was conducted using the web-based Graphical Codon Usage
Analyzer (http://gcua.schoedl.de/). In silico analysis of the scFv k18 gene identified nine
amino acid codons whose corresponding tRNA is present in low abundance in E. coli. To
compensate, expression studies were conducted in BL21 – Codon Plus – (RIL) E. coli, a
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strain that provides plasmid-encoded tRNAs for six of the nine rare codons. Expression in
this bacterial strain did not, however, improve scFv expression or solubility.
Although the pComb3 XSS vector provided the advantage of periplasmic localization,
other research groups utilize commercial vectors to improve expression and/or solubility
of scFvs (52, 54). The pProEx Htc, pET21c, and pET41c were chosen for cytoplasmic
expression of scFvs. Similar to pComb3 XSS, all vectors incorporated a terminal 6x His
tag onto the recombinant protein to allow for subsequent IMAC chromatography. The
pProEx and pET41 vectors incorporate the 6xHis affinity tag at the C-terminus while the
pET21 incorporates the sequence at the N-terminus of recombinant proteins. Expression
with the pET21 vector was investigated to determine if the position of the 6xHis epitope
affected expression or solubility The pET41 vector differed from the other two vectors in
encoding a portion of the glutathione-S-transferase (GST) protein upstream of the
multiple cloning site (MCS). The GST-fusion has been demonstrated to improve
expression and solubility of recombinant proteins (153). Since all vectors utilized a similar
MCS, a single set of primers were designed to facilitate the addition of BamHI and
HindIII restriction enzyme sites at the 5’ and 3’ ends of the scFv gene respectively. As
previously described, PCR products were purified using agarose gel electrophoresis and
cloned into the pCR Blunt II TOPO vector for confirmation of the DNA sequence. The
scFv gene was cloned into the aforementioned expression vectors using standard
restriction digestion, ligation, and transformation protocols.
Cytoplasmic expression of scFv k18 in pProEx or pET21 vectors did not result in
significant improvements in quantity or solubility of the scFv (Table 2). This observation
was consistent regardless of the expression conditions. In contrast, expression in the

129

pET41 vector did visibly improve the quantity of scFv k18 expressed. A defined protein
band of approximately 60 kDa (scFv 35 kDa , 25 kDa GST) was visible following SDSPAGE and Coomassie staining (Figure 43). The immunoblot, however, suggested that
translation was still slightly inhibited. A number of secondary products, which may be
the product of premature termination of translation, were identified on the immunoblot.
Expression conducted at lower temperatures (20 - 25 C) and IPTG concentrations had
little to no effect of the accumulation of these proteins. Expression at 16 C was not
examined, however, and may have decreased the accumulation of these molecules.
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Figure 43. Small-Scale Expression Trial of scFv k18 in the pET41 Vector
Expression of scFv k18 in pET41c vector was examined for various durations.
Individual 3 ml reactions were removed at the time points identified.
The GST-scFv fusion is visible on the Coomassie stained gel (left image) as an
over-expressed protein of approximately 60 kDa (arrow). The non-induced
sample (N) does not contain a corresponding band serving as negative control.
The immunoblot (right image) identifies several products that may represent
premature termination products. The uppermost band (arrow) is approximately 60
kDa and is likely the GST-scFv k18 fusion protein

Expression of the GST-scFv fusion protein was conducted in larger volumes to better
assess the solubility of scFv k18 and allow for subsequent purification and confirmation
of scFv k18 activity. The fusion protein was largely insoluble (Figure 44) when expressed
at either 25 C or 37 C, aggregates of scFvs were evident in the pellet samples when
visualized via immunoblotting.
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Figure 44. Assessing Solubility of pET41 Encoded scFv k18
Bacterial pellets were lysed using lysozyme, B-PER II, and sonication. Sample
loads consisted of a defined quantity of protein (25 g) for the pellet sample (P) gel
and an equivalent volume of the supernatant (S).
The GST-scFv fusion is clearly discernable (arrows) in the insoluble material on
both the Coomassie stained gel (left image) and the immunoblot (right image).
Aggregates and incomplete translation products of the GST-scFv fusion are evident
on the immunoblot.

Despite poor solubility, sufficient quantities of soluble GST-scFvs were available for
purification via Ni-NTA affinity chromatography. As with previous purifications (Figure
24), elutions contained numerous contaminating proteins in addition to the fusion
proteins. Although, the GST-tag could be used enzymatically removed, the fusion protein
was left intact to determine if the GST portion affected the affinity or specificity of the
scFv. If the GST portion did not affect scFv-binding properties it could potentially be
utilized for immobilization of scFvs for QCM and SPR studies improving the probability
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that scFvs will be immobilized in the proper orientating to ensure activity of the antigenbinding site.
The GST-scFv fusion proteins obtained via affinity chromatography were tested for
target affinity using the standard ELISA protocol. The scFv k18 fusion protein displayed
high affinity for all bacteria of the panel (data not shown). Given the initial, low targetspecificity of scFv k18 (Figure 25), the initial ELISA results for the GST-scFv k18 could
not be easily interpreted. To better characterize the effects of the GST-fusion, scFv s25,
an scFv with excellent target specificity, was cloned into the pET41c vector. Following
affinity purification, the binding characteristics of the two fusion proteins were examined
via ELISA. The two fusion proteins displayed proportional binding to all bacteria of the
panel (Figure 45). This suggested that binding of the bacterial targets occurred either with
the GST portion of the fusion protein itself or was the result of GST addition to the scFv
molecule leading to a disruption of the scFv structure. Further studies would be needed to
better characterize these fusion proteins and establish the potential usage of the pET41c
vector for expression of other scFvs.
Expression of scFvs was consistently low, regardless of bacterial strain, for all
expression vectors except pET41c. To be an effective alternative to monoclonal antibody
production, a system of producing large quantities of scFv would have to be developed.
These experiments indicated that this would not be accomplished through the use of
commercial vectors or bacterial strains. Although not investigated, yeast expression and
bacterial fermentors offer additional avenues of increasing scFv production.

133

Figure 45. Bacterial Specificity of GST-scFv k18 and GST-scFv s25
The scFv k18 and scFv s25 genes were cloned into pET41c. The pET41 vector
encodes a portion of the GST protein in frame with the scFv gene resulting in a fusion
protein. The fusion proteins were isolated from the soluble fraction of expression
cultures and purified via Ni2+-NTA affinity chromatography.
Both GST-scFv preparations demonstrated proportional binding to all bacteria of the
panel. The GST-scFv s25 fusion exhibited a complete loss of the specificity for B.
thuringiensis previously shown for scFv s25. The similar affinities demonstrated for the
two very different scFvs suggests GST interaction with bacteria of the panel.

Affintiy Purification of scFv
Because variation in recombinant protein expression and solubility existed between
individual clones, experimental conditions were maintained to allow for comparison of
results. Expression was induced in 500 ml cultures (OD600 = 0.6 – 0.8) with 0.5 mM
IPTG, and then conducted overnight (12-16 hours) at 25 C. Cell pellets were lysed with
lysozyme, B-PER II bacterial extraction reagent, and sonication as previously described.
The scFvs were recovered from the soluble fraction using Ni2+-NTA column with a 3 ml
bed volume. Proteins were eluted from the column with 250 mM imidazole and collected
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in three fractions, the volume of the first two fractions was equivalent to the bed volume,
while the third fraction was twice the volume. Elution and wash fractions from the
column were always examined at a maximum volume (25 l) on subsequent SDS-PAGE
gels. Unless otherwise stated, optimization of the purification protocols was
accomplished with clone k18.
ScFvs were routinely purified from the soluble material of expression cultures using a
Ni2+-NTA agarose resin. For all purification attempts, regardless of clone, a considerable
number of contaminating proteins were also retained by the column matrix and present in
the elution fractions. Initially, it was believed that due to the low concentration of the
scFvs within the soluble fraction, excess Ni2+ ions of the column matrix were binding
other cellular proteins. Significant reductions in the volume of the column bed were made
but with little benefit to the scFv purity. Additional modifications to the manufacturers
protocol included:
1)

Salt concentrations of the wash buffers increased to 300 mM NaCl in
buffers A/C and 1.5 M in buffer B

2)

Imidazole (25 mM) added to all column buffers

3)

pH of the wash buffers decreased to pH 6.0 for buffers A/C and to pH
4.0 for buffer B.

While none of these changes were definitive improvements to the protocol, utilization of
all three modifications did seem to diminish the number of contaminating proteins in the
elution fractions (Figure 46).

135

Figure 46. Comparison of the Abundance of Non-scFv Contaminants in Eluates
Obtained from Ni2+-NTA Chromatography
The elution fractions obtained from purifications conducted one year apart
were compared to visualize improvements in purification methods. The scFv
clone, expression conditions, and volume of elutions examined were consistent
between the two experiments.
Elutions from early purification attempts (left box) contained a high
concentration of non-scFv proteins as evidenced by the Coomassie stained gel
(left image). The concentration of contaminating proteins was reduced in later
purifications (right box) through adjustments to the salt concentration and pH of
the wash buffers.

Accurate quantitation of scFvs in elutions fractions was impossible due to
contaminating proteins that were present in greater abundance. To circumvent this
complication, a second purification strategy was employed. A small affinity column was
assembled using EZview red anti-HA affinity gel (Sigma) as the column matrix.
Although this purification step allowed for the removal of the majority of the
contaminating proteins from the elution fractions (Figure 47), the anti-HA matrix was
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only available as an immunoprecipitation reagent (500 l volume) and therefore not
feasible as a primary method of purification.

Figure 47. Purification of scFvs Using Anti-HA Affinity Chromatography
ScFv-containing elutions from Ni-NTA affinity chromatography were combined
and subjected to a second column purification using an anti-HA affinity matrix. The
flow-through (FT), and all three elutions (E1-E3) were loaded at equivalent volumes
(20 l) to a 12% denaturing, polyacrylamide gel. The scFvs were not visible on the
Coomassie stained gel (left image) due to low concentration. The scFvs, however,
could be detected in all three elution fractions via immunoblotting (right image).
Although some contaminating proteins are still faintly visible in the elution
fractions, the majority passes through in the initial column loading.

The scFvs eluted from the anti-HA column were concentrated with PEG-8000,
dialyzed, and quantitated via BCA. The purified scFvs were then included on
immunoblots to establish standards of scFv concentration. These standards provided a
method of calculating the concentration of scFvs in elutions from Ni2+-NTA columns
using densitometric analysis of immunoblots.
137

Given that most of the desired protein was separated into the insoluble fraction, a
denaturating Ni2+-NTA purification protocol was attempted as previously described with
the murine scFv 4-2. The scFvs k18 and s25 were refolded using an on-column
renaturation method prior to elution. For comparison of activity following purification,
scFvs were purified in tangent from the soluble and insoluble fractions of overnight
expression cultures and then assessed using a standard ELISA protocol (Figure 48). The
denaturing process directly affected the activity of both scFv k18 and scFv s25. The scFv
k18 preparations maintained affinity for target bacteria, however, as evidenced by the low
absorbances for each antigen, some portion of the scFvs had lost activity. The measured
absorbances for the denatured/renatured scFvs was three-fold less than those of scFvs
purified from the soluble fraction. The loss of activity was more dramatic for scFv s25
samples, a near complete inactivation of the scFv was observed. Since both scFvs
displayed a significant loss of binding activity, the denaturation/renaturation purification
method was deemed unsuitable for recovery of the scFvs from the insoluble pellet.
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A

B

Figure 48. Comparison of Target Affinity for scFvs Purified from the Soluble and
Insoluble Fractions of Expression Culture Cell Lysates
The scFv k18 (panel A) and scFv s25 (panel B) were purified from both soluble
and pellet fractions of an overnight expression culture.
Equal concentrations of total protein (eluates) were tested for target affinity via
ELISA. The scFv s25 subjected to denaturation/renaturation exhibited little to no
binding activity. In contrast, denatured/renatured scFv k18 continued to bind target
bacteria, however, absorbance values were decreased three-fold suggesting some
decrease in the number of functional recombinant antibodies.
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Several clones isolated during biopanning experiments exported scFvs to the culture
medium during expression trials (Figure 29). Although this phenomenon was not
observed with clone k18, clone s25 did export scFvs to the surrounding medium when
expression was conducted at 37 C (Figure 49). The scFvs were purified from the culture
medium using a standard IMAC protocol and tested for activity via ELISA (Figure 50).
Unfortunately, scFvs obtained from the culture medium exhibited different binding
interactions with the panel bacteria. In contrast to the highly specific activity of scFv s25
purified from the supernatant, culture medium purified scFv s25 bound several non-target
bacteria. Comparison of elution fractions from the two purification methods via SDSPAGE did not indicate degradation of the scFvs, therefore, the differences in activity may
have been the result of scFv tertiary structure.
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Figure 49. Small-Scale Expression of scFv s25
Expression was conducted at 37 C to encourage scFv export to the culture
medium. Equivalent concentrations of pellet (P) and supernatant (S) fractions were
examined in parallel to an aliquot (25 l) of the culture medium (CM) on a 12%
acrylamide gel.
Although the immunoblot suggests a minimal scFv concentration in the culture
medium, the volume examined is only a fraction of the available volume (1/20,000)
compared to the volume of the other two fractions (1/6,000).
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Figure 50. Comparison of Target Specificity of scFv s25 Purified from the Culture
Medium and the Soluble Fraction of Expression Culture Cell Lysates
The scFv s25 was purified using a Ni2+-NTA affinity column from either the
culture medium or the soluble fraction of the lysed cell pellet. Equivalent total
protein concentrations were examined via ELISA to assess specificity of the purified
scFvs.
The scFv s25 purified from the soluble fraction exhibit high affinity for the B.
thuringiensis target, in contrast to scFvs purified from the culture medium. The
scFvs obtained from the culture medium demonstrated not only a reduced activity
(lower absorbance values) but also a loss of target specificity.
Absorbance values above background (which was subtracted) were observed for
scFv from the soluble fraction. The duration of the colorimetric reaction was longer
than in previous trials, which may have contributed to this observation.
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The oxidizing environment of the periplasm allows for the formation of disulfide
bonds that are often critical for scFv activity. These bonds may not form in scFvs
exported to the culture medium or may be later oxidized while in the culture medium
itself. Although purification from the culture medium was not applicable to scFv s25, the
method may prove advantageous to purification of recombinant proteins from other
clones.
Several modifications to the manufacturer protocol for IMAC were employed to
improve the purity of scFvs obtained from expression cultures. These improvements did
eliminate some of the contaminating proteins present in the elutions of early
purifications, however, a second affinity purification method was required for complete
removal of these molecules. Purification of scFvs from both the insoluble pellet material
and the culture medium was also investigated. Although scFvs could be purified from
both fractions, the specificities and affinities of these scFvs were unlike those of scFvs
from the soluble fraction. The scFvs used in later ELISA and QCM studies were
therefore only obtained from the soluble portion of expression cultures.
Integration of Antibodies into the Quartz Crystal Microbalance (QCM) Detector
The prototype biosensor was modeled on a QCM platform for detection of bacterial
targets. The gold electrode of the QCM crystal is amenable to numerous attachment
chemistries making it well suited for the immobilization of target-specific scFvs.
Formation of the SAM generated a surface of free carboxylic acid groups to which
proteins could be immobilized through the formation of an amide bond facilitated by an
EDC/NHS reaction. Monoclonal antibody Ma1-6 and scFvs were attached directly to the
SAM layer through the EDC/NHS conjugation reaction. An additional immobilization
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protocol indirectly attached to the surface by way of an IgG molecule that was specific
for the C-terminal HA-epitope tag was also employed (Figure 51).

Figure 51. Diagrams of scFv Immobilization Strategies
The direct method of attachment (left panel) involved the formation of amide
bonds between the activated acid group of the SAM and a free-amine group of the
scFv. Neither orientation nor activity of the scFv was ensured.
The indirect method of attachment (right panel) utilized the rat anti-HA HRP to
immobilize the scFv to the surface. The scFvs were attached through a C-terminal
HA epitope that ensures both orientation of the scFv antigen-recognition domain and
activity.

Monoclonal antibody Ma1-6, purified via Protein G chromatography, was
immobilized to the surface at saturating concentrations based on the conclusions of
Prusak-Sochaczewski et al. (33). Bacterial detection was assessed using live P. putida
suspended in degassed PBS buffer. Bacterial concentrations of 102 cfu/ml and 103 cfu/ml
were repeatedly examined to establish a limit of detection for the sensor with a surface
comprised of immobilized mAbs. A consistent decrease in frequency ranging from -25
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Hz to -40 Hz was measured for bacterial concentrations of 103 cfu/ml. Analysis of
bacterial concentrations of 102 cfu/ml, however, demonstrated inconsistent measurements
that ranged from +5 Hz to -15 Hz. The limit of detection (LOD) for immobilized IgG
molecules was therefore established at 103 cfu/ml.
Initially, scFvs obtained from IMAC purifications were directly immobilized to the
surface through formation of the amide bond. A total of 3 g of total protein (8.7 pmoles
of scFvs based on densitometry) were used in the initial immobilization and detection
trials. S. typhimurium samples were tested at a concentration of 106 cfu/ml using the
standard detection protocols. A significant decrease in frequency was not attained
suggesting little to no interaction between bacteria and the surface. The scFv
concentration was increased to 7 g of protein (20.3 pmoles of scFv) in an attempt to
saturate the crystal surface. Again trials were conducted with cell densities of 106 cfu/ml.
A decrease in oscillation frequency was observed in the majority of experiments;
however, the frequency change was not consistent from between trials (Table 3).
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Table 3. Detection of S. typhimurium Using QCM and Direct Immobilization scFv k18
Frequency change

Resistance change

Concentration

(∆f)

2009-04-15

106

+3 Hz

-15

2009-04-16

106

-59 Hz

+38

2009-04-16

106

-16.7 Hz

+2

2009-05-14

106

-7.4 Hz

+2.5

2009-05-14

106

+1.4 Hz

+1

Date

(

)

Note.
A protein solution containing 20 pmole scFv k18 was directly immobilized to the SAM
using an EDC/NHS reaction to facilitate amide bond formation. S. typhimurium cells were
diluted in degassed PBS (pH 7.4) to OD600 = 1.0. A 10 l aliquot (106 cfu/ml) was added to
500 l PBS on the surface of the QCM crystal.
The frequency change ( f) was calculated from the subtracting the final frequency
measurement following three washes of the surface after sample incubation from the initial
baseline frequency.
Direct attachment of scFv to the surface lacked reproducibility in individual trials.

The direct attachment of scFvs proved an ineffective method of generating a QCM
crystal capable of consistent target detection. An immobilization scheme was developed
that utilized the C-terminal HA–epitope tag to ensure proper orientation of the scFv
antigen-recognition domain and therefore activity of the scFvs. The rat anti-HA HRP
antibody used for immunoblot and ELISA protocols was readily attached to the surface
by way of the standard carbodiimide reaction. This immobilization strategy had several
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benefits compared to the direct method of attachment. The IgG molecule is substantially
larger than the scFv and conjugation to the surface is less likely to occur at a position that
is critical for antigen recognition ensuring activity of the molecule. Each IgG molecule
tethered to the surface can bind two scFvs increasing target binding through avidity.
Additionally, the IgG molecule was commercially available and could be attached to the
surface at defined concentrations. Once saturation of the available IgG binding sites with
scFvs was determined, the indirect immobilization of scFv allowed for a greater
reproducibility of sample analysis (frequency versus concentration) compared to the
direct method of attachment.
For indirect attachment of scFvs, crystal surfaces were prepared by first immobilizing
37.5 units of the rat anti-HA HRP antibody using the previously described protocol,
followed by the addition of 5 g of total protein from the eluates of the Ni2+-NTA
chromatography columns (15 pmoles of scFv k18). Increasing the molar concentration of
the scFvs added to the anti-HA surface did not improve the frequency change for
bacterial samples. It was therefore concluded that saturation of the anti-HA surface had
been attained. A minimum molar concentration of scFvs required for saturation was not
determined. A standard curve of frequency change in relation to bacterial concentration
was constructed using the SRS system and scFv k18 (Figure 52). The data collected
would serve to both validate the biosensor during later trials and determine a limit of
detection (LOD) for the device.
The standard curve was constructed for bacterial concentrations ranging from 101 –
106 cfu/ml. Individual data points were the average of 15 – 20 trials, the majority of
which were obtained from single crystals measurements. In later trials it was determined
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that the crystal surface could be regenerated with a 0.2 M glycine-HCl (pH 2.5) solution
incubated on the crystal surface for 60 s followed by a second scFv incubation step. This
reduced some of the variability observed when using several different crystals. A linear
relationship was observed between the decrease in frequency and bacterial concentrations
between 101 – 104 cfu/ml. Cell densities greater than 104 cfu/ml, however, did not
conform to this linearity. It was suspected that the surface was saturated at these elevated

Figure 52. Standardization of S. enterica Detection Using a QCM Platform and
scFv k18
ScFv k18 was immobilized to the gold electrode using an indirect attachment
protocol. Baseline and final frequency measurements were recorded from a 500 l
volume of PBS (pH 7.4) solution.
A linear relationship between f and cell number was observed from 101 – 104
bacteria/ml. Cell densities above 104 did not conform to the linear relationship
suggesting saturation of the surface with bacteria
Error bars represent the standard error of the mean rather than standard deviation
since there was significant variation in the f value between individual crystals
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bacterial concentrations.
The standard curve was developed with scFv k18 due to the poor expression and
solubility of scFv s25, which limited the quantity of scFvs available. The lack of
specificity, however, made scFv k18 unsuitable for accurate validation of the prototype
biosensor since negative (non-target) controls were not available. In contrast, scFv s25
allowed for analysis of several non-target bacteria to demonstrate accuracy (low false
positive) of the device. The SRS system was initially used to confirm that scFv s25
produced frequency changes that correlated to the established standard curve. Real-time
frequency measurements could also be obtained using the SRS system permitting a
visible comparison of target and non-target bacterial interaction with the surface (Figure
53). Negative controls were repeated several times with both B. subtilis and S.
typhimurium.
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Figure 53. Real-time Analysis of Target and Non-Target Bacteria Using the
QCM Detector
The SRS system and scFv s25 were used to monitor the interaction of target
(B. thuringiensis -..-..) and non-target (B. subtilis ----) bacteria with scFv s25
immobilized to the surface. Bacteria were examined at a concentration of 103
cells/ml following a standard detection protocol. The frequency for both samples
demonstrated an increasing slope, however, the non-target bacteria plateaued
closer to the initial baseline following the wash steps. The target bacteria
produced a significant decrease in frequency (positive) while the non-target
returned to within error of the baseline (negative)

The biosensor was tested using the previously described protocol with both target and
non-target bacteria. Fifteen measurements of varying bacterial concentrations for the B.
thuringiensis target were obtained, of these trials, a single measurement failed to produce
a positive signal. The device was also tested with the aforementioned negative control
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bacteria with concentrations ranging from 103 - 105 cfu/ml. For all such trials the
instrument relayed the expected negative result. These experiments validated the
utilization of a recombinant single chain Fv antibody, immobilized indirectly through the
C-terminal HA-epitope, and the quartz crystal microbalance platform for the detection of
target bacteria from an aqueous sample.
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CHAPTER V
DISCUSSION
Systems for the production of full-length antibodies, from either polyclonal or
monoclonal sources, are established and routinely used by industry for the acquisition of
monospecific antibodies for commercial uses. However, obtaining antibodies from
animals and mammalian cell cultures is quite expensive and not feasible for application
in a mass-produced biosensor. To satisfy the low cost and adaptability requirements of
the biosensor, alternative systems that mass-produce recombinant antibody molecules
were explored. Two single-chain Fv antibody (scFv) libraries were constructed and a
high-throughput phage display system employed to select recombinant antibodies that
bound specific bacterial targets. This system was compared to full-length antibody
production to assess which method would best satisfy the requirements of a commercial
biosensor.
Monoclonal Antibodies from Bioreactors
Hybridoma cell cultures have been utilized for production of antibodies with defined
specificity since their initial discovery by Köhler and Milstein in 1975 (15). As demand for
antibodies increased, several commercially available systems of maintaining dense
hybridoma cell cultures were developed to facilitate the large-scale production of
monoclonal antibodies (mAbs). These bioreactors utilize a hollow fiber network of
permeable membranes that allow the passage of nutrients into and removal of waste
products from the growth chamber in which cells are maintained (Figure 7). Great
success has been demonstrated with these systems and yields of up to 10 g/L of mAb
from harvested media have been reported (131, 132).
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The Fibercell System (Frederick, MD) was utilized for the maintenance of the murine
hybridoma cell line Ma1-6 (ATCC CRL-1783). Although the growth conditions of
hybridoma cultures are similar in most regards, subtle differences in antibody production
and nutrient requirements are commonly observed between individual cell lines (154, 155).
To optimize antibody production for the Ma1-6 cell line, the quantity of antibody purified
from the ECS media was examined in tandem with the rate of glucose consumption and
the pH of the circulating media on a daily basis. Antibody production was optimal when
cells consumed half of the available glucose of the circulating media every two days.
Increased consumption was the result of excessively high cell densities, which did not
exhibit an equivalent increase in antibody production. On average, a single cartridge of
the Fibercell system could produce 3 – 4 g of mAb per month at a cost of $200 per
bioreactor for media and supplies. The cost of the bioreactors themselves, in addition to
that of the media and fetal bovine serum supplement, made mAb production quite
expensive.
Purification of mAbs was accomplished with either Protein G or DEAE Affi-gel blue
chromatography. Both purification strategies produced a mAb free of contaminating
serum proteins that maintained antigen recognition when tested via immunoblotting.
Although purification using the DEAE Affi-gel Blue column required an initial
ammonium sulfate precipitation and concentration of column elutions, the method was
considerably more cost effective than purification using Protein G- based affinity
columns. It is feasible that the protocol developed for DEAE Affi-gel Blue purification
could be adapted for commercial production of monoclonal antibodies, although the true
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cost would have to account for delays associated with the initial precipitation and
subsequent concentration steps.
Production of mAbs from hybridoma cell cultures is not without its disadvantages.
Aside from the cost and difficulties of maintaining these bioreactors for long periods of
time, the process of isolating hybridoma cultures that produce a target-specific antibody
is also quite laborious. Generation of hybridoma cell lines requires immunization of
animals, typically mice, over a span of 8 – 12 weeks. This is followed by cell fusions to
form the hybridoma cultures and limiting dilutions to isolate clonal cultures, a process
which often requires several weeks (156, 157). Selection of cell lines that produce a mAb
with the desired characteristics of affinity and specificity requires an additional 3 – 9
months. This process would have to be repeated for each new target antigen.
Additionally, once the hybridoma cell line is established the scaling up of the culture
from T-flasks to the bioreactor can take 3 – 4 weeks. In total, six months to a year are
required to establish a hybridoma cell line that produces antibody specific for a new
target antigen on a commercial scale.
Although large-scale hybridoma production of mAb was successful, this system of
obtaining target-specific antibodies is likely too costly to be integrated into a commercial
biosensor that is capable of identifying multiple bacterial pathogens. Additionally, the
time constraints inherent in the development of new cell lines limit the adaptability of the
system to emerging threats. In contrast, recombinant antibodies constructed from only the
antigen-binding domain of full-length antibodies can be produced in bacteria in a
considerably shorter time frame, thereby significantly reducing the expense associated
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with antibody manufacture. Large-scale growth in fermentors would allow for bacterial
production of antibodies significantly decreasing the cost of biosensor commercialization.
A Recombinant Antibody Was Constructed from the Genes Encoding
the Fv Region of the Ma1-6 Monoclonal Antibody
Construction of scFvs from the mRNA of hybridoma cells is well documented in the
literature (18, 23, 63). Primer sequences for amplification of the heavy and light chain
variable domain sequences from mouse had previously been described by Zhou et al. (67).
These primers were designed to bind conserved sequences of the 5’ and 3’ ends of both
heavy and light chains. Although there is substantial sequence conservation in these
regions, the primer pool was still large, consisting of ten reverse and four forward primers
for the heavy chain and nine reverse and six forward primers for the light chain. Zhou et
al. performed extensive in silico sequence analysis to ensure that this primer pool was
sufficiently degenerate to amplify the vast majority of murine IgG variable domain genes.
The determination of effective primer sequences by Zhou et al. expedited construction of
the murine scFv.
Krebber et al. suggested that not all scFvs derived from hybridoma cells are functional
molecules capable of binding the target antigen (18). Often this is the result of nonfunctional mRNAs, contributed by the endogenous IgG genes of the myeloma cells,
which may be amplified and incorporated into the scFv constructs (18, 55, 158). Such events
can significantly complicate the interpretation of results from in silico analysis since
genes originating from the myeloma cells contain sufficient homology to be identified as
an Fv gene. Plasmid DNA from twelve clones derived from the heavy chain PCR
reactions of scFv 4-2 was sent for DNA sequence analysis to verify that they contained
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the mouse immunoglobulin gene. Of the twelve, six were identical to one another and
contained an open reading frame (ORF). A BlastN analysis of the nucleotide sequence
suggested a high similarity to other reported mouse immunoglobulin gene sequences (E
value = 5e -141). Four of the remaining clones were nearly identical to the preceding six
sequences (98% similar), but contained a stop codon close to the 3’ end and two silent
mutations. The final two clones exhibited regions of similarity to the preceding clones
(74% similarity) and were identified as potential murine immunoglobulin genes (E value
= 1e -84), however, these sequences did not contain an ORF. While the genes of four of
the clones may have been the result of mutations incurred during PCR, the final two
clones were dissimilar enough from the other clones to have originated from a different
DNA sequence, potentially an endogenous myeloma gene. Although a putative heavy
chain gene was identified, the Ma1-6 variable gene sequences have not been reported in
the literature and therefore validation of their identity was not possible.
As was seen with scFv 4-2, scFvs often aggregate during protein expression (159-161).
Although recovery of the insoluble scFvs from the pellet fraction was possible, the
recombinant antibodies exhibited no target binding ability. Purification of denatured
recombinant proteins is often used for the recovery of scFvs from the insoluble pellet of
bacterial expression cultures (54, 159, 162), however, the conditions of purification, as
potentially seen with scFv 4-2, may prove too harsh for the recovery of active scFvs from
some clones.
The constant domains of a full-length antibody, which are absent in scFvs, contribute
to the stability of the protein (34). The absence of these stabilizing regions may have
contributed to the lack of binding affinity exhibited by scFv 4-2, which may have been
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unable to refold properly following denaturation. The addition of constant domain
sequences to form a recombinant Fab has been shown by some research groups to recover
or improve the antigen-binding activity of poorly functioning scFvs (163-167). The DNA
sequence of scFv 4-2 suggested that the gene did encode the IgG heavy and light chain
variable domains, and the protein therefore should have folded into an active recombinant
antibody. Since no target affinity was observed for the renatured scFv 4-2, it is possible
that there were inadequate interactions between the heavy and light chain scFv subunits
to stabilize the antigen-binding domain.
Although other research groups have successfully employed hybridomas as the source
of the genetic material for construction of scFvs (18, 23, 63), the Ma1-6 cell line did not yield
a functional scFv. Therefore, continuation of recombinant antibody research focused on
the construction of a larger, more diverse pool of immunoglobulin heavy and light chain
genes that would improve the probability of isolating scFvs that can detect a variety of
bacteria. Additionally, an antibody library lends itself to high throughput selection of
scFvs based on their binding affinity and specificity, circumventing the difficulties
observed with the potential lack of stability shown by an individual scFv. To expedite the
identification of scFvs specific for a defined target (B. thuringiensis), an immunized scFv
library was therefore constructed.
Target-Specific scFvs Can be Isolated from an Immunized Library
An scFv library with a clonal diversity of 5x106 was constructed from the spleen of a
rabbit immunized with formalin-killed Bacillus thuringiensis. The clonal diversity of the
scFv library was initially calculated at 7x106 determined from the number of
transformants obtained following electroporation. However, analysis of individual clones
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following biopanning indicated that many lacked the scFv gene insert. The pComb3 XSS
vector was designed with SfiI restriction sites that are dissimilar in their nucleotide
sequence and therefore facilitate proper orientation of the scFv gene in the vector during
ligation. Restriction digest analysis, however, confirmed that ligation of the vector
backbone without an scFv insert did occur with appreciable frequency. A random
sampling of 50 clones from the initial library indicated that 70% contained the scFv gene.
The calculated clonal diversity was adjusted to 5x106 based on this observation.
The rabbit was chosen as the host largely due to its ability to generate antibodies to
antigens that are often not immunogenic in other rodents (168-170). Additionally, rabbits
tend to use a single heavy chain gene that undergoes somatic hypermutation during
diversification. This characteristic requires a smaller primer pool for library construction
compared to other organisms (56, 64, 171).
The initial rounds of selection demonstrated some complications inherent in the
biopanning process and the pComb3 XSS phagemid vector. Individual colonies were
examined with a colony lysis/restriction digest protocol to detect the scFv gene following
four rounds of biopanning. The majority (89%) of the colonies examined lacked an scFv
gene insert, a significantly higher percentage than observed with the initial library. As
shown in Figure 22, a careful inspection of the digestion products for samples lacking the
scFv gene revealed a DNA species of approximately 3000 bp at a position similar to that
of the linearized vector backbone. Since the SfiI restriction sites were likely corrupted
during ligation, uncut plasmid DNA from these aberrant clones probably migrated during
electrophoresis as a compact circular molecule with an apparent size of 1500 bp.
Although similar results are not described in the literature, the high abundance of the
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empty vector compared to scFv gene-containing clones was explained by Krebber et al.,
who suggested that E. coli containing empty plasmid vectors would possess a growth
advantage over those having to replicate larger plasmids with inserts (18, 172, 173). Given
that the frequency of empty vectors was greater following four rounds of biopanning, the
results of restriction analysis of individual clones from biopanning output plates agree
with Krebber’s explanations.
Recombinant antibodies were isolated from clones that contained a confirmed scFv
gene insert and their specificity and affinity assessed via ELISA. Although, like scFv 4-2,
many of the scFvs were insoluble (six of the initial seven tested), scFv k18 was
sufficiently soluble to allow for subsequent purification. Specificity assays, however,
established a potential complication associated with biopanning against whole bacterium,
since scFv k18 readily bound the majority of the panel bacteria. Because of the
complexity of the bacterial surface, some cross-reactivity was expected due to conserved
bacterial epitopes such as flagella, common receptors, etc. To diminish the scFv
population that recognized these conserved bacterial epitopes, a negative selection
protocol was adopted. The method was quite successful according to the initial trial,
resulting in the isolation two scFvs (scFv s24 and scFv s25) that were highly specific for
the target bacterium B. thuringiensis (Figures 26 and 27). Although scFv s24 was
insoluble and could not be tested against the entire bacterial panel, ELISA results
suggested that scFv s25 exhibited a high degree of specificity. This scFv could not be
declared monospecific based on tests with the limited bacterial panel; the high specificity
indicated that the negative selection protocol was a powerful tool for limiting scFv cross
reactivity. Based on these results, particularly the lack of binding interaction observed
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with other Gram-positive bacteria such as B. subtilis, it was assumed that the epitope
recognized by scFv s25 was unique to B. thuringiensis.
The initial scFv library was constructed from the spleen of a rabbit immunized with a
specific antigen to ensure enrichment of scFvs capable of binding a particular target
bacterium. However, the spleen, a primary lymph node, should also contain mature
lymphocytes that produced antibodies specific capable of targeting other antigens.
Through the random combination of these and other heavy and light chain variable
domain genes the library should display a highly diverse population of recombinant
antibodies that could potentially bind other antigens. To assess the potential of using the
immunized library for selection of scFvs specific for other bacteria, several alternate
bacterial targets were used as antigens in biopanning experiments.
Biopanning of the Immunized Library against Non-BacillusTargets
Produced scFvs with Affinity for Multiple Bacteria
Because B. anthracis, B. thuringiensis, and B. cereus belong to the same family of
highly similar bacteria (174-176), B. thuringiensis is often used as a simulant for the more
pathogenic Bacillus species. The scFv s25, isolated through biopanning against B.
thuringiensis, exhibit only minimal interaction with B. anthracis when tested via ELISA.
It was therefore, assumed that scFv s25 bound an epitope unique to the B. thuringiensis
species and not other closely related bacilli. Since the immunized library was generated
against a highly similar, simulant bacterium; the immunized library was screened for
scFvs that bind epitopes conserved among Bacillus species.
Five rounds of biopanning were conducted against the B. anthracis bacterium from
which the recombinant antibodies scFv k4 and scFv k5 were isolated. These two scFvs
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bound B. subtilis and B. thuringiensis with high affinity, but did not demonstrate similar
affinity for the antigen used during selection, B. anthracis (Figure 30). The low affinity
for B. anthracis compared to other gram-positive bacteria can be attributed to the high
spore content and low vegetative cell content in the ATCC sample, which led to a
miscalculation of cell number for biopanning rounds and ELISAs. This observation,
however, does not explain the lack of specificity for B. anthracis, nor does it explain why
scFvs were not isolated against the spore of this bacterium. Although these scFvs lacked
the specificity needed for incorporation into the biosensor, their further characterization
did yield important information for to future work to improve scFv affinity and bacterial
expression.
Interestingly, the absorbance measurements for target and non-target bacteria from
specificity ELISAs were proportional for scFv k4 and scFv k5 (Figure 30), with those for
scFv k4 consistently three-fold less than those of scFv k5. This similar binding pattern
suggests that the two scFvs may target the same surface epitope. The concentration of
scFvs in eluted fractions could not be determined and the differences observed in ELISA
may be attributed to this. While the concentrations of the partially purified scFvs may
have contributed to the ELISA results, the two scFvs also differed significantly in the
amino acid sequences of their respective complementarity determining regions (CDRs),
which form the antigen-binding domain. Alignment of the amino acid sequences for the
entire protein (ClustalW) indicated that the two scFvs were 76.2% similar. As expected,
the amino acid compositions of framework regions of both heavy and light chains were
very similar. The greatest variation in sequence was observed within the CDR3 loop of
the heavy chain gene. The scFv k4 contains two more arginine residues than scFv k5,
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which possesses an additional aspartic acid residue not present in scFv k4. The charge
differences in this region, since CDR3 is reputed to be most involved in antigen
recognition (177), likely contributes to the observed differences in epitope affinity. These
observations suggest that the CDR3 domain of the heavy chain could serve as an initial
target for mutagenesis to improve scFv affinity. In support, several research groups have
targeted this region of the heavy chain to improve the characteristics of scFvs (178, 179).
Both scFvs exhibited improved solubility and expression levels compared to other
scFvs isolated from the immunized library (scFv k18, scFv s24, scFv s25). Kipriyanov et
al. demonstrated that specific amino acid residues could be changed to improve solubility
of scFvs and encourage their export into the culture medium (180). A comparison of their
primary structures with those of other scFvs with similar characteristics (export – scFv
s25; improved solubility – scFv k18) may be able to identify specific amino acid residues
or motifs that are linked to these properties and may represent good targets for
substitution. This analysis was not performed at this time, however, since the number of
scFvs available for comparison was too low to yield reliable prediction.
In addition to biopanning against B. anthracis, the immunized library was screened
against the gram-negative bacteria P. aeruginosa and P. putida, whose outer surface was
expected to differ significantly from that of the initial gram-positive immunogen.
Biopanning rounds with P. aeruginosa and P. putida as antigens failed to generate any
significant enrichment of scFvs, as evidenced by the phage ELISA results (Figure 31).
Further analysis of individual clones from biopanning output plates, however, suggested
different reasons for this lack of success.
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The inability to select P. aeruginosa-specific scFvs by biopanning was probably the
result of non-specific interaction between the bacteria and the M13 filamentous phage,
which is known for non-specific binding to a number of different substances (142). Nonspecific interactions with P. aeruginosa samples (attributed to the bacterial capsule) and
secondary antibodies (Figure 17) were repeatedly observed in experiments. Previous
displacement assays with latex beads showed similar interaction and binding of P.
aeruginosa to gold surfaces through capsule and formation of a biolayer has been
documented in the literature (181, 182). In combination, these binding events would ensure
that phages would be recovered from each round of biopanning regardless of the presence
or absence of target-specific scFvs. Phage clones that do not express an scFv fusion
protein are considerably more abundant than those displaying recombinant scFv protein,
since the empty phagemids have a significant growth advantage, as previously discussed.
Although the biopanning protocol could have been adapted to include washes of
increased stringency that eliminate non-specific interactions, attempts to isolate scFvs
specific for this antigen were not continued in favor of trials with antigens that pose
fewer potential complications.
Unexpectedly biopanning against the P. putida antigen also met with little success.
Similar to P. aeruginosa, P. putida possesses a capsule at the mid-log stage of growth,
however it was likely absent from the overnight stationary-phase cultures used for
biopanning (183). The phage clones that were recovered following each round of selection
were likely not the product of non-specific interactions as was observed for P.
aeruginosa, since several clones contained an scFv gene insert. Two unique clones, p6
and p12, isolated from the final round of P. putida biopanning, produced sufficient
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quantities of soluble scFvs for subsequent ELISA analysis. Although these scFvs did bind
a number of non-target bacteria of the panel, they exhibited little affinity for P. putida
itself (Figure 32). In combination with the phage ELISA results (Figure 31), which
suggested no significant enrichment of scFvs that recognized the bacterial antigen, the
results of the specificity ELISA suggested that the scFvs expressed from clones selected
through biopanning exhibited poor antigen affinity. The low affinity scFv-phage from
each round of selection would have readily been displaced during the phage and
specificity ELISA since theses protocols involve more stringent wash conditions than
those employed in typical biopanning.
Although two low-affinity scFvs were isolated from the immunized library, based on
affinities demonstrated by other scFvs (scFv 18 – Figure 25, scFv k5 – Figure 30) for
Pseudomonas species, greater success was expected. The scFv k18 readily bound P.
putida with only slightly less affinity than that demonstrated for its target antigen of B.
thuringiensis. Similarly, although the affinity was three-fold less than for target bacteria,
both scFv k4 and scFv k5, isolated through B. anthracis selection, bound P. fluorescens
and P. putida. Although none of these scFvs bound Pseudomonas species with high
specificity, they did indicate that scFvs with higher affinities for Pseudomonas surface
epitopes were present in the initial scFv library. Although repeating the biopanning
process against P. putida may have yielded scFvs with improved affinities, additional
selection against the P. putida antigen was not conducted. The P. putida bacterium, in
contrast to P aeruginosa, was not deemed an antigen of sufficient concern to any of the
target fields (agricultural, medical, biodefense) to justify additional selection
experiments.
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Based on the results from biopanning against bacterial targets other than B.
thuringiensis, it was assumed that the immunized library lacked the clonal diversity
necessary to isolate scFvs with high specificities for other bacterial antigens. The project,
therefore, shifted to the construction and selection of scFvs from a naïve scFv library.
Unlike the immunized library, which was constructed from tissues containing an
abundance of matured lymphocytes in response to immunization, a naïve library is
expected to contain a gene reservoir of improved diversity. Since there is not an excess of
mature immunoglobulin genes that produce antibodies for a specific target, variable
domain genes present in low copy in the immunized tissues may be more likely to be
included in the scFv repertoire of the naïve library (57).
A Naïve Library Was Constructed to Increase scFv
Diversity against Bacterial Targets
The naïve library was constructed to determine if scFvs with improved target
specificity could be isolated from an antibody reservoir of increased diversity and
assembled from genes obtained from lymphocytes not matured toward a specific antigen.
Since all of the scFvs isolated from the immunized library exhibited some affinity for B.
thuringiensis regardless of the antigen used during biopanning, the naïve library was
constructed to determine if this was the result of the limited diversity of immunoglobulin
genes of the lymphocyte pool obtained following immunizations.
While the successful acquisition of target-specific scFvs from the immunized library
relies on a large scFv population with affinity for the target antigen, the naïve library
depends on a high clonal diversity (109 – 1010 clones) and high-throughput selection to
isolate scFvs with the desired specificities and affinities against a larger, more diverse
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range of antigens (20, 184, 185). To increase clonal diversity, primers for IgG and IgM
constant domains were used during library construction. Antibodies of the IgM isotype
are produced during the primary immune response. Generally exhibiting low affinities for
the target antigen, the immunoglobulin genes encoding IgM antibodies have undergone
little to no gene recombination and are therefore most similar to initial germline genes (35,
36, 186)

. Combining variable domain sequences for both IgG (matured) and IgM (naïve)

genes would increase the diversity of the scFv library. Finally, since clonal diversity is
limited by the efficiency of bacterial transformation, a highly electrocompetent E. coli
strain was generated. Despite these efforts, the calculated clonal diversity of the naïve
library was 8x108. Although an order of magnitude lower than desired, it was considered
acceptable for proof-of-concept trials.
Salmonella typhimurium was chosen as the initial bacterial target with which to test
the naïve library against gram-negative bacteria. As shown with the Pseudomonas
species, the immunized library was only minimally successful with these antigens.
Additionally, this bacterial target promoted the applicability of the device to prominent
agricultural outbreaks that were occurring at that time. The standard biopanning protocol
produced several clones that expressed scFvs with varying levels of affinity for target and
non-target bacteria (Figure 34). Although a greater affinity for gram-negative bacteria
was shown by scFv s26 and scFv s27, substantial binding of the gram-positive bacterium
L. monocytogenes also occurred. Given the successes of the previous negative selection
biopanning experiment, in which highly specific scFv s24 and scFv s25 were selected
(Figure 26), L. monocytogenes was employed as the non-target antigen to remove scFvs
that may have been targeting epitopes conserved among enteric bacteria. However, rather
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than improving specificity for S. typhimurium, all scFvs from the final round of selection
had no affinity for the original antigen (Figure 39a). These experiments, while
unsuccessful in isolating a suitable scFv, led to several insights about the recombinant
antibody system.
The scFvs isolated from the last round of negative selection were comprised of only
the heavy chain variable domain, as evidenced by DNA sequence analysis (Figure 37). In
contrast to full-length scFvs, these truncated molecules would rely on the three CDRs of
the heavy chain to form an antigen-binding domain. It is well documented that the heavy
chain variable domain can, by itself, bind target antigens independent of contributions
from light chain CDRs (187-189). Although not seen with the clones isolated in this study,
single domain antibodies can show significant specificity for their target antigens (190, 191).
The absence of the light chain CDRs in the antigen-binding domain was therefore most
likely not the primary contributor to the observed lack of scFv specificity. As with nonspecific interactions observed with other scFvs, this was liley a consequence of whole
bacteria as the antigen and the presence of numerous conserved surface epitopes that
must exist between bacterial species. Although an scFv specific for S. typhimurium was
not isolated, these experiments did show that clones with truncated scFv genes, which
were not characterized in previous biopanning rounds, could prove suitable for bacterial
detection in later studies.
The naïve library was generated to improve the potential acquisition of scFvs with
high target specificity. However, clones isolated from the naïve library continued to
exhibit specificity for multiple bacterial targets similar to those scFvs obtained from the
immunized library. This observation suggested that the inability to isolate scFvs for non-
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Bacillus bacteria from the immunized library was probably not attributable to the low
library diversity but likely the result of either biopanning conditions or the complexity of
the bacterial surface as a selection antigen. The bacterial surface, particularly that of
gram-positive bacteria, contains countless membrane proteins and structural features that
could potentially serve as epitopes to which scFvs can bind (192). Invariably, some
epitopes are conserved or very similar among bacteria and contribute to the potential for
cross-reactivity of scFvs with non-target bacteria. Epitopes unique to a particular
bacterium may not be abundant on the bacterial surface and therefore scFvs specific for
these structures may easily be lost through iterative rounds of biopanning.
The vast majority of biopanning experiments reported in the literature are directed
against specific, purified antigens (proteins, carbohydrates, or small molecules). Utilizing
a defined epitope allows for enrichment of a limited pool of scFvs during biopanning. In
contrast, biopanning against the complex bacterial surface leads to an enrichment of
scFvs that may bind any one of countless epitopes that may or may not be unique to the
particular bacterium. To improve the probability of isolating Salmonella-specific scFvs,
the naïve library was subjected to five rounds of selection against a purified
oligosaccharide, the O-antigen, of S. typhimurium. Restriction analysis of phagemid DNA
from individual clones again showed a high frequency of vectors that lacked the scFv
gene, further validating the explanation offered by Krebber that clones containing an
empty phagemid vector have a significant growth advantage over those that harbor the
scFv gene (18). A single clone, k2, was obtained from the last round of biopanning. The
scFv expressed by this clone bound the O-antigen, whole S. typhimurium cells, and all
other bacteria of the test panel with varying degrees of affinity (Figure 42). Cross-
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reactivity with other gram-negative bacteria was anticipated, since these have similar
carbohydrate structures on the outer lipopolysaccharide (LPS) layer. The scFv k2,
however, also readily bound gram-positive L. monocytogenes and Bacillus species with
very high affinity. Although scFv k2 was selected with a carbohydrate antigen isolated
from a specific bacterium, this scFv continued to display affinity for all bacteria of the
panel. The LPS does contain unique epitopes since antibodies against bacteria-specific
LPS have been previously isolated (150, 151, 193). The lack of specificity of scFv k2 and the
absence of other clones available for characterization suggest a complication with current
biopanning protocols, perhaps with the stringency of washes or the inability to limit
amplification of the clones containing the empty phagemid vectors.
The poor specificity exhibited by scFv k2, and many of the other clones isolated in
previous trials, illustrated a difficulty that was encountered throughout the various
selection experiments. The bacterial surface contains countless potential epitopes formed
from both unique and conserved bacterial structures. Epitopes that are highly abundant on
the bacterial surface will likely be the target of scFvs that are enriched through iterative
rounds of selection. Those scFvs that target low-copy epitopes will be less abundant
during phage amplification and, since clones expressing full-length scFv already have a
growth disadvantage, may gradually be lost through iterative rounds of selection.
Therefore, using the current protocols, it would be nearly impossible to isolate scFvs with
affinity for low-copy unique bacterial epitopes. In contrast, unique bacterial epitopes that
are abundant on the bacterial surface would allow for the selection of scFvs from the
library. Although other researchers have been able to isolate scFvs that recognize their
bacterial targets, in these studies only limited screening was performed to assess
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specificity for non-target bacteria and significant cross-reactivity was observed between
closely related species (88, 194). The high target specificity of scFv s25 may be the
exception rather than the norm when panning against whole bacteria.
Although only limited success was achieved in isolating scFvs with high target
specificity from the rabbit scFv libraries constructed in this project (scFv s24 and scFv
s25), the successful selection of scFvs from a library with desired binding characteristics
for a specific antigen is well documented in literature (60, 92, 195, 196). What is evident in
both the literature and these experiments is that individual antigens will likely require
unique selection strategies to improve specificity. This includes not only the stringency of
washes but also the platforms used for antigen immobilization (58, 69, 89, 197, 198).
The biopanning protocol could almost certainly be manipulated by increasing the
stringency of washes beyond that of the standard protocol. In combination with phage
ELISA assays, changes in selection conditions could be assessed to determine if this
leads to an enrichment or loss of scFv with affinity for the target antigen. Similarly, the
negative selection protocol, which was successful in initial trials, may also prove suitable
for later selection rounds. However, rather than using a single bacterium as the negative
agent, selection against several non-target bacteria could be conducted to assess which is
most beneficial for the elimination of non-specific scFvs. Finally, the greater the diversity
of the scFv library, the more likely an scFv with particular characteristics can be
recovered. The naïve and immunized library were of sufficient calculated clonal diversity
compared to libraries used by other researchers, however, improving diversity should
lead to greater success in isolating a target-specific scFv. Although these methods were
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not explored, there are many methods of improving clonal diversity during library
construction.
The naïve library was constructed from cDNA synthesized from the mRNA of spleen
cells using protocols described in the literature (18, 56, 57). In rabbits, however, the appendix
is also a location of B cell maturation and may serve as secondary source of lymphocytes
that can be used for library construction (171, 199, 200). The appendix, or gut-associated
lymphoid tissue (GALT), develops lymphoid follicles shortly after birth and maintains a
high population of mature B cells. Knight suggests that greater than 50% of the B-cells
within the GALT are actively dividing at the early stages of development (171). Given the
age of the donor rabbit (4-6 weeks), the GALT would have also been an excellent source
of diverse variable domain genes. Including the GALT tissues as a source of RNA during
library construction would have improved library diversity.
Naïve libraries assembled from the immunoglobulin genes of multiple donors are
frequently reported in the literature (21, 62, 78). Although such libraries are usually
generated from human peripheral blood lymphocytes, the concept of utilizing several
donors could be explored using the protocols already developed for the construction of
the rabbit scFv library. Particularly with older rabbits, matured heavy and light chain
genes would be present in varying ratios in the spleen tissue depending on antigen
exposure of the animals. Within the spleen of a single rabbit, certain variable domain
sequences may exist in such low abundance that they could potentially be lost during
library construction, particularly when the library is of limited complexity. Utilizing the
spleens of several rabbits would increase the miscellany of variable domain sequences
available for library assembly.
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As an alternative to the aforementioned methods, the CDRs of the heavy and light
chains can be randomized directly utilizing a variety of PCR techniques during library
construction. Methods such as CDR shuffling (60, 201) and direct randomization of CDRs
(69)

have been used as effective methods of substantially improving the diversity of the

scFv library. With CDR shuffling, forward and reverse primers are designed for
conserved nucleotide sequences of framework region 2 and framework region 3.
Following the initial PCR to isolate the heavy and light chain genes, a second PCR
amplification using the original primers and the primers of the framework regions
segments the variable domain genes. These segments are then recombined randomly
through regions of complementarity in a third oePCR reaction. Goldman et al. utilized
CDR shuffling to increase the diversity of a llama single-domain antibody library from
106 to 109 (60). Liu et al randomized the nucleotide sequence and length of CDR3 in an
scFv library derived from spiny dogfish sharks (69). The randomized CDR3 genes were
then cloned back into the library, thereby substantially improving the diversity of the
existing library. Application of these methods to the naïve and immunized rabbit libraries
constructed in this study may increase the scFv diversity and eliminate the need to
generate additional libraries from other rabbits.
A final alternative that deviates from the strategy of using a naïve library to isolate
target-specific scFvs is based on the work of Li et al. who immunized rabbits with
multiple haptens (73). It should be possible to use several bacteria as immunogens to
simultaneously enrich for lymphocytes producing multiple target-specific antibodies. The
spleen could then be extracted for construction of a library that is already enriched in
matured heavy and light chain genes that are specific for all of the immunogens. Given
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the success with the initial B. thuringiensis immunized library, this method should
improve the potential for isolating target-specific scFvs against bacterial antigens.
Additionally, since numerous immunogens can be used, a single library could potentially
yield several scFvs that are specific for different targets. Selection of the bacterial
immunogens would be critical to the success of this method, and it would need to be
determined experimentally whether rabbits should be immunized with bacteria that are
similar or diverse in nature with respect to habitat, Gram classification, possession of
flagella, etc..
Only Limited Quantities of scFvs are Obtained from Small-Scale
Bacterial Expression Cultures
Poor solubility is an inherent complication associated with bacterial expression of
scFvs (195, 202). In addition, poor expression levels, with yields ranging from 0.05 – 1 mg
scFv / L, are also not uncommon (203-205). Expression trials of scFvs were conducted in a
number of bacterial strains, and with different expression vectors. However, only limited
improvements in the solubility or expression levels were achieved. Cytoplasmic
expression conducted in the pProEx and pET21 vectors did not yield increased amounts
of recombinant protein. In contrast, cytoplasmic expression using the pET41c vector,
which generates an N-terminal GST fusion, did improve expression but not solubility.
The GST-scFv fusions, however, no longer exhibited bacterial specificity in ELISAs
(Figure 45). This lack of specificity may have been the result of the GST portion of the
molecule interacting with the bacterial surface and would explain why GST-scFvs s25
exhibited affinities that were similar to GST-scFv k18. The pET41 vector encodes a
cleavage site downstream from the GST position of the recombinant protein that can be
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used to remove the non-scFv portion of the fusion. Removal of GST was not explored in
this study because the necessary protease can only be obtained commercially and at
significant expense. Should this additional step be required for the purification of scFvs,
the cost of biosensor production would rise considerably.
Poor solubility of scFvs was an inherent condition of all clones during expression
trials (Figures 23, 28, and 49). Although solubility of all scFvs could be improved
slightly by lowering the induction temperature during expression and decreasing the
IPTG concentration, scFv yields from the soluble material were low (45 – 60 g / L). To
aid in the recovery of scFvs, denaturing chromatography and renaturation through stepwise removal of the denaturant by dialysis were used for the purification of scFv k18 and
scFv s25 from the insoluble pellet. This method of purification was marginally successful
for scFv k18 but completely ineffective for scFv s25. The renatured scFv k18 did
maintain some bacterial affinity, however, when tested via ELISA, eluates obtained from
standard and denaturing chromatography (Figure 48a) showed significant differences in
affinity for bacterial targets.
Eluates from both purification methods were resolved using SDS-PAGE. Densitometric
analysis of immunoblots indicated only 25% less recombinant antibody in the eluates of
the denaturing column, an insufficient difference to account for the three-fold lower
affinity observed in ELISA. These observations suggested that some portion of the scFvs
recovered from the pellet fraction did not refold into the native, functional conformation.
The renatured scFv s25 eluates exhibited only minimal activity that was eight-fold lower
than that of scFv s25 eluates recovered with the standard purification (Figure 48b).
Success in obtaining a functional molecule following denaturating affinity purification
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appear to vary with individual scFvs and must be determined experimentally for each
clone since other research groups have been able to successfully isolate scFvs using the
denaturation/renaturation purification method (206, 207).
High-level accumulation of recombinant proteins within in the periplasm can often
lead to secretion of these proteins into the culture medium when expression is conducted
at temperatures between 25 C and 37 C

(128, 140)

. This phenomenon was observed for

several of the scFvs isolated in these studies (scFv s25, scFv k4, and scFv k5). Since
scFvs exported to the culture medium were soluble, a standard affinity purification
protocol could be utilized. The scFv s25 was purified from the culture medium and tested
for target specificity via ELISA. Unfortunately, the extracellular scFvs did not exhibit the
high specificity for B. thuringiensis characteristic of scFv s25 purified from a soluble
cellular protein extract (Figure 50). The ompA leader sequence of the pComb3 XSS
vector targets scFvs to the periplasmic space, which provides an oxidizing environment
to facilitate disulfide bond formation during expression. Georgiou et al. suggested that
high level expression of recombinant proteins can lead to an inhibition of the synthesis of
native outer membrane proteins, which compromises the integrity of the outer membrane
leading to semi-specific secretion of periplasmic recombinant proteins to the culture
medium (140). In conjunction with early studies by Bowden et al. which showed that highlevel expression and targeting of recombinant proteins to the periplasm often overwhelms
the folding machinery (208), it is possible that scFvs within the culture medium are not
folded into a native conformation, perhaps lacking the disulfide bonds formed within the
periplasmic space. Reduced stability of the antigen-binding domain would explain why
scFv s25 was still capable of binding bacterial targets, but no longer demonstrated the
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high specificity characteristic of a well-defined antigen-binding domain. While scFv s25
purified from the culture medium did not exhibit typical target affinity, the method per se
may hold potential for the purification of other scFvs since the success with this method
has been documented in the literature (209, 210).
The expression and purification of scFvs using bacterial shake flasks (50 ml – 2 L
volumes) was a limiting parameter in scaling up the recombinant antibody system,
because of the low yields of recombinant antibodies obtained in these studies (45 – 60 g
scFv/L of culture) and documented in the literature (52, 195, 211). Recovery of scFvs from
expression cultures would need to achieve higher yields equal to those obtained with
hybridoma bioreactors to be a successful substitute. Alternatives, although not explored,
are available for the large-scale production of recombinant proteins and have been
demonstrated an as effective method of mass-producing functional scFvs.
The research groups of Feldhaus et al. and Liu et al. have demonstrated that
expression in Saccharomyces cerevisiae and Pichia pastoris yeast cultures significantly
increases that quantity of scFv that can be recovered, with yields ranging from 0.4 -15
mg/L (54, 212, 213). Yeast expression cultures are, however, not without their own problems.
Liu et al. showed that further genetic manipulation of the scFv gene was necessary to
correct for codons bias of P. pastoris (212), and Feldhaus et al. demonstrated that
expression in S. cerevisiae often leads to hyperglycosylation of the recombinant protein,
which was shown to interfere with binding affinity (54).
Expression of scFvs in E. coli quiescent cells maintained in bacterial fermentors has
been shown to produce significant levels of recombinant protein (141, 159, 214). Quiescent E.
coli cells are non-growing, yet metabolically active cells generated through the over-
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expression of the Rcd transcript (215). The Rcd protein represses chromosomal genes
through nucleoid condensation (141). Because quiescent cells are no longer dividing, cell
resources are focused on the production of plasmid-encoded foreign gene products (216).
Summers et al. utilized quiescent cells to express scFvs with yields of 37 mg/L in
traditional baffled flasks, a nearly three orders of magnitude higher yield than that
obtained in this study for scFv k18 expression cultures. The group typically obtained 150
mg/L of recombinant scFv from fermentors (141). Yields from fermentors vary between
individual clones, however, recoveries greater than 3 g of scFv/L culture are routinely
demonstrated in the literature (159, 203). Utilization of either of these methods for scFv
manufacture would ensure low-cost production of sufficient quantities of target-specific
scFvs for integration into a commercial biosensor.
Monoclonal and Recombinant Antibodies Suitable for Biosensor Applications
Full-length mAb and recombinant scFvs were tested with the QCM platform to ensure
that either type of antibody could be used in the biosensor. Full-length immunoglobulin
molecules are routinely employed in QCM sensors for the detection of bacterial targets
(26, 28, 30, 109, 112)

. The Ma1-6 mAb was tested to examine the efficiency of attachment to the

mixed acid self-assembled monolayer and to determine the limit of detection. Consistent
measurements sufficient to generate a positive signal were obtained for concentrations of
103 cfu/ml, consistent with LOD values reported by other research groups (30, 109, 110).
Although lower LOD values have been reported for QCM detectors that utilize mAbs,
significant differences in variables such as the crystal oscillation frequency and antibody
immobilization strategy in these systems prevented a meaningful comparison of the
performance to the prototype biosensor (31, 32). To lower the overall cost of biosensor
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production, the recombinant antibodies isolated from the scFv libraries were examined to
determine if they would be sufficient substitutes for the mAb, capable of LODs equal to
that of Ma1-6.
Two different methods of scFv immobilization were employed to activate the QCM
crystal for bacterial detection. Initial experiments were conducted using a strategy
identical to the one employed for immobilization of monoclonal antibodies. While
successful for the Ma1-6 antibody, the direct method of immobilization was unsuccessful
for scFvs. In trials with immobilized scFv k18, QCM analysis of bacterial samples
produced highly variable frequency measurements for each of the concentrations
examined (Table 3). This was observed regardless of the molar concentration of scFvs
immobilized to the surface and can most likely be attributed to the structure of the scFv
protein, which is primarily comprised of amino acids that are either part of the antigenbinding (CDRs) or structural stability (framework). The scFv k18 contains seven lysine
and eight arginine residues, the primary targets of the carbodiimide reaction. Three of the
lysines and three of the arginines are located within the CDRs themselves, which form
loop structures that project away from the ß-sheets formed by the framework regions. The
lysines and arginines of the CDRs are therefore excellent targets for the formation of
amide bonds with the SAM of the crystal. In the event that attachment to the surface
occurred through one of these residues, the antigen binding capabilities of the scFv could
be lost due to steric hindrance as the binding domain would be oriented toward the crystal
surface. Similarly, a reaction that targets amino acids of the framework regions may also
lead to loss of scFv activity by disrupting the tertiary structure of the molecule. Although
amino acids of the framework regions and CDRs can be identified using the variable
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domain numbering system established by Kabat (123), which amino acid are utilized for
attachment to the surface cannot be determined a priori. Although some success in
generating a functional crystal surface has been reported when free cysteine and histidine
and residues were used for surface immobilization of the scFv (217-219), these methods
were not attempted in this study.
The indirect method of scFv immobilization to the QCM slide, in which the Cterminal HA eptiope tag of the scFv binds to a monoclonal anti-HA antibody that is
immobilized on the surface, proved significantly more successful in demonstrating a
linear relationship between bacterial concentration and frequency change. This method of
coupling ensured orientation of the scFv antigen-binding domain and therefore the
capability to bind target bacteria. Purified monoclonal anti-HA IgG antibody is
commercially available and therefore could be immobilized in well-defined quantities.
Utilizing an excess of the scFv containing fractions obtained from Ni2+-NTA
chromatography ensured saturation of the available HA-binding sites of the IgG
antibodies. As shown in the standard curve (Figure 52), scFvs immobilized using this
method were repeatedly able to detect 102 cfu/ml, a improvement in sensitivity by an
order of magnitude.
The scFv s25 was first tested with the Stanford Research System QCM apparatus to
ensure that the target specificity observed with ELISA would be maintained following
immobilization to the gold electrode. These initial trials allowed for the acquisition of
real-time frequency measurements that visualized target and non-target bacterial
interactions with the crystal surface (Figure 53). Once the specificity of scFv s25 was
confirmed, the prototype biosensor was tested with bacterial samples of B. thuringiensis,
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B. subtilis, and S. typhimurium to establish the LOD for the detection of target bacteria
and to assess the accuracy of identifying target bacteria compared to non-target bacteria
(false positive / false negative). The LOD measured with the biosensor correlated with
the results obtained with the SRS system and scFv k18 exhibiting a LOD of 102 cfu/ml of
B. thuringiensis in a PBS solution. Samples containing non-target bacteria did not
generate a frequency change sufficient to produce a positive result.
This project concluded that recombinant antibodies could be isolated from an scFv
library using high-throughput techniques. The scFvs selected in that manner could readily
be incorporated into a QCM-based biosensor for the detection of target bacteria.
Although additional studies are required to optimize scFv production, bacterial
expression of scFvs offers a low cost alternative to hybridoma-derived mAbs. While
several complications with the phage display system were encountered, future endeavors
with more diverse libraries may overcome these difficulties. The scFvs isolated through
biopanning were expressed in bacterial hosts and utilized for detection using both a
commercially available QCM apparatus and the prototype biosensor constructed by
collaborators. A method of immobilizing scFv to the gold electrode was developed that
ensured both directionality of the antigen-binding domain and activity of the scFv. The
prototype biosensor was successfully employed in the detection of target bacteria.
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CHAPTER VI
CONCLUSIONS AND FUTURE WORK
Methods of producing bacteria-specific IgG antibodies and recombinant scFvs were
explored for the development of a QCM-based biosensor. Both types of antibodies were
amenable to integration into the QCM-platform and demonstrated reproducible detection
of target bacteria to concentrations of 103 and 102 CFU/ml, respectively. The recombinant
antibody system, however, offered several advantages over monoclonal antibody
production and suggests that scFv libraries are a superior system for application into an
adaptable biosensor.
Selection of unique clones, whether from hybridomas or scFv-expressing E. coli
cultures, requires a considerable initial investment of time as immunizations of a host
organism with the target antigen are conducted. The immunization process, excluding
complications such as antigen purification, requires several months before necessary
materials can be obtained for both hybridoma (lymphocytes) and library (spleen or
similar material) generation. While both full-length and recombinant antibody production
both require these initial immunizations, a single scFv library could yield recombinant
antibodies for several target antigens. In contrast, development of a hybridoma cell line
would require immunizations for each target antigen. Although highly specific scFvs
were not isolated from the naïve library, such a source of recombinant antibodies has
been utilized by other research groups with great success (63, 72, 184). Through a
combination of DNA techniques (mutagensis, CDR shuffling, etc) to improve diversity
and adjustments to the biopanning protocols, the scFv libraries generated in this study
could be further utilized to screen for scFvs with the desired binding characteristics.
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The diversity of the scFv library and power of phage selection provide a highthroughput method of isolating scFv with desired target-specificity and stability. Future
endeavors with the phage display system would need to employ selection strategies that
ensure scFv binding specificity and affinity under harsher conditions than utilized in the
preliminary trials of this study. Since the biosensor will likely be used to analyze
complex aqueous samples or unknown solids, inclusion of detergents in the sample
buffers will likely be required to limit non-specific interactions. The biopanning process
is ideally suited for the manipulation of binding conditions with respect to temperature or
chemical composition to isolate scFvs that are tailored to particular applications (60, 88).
In addition to the benefits of high-throughput selection, the recombinant antibody
system allows the antigen-binding domain to be reshaped through direct manipulation of
the heavy and light chain genes themselves. It has been extensively demonstrated that
scFv affinity for a specific target can be improved through an affinity maturation process
(50, 220-222)

. The scFv gene can be subjected to mutagenesis, followed by high-throughput

screening of the biopanning process to identify clones with improved affinity. A suitable
protocol for assessing affinity of the new scFvs would need to be developed based on
surface plasmon resonance or flow cytometry.
Of primary concern in the development of any commercial product is the cost of
production. Production and purification of monoclonal antibodies are considerably
expensive, a single Fibercell bioreactor cartridge maintaining the Ma1-6 cell line
produced an average of 3 – 4 g of antibody per month at a cost of approximately $200 in
media and reagents. Although several of these cartridges could be maintained
concurrently, the expense of fetal bovine serum and DMEM media made antibody
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production prohibitively expensive. In contrast, scFvs could be produced in high yields in
bacterial fermentors. Medium for E. coli growth can be prepared at a fraction of the
expense for hybridoma maintenance and reported yields for scFvs produced in fermentors
are comparable to those for hybridoma-derived monoclonal antibodies. Large-scale
production of scFvs in quiescent cells of fermentors should be explored to ensure that
commercial production of the biosensor is feasible.
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